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ABSTRACT 
The autonomic nervous system (ANS) controls several vital functions of the body, 
especially the autonomic regulation of respiratory and cardiovascular systems. Dysfunction of 
either can be life-threatening. Some of cellular and molecular mechanisms underlying the 
respiratory and cardiovascular dysfunction is more critical and general. The demonstration of 
such general processes not only may help the understanding of etiology and pathophysiology of 
the diseases, but also suggests potential therapeutic modalities for the diseases. Severe breathing 
disorders including high apnea rate and breathing irregularity are found in Rett syndrome (RTT). 
In a novel rat model of RTT, we compared rat physical condition and behaviors with traditional 
mouse models of RTT. We found that the novel Mecp2−/Y rat model as an alternative RTT model 
  
recapitulated numerous RTT-like symptoms. To uncover the neuronal mechanisms underlying 
the RTT respiratory disorders, we performed in vivo recording from brainstem neurons in ventral 
respiratory column (VRC). Excessive activity of both inspiratory and expiratory neurons as well 
as ectopic discharge of phrenic nerve were detected in null rats. Such defects were likely caused 
by hyperexcitability of respiratory neurons due to inadequate synaptic inhibition necessary for 
phase switching. Then we took the GABAergic intervention to hyperexcitability of respiratory 
neurons, and successfully corrected the defects in neuronal firing patterns as well as the RTT 
breathing phenotypes.  
Similarly, change of cellular excitability was also observed in diabetic vascular 
complications. A critical player for the membrane excitability of vascular smooth muscle cells 
(VSMCs) is the KATP channel that is strongly suppressed by methylglyoxal (MGO) known to be 
overly produced with persistent hyperglycemia. The elevated level of microRNA (miR)-9a-3p 
contributed to the down-regulation of vascular KATP channels. miR-9a-3p inhibition using 
antisense oligonuecleotides corrected the dysfunction of KATP channels. Since VSMC membrane 
excitability plays an important role in vascular tone regulation, we generated a new strain of 
transgenic Tagln-ChR mouse model and demonstrate an alterative to manipulate VSMC 
membrane excitability and vascular tone using optogenetic approaches. Thus several molecular 
targets in cardiorespiratory system have been demonstrated underlying membrane excitability 
and the developments of several disease conditions in this thesis study. 
 
INDEX WORDS: Autonomic nervous system, Respiratory system, Vascular system, Cellular 
excitation, Rett syndrome, Ventral respiratory column, Diabetic vascular dysfunction, 
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1 HYPOTHESES AND SPECIFIC AIMS   
The autonomic nervous system (ANS) controls involuntary and visceral functions.  Two 
of them are respiration and the cardiovascular system which are essential for survival. Breathing, 
a perpetual process in life, is controlled by the brainstem as well as higher brain areas. 
Cardiovascular function relies on the heart, blood vessels and their controlling system. 
Dysfunction of the respiratory and cardiovascular systems often leads to some of the most 
challenging diseases and death.  
As the intrinsic property of excitable cells, such as neurons and muscle cells, membrane 
excitability is a critical factor determining the output of a neuron and the performance of smooth 
muscles in physiological and pathophysiological conditions. Although the understanding of the 
function of ANS has advanced tremendously over past decades, many questions related to the 
role of cellular excitability in health and diseases remain open. For instance, how does the ANS 
dysfunction lead to respiratory and cardiovascular diseases? What cells in the control line of 
ANS are involved in the respiratory and cardiovascular diseases? Does a change in membrane 
excitability of these cells play a major role? What are molecules critical for the change in 
membrane excitability? Can these molecules be targeted to manipulate cellular excitability for 
therapeutic purposes? To address these questions, we performed these studies using a 
multidisciplinary approach with RNA interference, optogenetics, transgenic animal models, in-
vitro organ, tissue and cellular physiology, in vivo electrophysiology and behavioral studies. My 
hypothesis is that several receptors and ion channels controlling membrane excitability in the 
ANS not only are involved in the development of certain pathological conditions when they are 
defective, but also provide specific accesses to the diseases for therapeutic purposes. 
Specific Aim 1: The novel Mecp2-/y rat model recapitulates numerous RTT-like symptoms. 
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Respiratory system as a part of ANS is critical for lives and can become abnormal in 
certain genetic diseases such as Rett syndrome (RTT). RTT is a neurodevelopmental disease 
caused mostly by mutations of Methyl CpG binding protein 2 (MECP2) gene. With the 
mutations patients usually suffer from life-threatening breathing disorders. Although there are 
mouse models of the disease currently, the body size of mice limits the understanding of cellular 
physiologic approaches for mechanistic studies. A novel rat model of RTT was generated 
recently, which is ideal for the studies of cellular mechanisms for the breathing disorders. We 
thus performed studies in the rats focusing on several representative RTT phenotypes, including 
motor dysfunction, defects in social behaviors, breathing abnormalities and brainstem neuronal 
excitability. 
Specific Aim 2: Hyperexcitability of medullary respiratory neurons is responsible for 
breathing abnormalities in Mecp2 disrupted rats.  
Breathing abnormalities are contributing to the high incidence (26%) of sudden death in 
RTT patients, while the underlying neurobiological mechanisms are still unknown. Using the rat 
model of RTT, we recorded directly from brainstem respiratory neurons in vivo, and showed how 
the Mecp2 disruption affected neuronal excitabilities, discharge patterns, as well as cellular 
grouping, how these changes were closely associated with abnormal phrenic nerve discharges, 
and how the abnormal respiratory neuronal activity together with breathing disorders responded 
to pharmacologic agents. 
Specific Aim 3: miRNA as a genetic mechanism targets the SUR2B subunit of rat vascular 
KATP channel.  
Cardiovascular diseases are the major causes of deaths world-wide. Excitability of 
vascular smooth muscle cells (VSMCs) determines the vascular tone, blood pressure and 
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regional blood flow, while a critical regulator of VSMC excitability, the ATP-sensitive K+ 
(KATP) channel, is known to be disrupted in diabetic conditions. Thus, we screened the 
expression levels of potential microRNAs (miRNAs) targeting on the KATP channel in rat 
VSMCs treated with diabetic metabolites, and investigated the functional consequences. 
Specific Aim 4: Optogenetic intervention manipulates the vascular smooth muscle 
excitability and the consequent vasoconstriction.  
Currently, studies of the cardiovascular system heavily rely on pharmacological 
strategies. The emerging optogenetics technique provides an alternative approach to the 
cardiovascular system. By expressing exogenous rhodopsin genes, cells can be selectively 
inhibited or excited with lights. Therefore, we generated a novel mouse strain allowing real-time 
manipulation of membrane excitability of VSMCs, and studied vascular tones by optical 
activation in a temporally and spatially specific manner. 
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2 INTRODUCTION 
2.1 Cellular and molecular basis of autonomic function 
Autonomic nervous system (ANS) controls involuntary and visceral functions and 
systems such as respiration, cardiovascular system, gastrointestinal (GI) tract, genitourinary 
system, pupillary response, sweating and certain reflex actions such as swallowing, vomiting, 
coughing and sneezing. It is also called vegetative nervous system. The control center of ANS is 
located in the hypothalamus and the brainstem, which act as integrators of sensory inputs and 
higher levels of central nerve system (CNS). Neurons from these areas project to motoneurons 
located in the brainstem and spinal cord. The motor outputs can be involuntary and voluntary 
(see Section 2.2). Involuntary functions are carried out by the conventional ANS consisting of 
the sympathetic nervous system, the parasympathetic nervous system and the enteric nervous 
system (also called metasympathetic system) 1. The sympathetic nervous system with central 
nervous connections in the thoracic and lumbar segments (T1 to L2-3) of the spinal cord is often 
called the “fight or flight” system which is a physiological reaction that responses to a sudden 
event. The parasympathetic nervous system with the cranial connections and connections in the 
sacral segments (S2-S4) is considered as the “rest and digest” or “feed and breed” system which 
responses to stimulate activities related to digestion, salivation, urination, lacrimation and sexual 
arousal. The enteric nervous system is the intrinsic nervous system in the GI system.  
The major divisions of the ANS include sympathetic and parasympathetic nervous 
systems which have a complementary functions to each other. In many cases, the sympathetic 
and parasympathetic nervous systems work in opposition to each other, even though they 
sometimes complement each other. Many of the tissues are innervated by both systems. The 
activation of sympathetic nervous system dilates the bronchioles of the lung for better oxygen 
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exchange, triggers vasoconstriction tract to divert blood flow away from skin and GI tract (non-
essential organs) to skeletal muscles and lungs, increases heart rate and the contractility of 
cardiomyocytes, relaxes the ciliary muscle to dilate the pupils, provides vasodilation in coronary 
vessels and inhibits peristalsis. These changes make body able to take the “fight or flight” 
responses. In contrast, the activation of parasympathetic system constricts the bronchioles to 
diminish the oxygen exchange, dilates blood vessels in GI tract to help digestion, reduces heart 
rate, contracts the ciliary muscles to constrict the pupils, accelerates peristalsis and stimulates 
saliva secretion. Generally, one system prepares the body for emergency situations, and another 
controls body processes during ordinary situations. The functions of the ANS in effector organs 
rely on the anatomic distribution of the sympathetic and parasympathetic nervous systems, the 
types of the ganglionic fibers and the expression of the neurotransmission receptors in target 
organs. 
Both sympathetic and parasympathetic efferent pathways have two neurons before 
reaching the target tissues and organs. The preganglionic neurons form synapse onto the 
ganglionic neurons. Sympathetic ganglia are located adjacent to the spinal cord, then the 
ganglionic fibers run from the ganglia to the effector organs. The preganglionic fibers in the 
parasympathetic system exiting from brain and sacral spinal cord exchange neurons in the 
ganglia located within the effector organs. The preganglionic nerves of both systems release 
acetylcholine (ACh) activating nicotinic ACh receptors on the postsynaptic ganglionic cells. The 
ganglionic cells release norepinephrine (NE) to target organs acting on adrenergic receptors in 
sympathetic system, while ACh is the neurotransmitter released from ganglionic cells to internal 
organs acting on muscarinic receptors in parasympathetic system.  
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There are exceptions in neurotransmission of sympathetic system. The adrenal medulla is 
directly stimulated by ACh released from preganglionic neurons of sympathetic division, acting 
on nicotinic ACh receptors. Working as the principal site to release catecholamines, stimulation 
of adrenal medulla secretes NE and epinephrine (EPI) directly into the bloodstream, which 
quickly triggers a widespread sympathetic activity 2. Sweat secretion controlled by the ANS is 
another exception. Efferent innervation to sweat glands is from preganglionic sympathetic 
neurons of which ACh mediates the sweat gland secretion. On the other hand, sweating is also 
mediated by the release of catecholamines, NE and EPI, from the adrenal medulla 3. In addition, 
renal blood vessels are mediated by dopamine released in the kidney from sympathetic nerve 
terminals 4. 
In the effector organs, NE released from sympathetic ganglionic cells and other 
catecholamines, such as EPI and dopamine, acts on adrenoceptors, a class of G protein-coupled 
receptors (FPCRs). There are two major groups of adrenoceptors, α and β. Each of them has 
several subtypes. Activation of α1 receptor coupling to Gαq protein results in increase of 
intracellular Ca2+ though phospholipase C (PLC) pathway. The activation of α2 receptor coupling 
to Gαi protein has an inhibitory effect on adenylate cyclase (AC) from generating cyclic 
adenosine monophosphate (cAMP) from cytosolic adenosine triphosphate (ATP), then inhibiting 
the downstream protein kinase A (PKA) signals. The β receptor has three subtypes, β1, β2 and β3, 
which are linked to Gs proteins with AC pathway. The β2 receptor also couples to Gi proteins 5.  
These receptors play different roles in different organs and tissues. The main function of 
α receptors that are broadly expressed on most cells is vasoconstriction 6. The α1 receptors are 
expressed in most of the organs, including heart, blood vessels, brain, liver, prostate, kidney and 
spleen, in which they function in regulation of the cardiac inotropy and chronotropy, 
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vasoconstriction, neurotransmission and metabolism 7. The α2 receptors also mediate responses 
to their ligands in central nervous system and peripheral tissues, such as heart, blood vessels, 
pancreas, adipose tissues and platelets 8,9. Besides the general functions of the α receptors, the α2 
receptors have a negative feedback effect on mediation of synaptic transmitter, inhibiting insulin-
release and inducing glucagon release from pancreas, inhibiting lipolysis in fat cells and 
promoting thrombocyte aggregation 10. The β1 receptors are majorly expressed in heart, whose 
activation has positive chronotropic and inotropic effects. Their activation increases the secretion 
of renin in kidney and ghrelin in stomach as well 11. The activation of β2 receptors has minor 
cardiac effect compared to β1 receptors. In addition, their activation promotes vascular and 
nonvascular smooth muscle relaxation, dilation of bronchiole, lipolysis in fat tissue, insulin 
release, glycogenolysis and gluconeogenesis and renin secretion in kidney. The β3 receptors 
mainly exist in adipose tissues, in which their activation enhances the lipolysis 12.  
The release of ACh from parasympathetic ganglionic fibers triggers the activation of the 
muscarinic (M) cholinergic receptors in effector organs. There are five subtypes of M receptors 
whose activation is through binding to G proteins 13. M1, M3 and M5 activate the PLC pathway 
through Gq. M1 receptor is common in CNS and exocrine glands, whose activation facilitates the 
transmitter or hormone release. It is predominantly bound to Gq proteins upregulating PLC and 
consequent increasing intracellular Ca2+. In certain tissues, activation of M1 receptors can also 
activate Gi and Gs pathway. The M3 receptors coupled to Gq proteins are expressed in many 
tissues and organs, such as smooth muscles in lung, endothelial cells in vessels and the endocrine 
and exocrine glands, in which their activation leads to bronchoconstriction, vasodilation, and 
gland secretion respectively. M3 and M5 are also found in the brain, but in low abundance. The 
inhibitory M2 and M4 receptors act via Gi proteins. They modulate several types of ion channels, 
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thus regulating the activities of the neurons in CNS 14. In addition, the M2 receptors act to slow 
down the heart rate and reduce the contractile forces of cardiomyocyte as well as the conduction 
velocity of atrioventricular (AV) node. The M4 receptors are one of the predominant muscarinic 
ACh receptors expressed in the CNS 14. Activation of M4 inhibits the ACh released in brain. 
In summary, the ANS regulates many critical body processes, such as blood pressure, 
heart contraction and breathing. Disorders of this system can lead to severe health problems 
affecting many body parts due to its wide range of coverage. Some can be acute and life-
threatening, others are progressive and reversible. This thesis will focus on the autonomic 
functions and dysfunctions in cardiovascular and respiratory systems, top two systems that are 
closely linked to our health. 
2.2 Autonomic regulation of respiration 
Breathing is a special automatic function as its activity can be voluntary and involuntary. 
An adult human breathes about 20 times per minutes, while the breathing rate in an adult mouse 
can be up to 200/min. Breathing allows inhalation of O2 and exhalation of the CO2. In addition, 
the respiratory system plays a role in speaking, singing, eating, drinking, body postures，
defecation, childbirth, body temperature regulation, pH regulation, etc.  
2.2.1 Respiratory rhythm generation and modulation  
2.2.1.1 Respiratory centers 
Breathing is a complex motor act, the control of which engages widespread parts of the 
central nervous system. The breathing controlling centers are located in brainstem, specifically 
medulla oblongata and pons. There are two medullary respiratory centers, dorsal respiratory 
group (DRG) and ventral respiratory group (VRG), and two pontine respiratory centers, 
apneustic center and pneumotaxic center. All the respiratory centers are located bilaterally in the 
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brainstem. These respiratory groups function in an integrated manner, precisely controlling the 
breathing rate and ventilation depth to accommodate the sufficient oxygen supply to the body. 
In the medulla, the DRG contains mainly inspiratory neurons, whereas the VRG contains 
both expiratory and inspiratory neurons. The DRG is located in the nucleus tractus solitarius 
(NTS) within periaqueductal gray (PG), sending signals to the motor neurons of external 
intercostal muscles and diaphragm. In addition, the DRG receive sensory impulses through vagus 
and glossopharyngeal nerves from upper and lower airways, peripheral chemoreceptors and joint 
proprioceptors 15,16. Neurons in DRG are stimulated by the impulse from the apneustic center, 
and are inhibited by the signal from the pneumotaxic center. The VRG is located around nucleus 
ambiguus (NA) in rostral retrofacial nucleus area (expiratory Bötzinger complex (BötC), pre-
Bötzinger complex (preBötC) (inspiratory), nucleus paraambiguus area (inspiratory rostral VRG 
(rVRG) and nucleus retroambiguus area (expiratory caudal VRG (cVRG) 17-20.  The VRG is 
considered as one ventral respiratory column (VRC) in some cases. The inspiratory VRG 
neurons transmit impulses to the laryngeal and pharyngeal muscles through vagus nerve and to 
diaphragm and external intercostal muscles through their motor nerves. Whereas, the expiratory 
impulses from cVRG are sent to abdominal and internal intercostal muscles. The most rostral 
group of the VRG, BötC, also fires an expiratory pattern, which is mainly thought as an 
inhibitory nucleus sending signals to inhibit VRG and DRG impulses 21-23.  
The pontine respiratory groups are involved in controlling the rhythmic breathing pattern 
as well. The pneumotaxic centers are identified in the dorsolateral pons, caudal to the inferior 
colliculus in most of species, while the apneustic center is thought in central area of the lower 
pons without anatomical certainty. The names of “apneustic” and “pneumotaxic” are inspired by 
the transection experiments observing the breathing patterns 24,25. The absence of the rostral pons 
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(cut both vagus nerves and pneumotaxic center) produces the prolonged inspiratory gasps 
interrupted by occasional expirations (apneusis). Transections at the pontomedullary junction 
result in gasping and irregular breathing. The pneumotaxic centers contain medial parabrachial 
nucleus (mPB) and Kolliker-Fuse nucleus (K-F) 26. They play an important role in rhythmic 
generation, respiratory phase switch and modulation of respiratory reflex. There are inspiratory 
and expiratory cells as well as phase-spanning cells in pneumotaxic centers. Although the 
interactions between the pneumotaxic and apneustic centers are still poorly understood, the 
pneumotaxic centers are considered to limit the inspiration and increase the respiratory rate via 
sending inhibitory impulses to medullary inspiratory neurons, acting as an antagonist to the 
apneustic center 27. In contrast, apneustic center causes switch-off failure of DRG inspiratory 
neurons and consequent larger tidal volumes if pneumotaxic signals are severed. The existence 
and the function of the apneustic center can only be demonstrated only if its connection to 
pneumotaxic centers are interrupted and the vagus nerves are cut. 
Therefore, the general function of the medullary respiratory centers is to produce the 
basic inspiration and expiration, while the pontine respiratory centers are in charge of modulating 
the breathing pattern.  
2.2.1.2 Respiratory phases  
The eupneic respiration can be commonly divided into three phases: inspiration (I), post-
inspiration (post-I) or “passive” stage 1 expiration (E1) and “active” stage 2 expiration (E2) 28,29. 
Some studies further divided inspiratory phase into three subtypes 30. The inspiratory premotor 
neurons start a sudden onset and increases gradually at the end of the expiration probably due to 
a retreat of inhibitory signals on them, leading to a progressive contraction of inspiratory 
muscles. This ramp pattern makes the inflation of the lungs smooth. As the inspiratory ramp 
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signal strengthens, the off-switch mechanisms are recruited and finally strong enough to switch 
off inspiratory signals. The subsequent termination of inspiration is followed by post-I or E1 
stage during which some inspiratory muscles are being activated again while the expiratory 
motor activity is not facilitated yet 31. The post-I activity exhibits an initial maximum and a 
gradual decline in inspiratory promotor activity. Expiratory motor activity is recruited only in E2 
phase when the ventilation needs are increased, especially during exercise31. During exercise, 
when the quick and frequent gas exchange is required, various peripheral reflexes and receptors 
are involved to influence the medullary respiratory neurons, steepening the inspiratory ramp 
signal and making inhalation faster. 
2.2.1.3 Central pattern generators (CPG) of respiration 
The exact origin of the breathing rhythm and the interplay of the inspiratory and 
expiratory neurons in respiratory centers still need to be unveiled in neuroscience. Currently, 
there are two predominant theories of respiratory rhythm generation. One classical theory 
suggests that the rhythmic breathing is the results of reciprocal inhibition between the pools of 
inspiratory and expiratory neurons in medulla 32. However, this theory seams untenable with 
cumulated evidence 28,30,33,34. The rhythmogenesis theory is the dominant concept currently. This 
theory proposes that certain medullary neurons have intrinsic pacemaker properties. And 
rhythmic breathing is the consequence of the neuronal interactions between independent 
oscillatory neuronal networks. The three basic respiratory phases are generated by anatomically 
distinct rhythm-generating networks. The preBötC is the undisputed generator of inspiration (I) 
18,35,36. The retrotrapezoid nucleus/parafacial nucleus (RTN/pFRG) is the widely accepted site for 
the generation of active expiration (E2). Recently, a special excitatory group of cell around BötC, 
the post inspiratory complex (PiCo), has been described responsible for post-I (E1).  
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The preBötC is considered both sufficient and necessary for the generation of inspiratory 
motor output. No matter in in vivo rat brain stem transection preparation 37, in in-situ heart-
brainstem preparation 36, or in in-vitro rodent slice preparations 18, the preBötC has been 
confirmed able to generate rhythmic inspiratory breathing patterns. There are about 5-25% of the 
preBötC inspiratory cells exhibit bursting pacemaker properties. In addition, targeting lesioning 
of the preBötC neurons by neurotoxin in intact adult rats leads to the disturbed breathing with 
ataxic breathing and even apneas 38,39. Its “pacemaker” bursts is associated with the persistent 
Na+ current (INaP) and the Ca
2+-activated nonspecific cation current (ICAN) in the preBötC 
36,40,41. 
But these currents are not unique in preBötC neurons. One view believes that the preBötC starts 
the timing signals which are broadcast to the rest of the network transforming these timing 
signals into appropriate motor patterns 33. Breathing rhythm may be initiated by special group of 
glutamatergic pacemaker neurons within the preBötC without requirement of conventional 
postsynaptic inhibition on phase transitions 42-44. But this does not appear to be the case, because 
of the existence of the distinct oscillatory populations for both inspiration and expiration. 
Therefore, how the rhythm is originated in preBötC is still elusive. Rhythmicity may need 
bursting pacemaker neurons, and reciprocal inhibition and excitatory synaptic transmission. 
RTN/pFRG as the likely location of the central pattern generation for active expiration is 
proposed recently. The pFRG overlaps with RTN anatomically, whose activation is observed 
prior to the onset of inspiration 45. RTN is a site for central chemoreception for H+ and CO2 
46,47. 
These two groups are usually referred to as the RTN/pFRG located ventral to the facial nucleus 
and rostral to the BötC. The non-chemosensitive function of the RTN/pFRG is identified through 
transection of the brainstem just caudal to it, after which the active expiration is abolished 
without much effect on inspiratory phase 37. In addition, the brainstem-spinal cord preparation 
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containing the RTN/pFRG but conditionally muting the rhythm of the preBötC with opioid 
inhibition adds another piece of evidence for the RTN/pFRG as a conditional oscillator of active 
expiration 48. Furthermore, the stimulation of the RTN/pFRG transforms a resting breathing 
pattern without active expiration into an active expiration pattern with tonic activity of 
abdominal muscles in E2 phase 
49. Therefore, the RTN/pFRG is defined as an independent but 
conditional oscillator of active expiration. 
There is still debate on the generator controlling the post-I phase of breathing. The 
glutamatergic PiCo located dorsal and caudal to the facial nucleus is recently identified as the 
putative site for post-I generation 50. It is believed that its oscillatory activity is independent of 
inspiratory activity, but receives dominate GABAergic modulation over the concurrent 
glutamatergic excitation from the preBötC. Post-I activity may have mutually inhibitory 
relationship with inspiratory activity. In addition, the PiCo rhythm could be modulated by 
cholinergic mechanisms as well. Other researchers suggest that the site gating post-I activity is 
located in the pons instead of the medulla 36. Pontomedullary transection at various levels of the 
facial nucleus in rat transforms the normal three-phase respiratory pattern to a two-phase pattern 
making post-I activity missing in respiratory cells in VRG area. In pons, the K-F in the 
pneumotaxic centers is the nucleus hypothesized gating post-I phase 51. It seems like the post-I 
may not be generated by a single oscillatory network. Because the post-I activity in crural 
diaphragm can be abolished via stimulation of the midbrain PG 52. 
2.2.1.4 Respiratory neuronal circuits 
The underlying neural machinery is an integration of the physiology and the behavior, 
and a quite complicated process. Current view about the brainstem circuits of respiratory 
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generation and control is that the respiratory neurons in VRC interact within VRC as well as 
interconnected with several pontine nuclei. 
Even though original concept of the respiratory circuits that the inspiration-expiration 
cycle is generated by the reciprocal inhibition of two groups of interneurons is not rigorously 
tested, the role of inhibitory neurons in the respiratory circuits cannot be underestimated. It is 
believed that the BötC and preBötC are the major components of the VRC generating respiratory 
patterns in rhythmogenic circuits. BötC is the population proposed playing important inhibitory 
role. In BötC, over 50% neurons are inhibitory, mostly glycinergic, some GABAergic 53. A 
hypothesis proposes an “inhibitory ring” model taking preBötC as the center of timing signals 
with reciprocal inhibition between the preBötC and other respiratory centers, such as BötC, 
producing the three-phase breathing pattern 54. In this model, the kernel reciprocal inhibitory 
connectivities include direct inhibitory connection or connection through inhibitory interneurons 
between early-inspiratory (early-I) neurons in preBötC and post-I neurons in BötC, and the 
inhibitory connection between these inhibitory neurons and the neurons such as pre-
inspiratory/inspiratory (pre-I/I) excitatory neurons in preBötC and augmenting expiratory (E2) 
neurons in BötC. The latter connection allows the coordination of I and post-I activities. In some 
studies, the kernel reciprocal “inhibitory ring” is composed of early-I, post-I and E2 neurons 55.  
The excitatory neuronal circuits between respiratory components are not very clear. 
Neurons within the compartments in VRC, including BötC, pre-BötC, rVRG and cVRG, are 
proposed to receive drives from the pontine respiratory groups, medullary DRG and other 
respiratory related medullary nuclei. It is believed that most of these drives are tonic, phasic or 
rhythmic excitatory inputs 55. Furthermore, the two neuron groups in rVRG and cVRG are 
mainly premotor neurons. The excitatory kernel of the respiratory network, the pre-I/I neurons in 
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pre-BötC, projects to different cranial premotor neurons (the promotor neurons of vagus and 
hypoglossal motor neurons) and to excitatory inspiratory premotor neurons in rVRG (the 
promotor neurons of phrenic motor neurons). The projection to abdominal and thoracic 
expiratory motor neurons in spinal cord is from excitatory expiratory premotor neurons in cVRG. 
Spinal cord contains the interneuronal circuits controlling respiratory motor activities as well. 
Although the work of understanding how respiration is generated is far from complete, 
there have some evidences suggesting the interaction between the main rhythmic generators. 
Some progress has been made. There are some evidence supporting the interaction between the 
preBötC and the RTN/pFRG. In postnatal stage, animal experiments suggest the RTN/pFRG 
provide only excitatory drive to the preBötC, while the preBötC provides both expiratory and 
inhibitory influences on RTN/pFRG neurons 34,56.  As mentioned above, the RTN/pFRG is 
conditionally activated to generate active expiratory activity. Thus the preBötC is probably as the 
source of excitation simultaneously required for the activation of E2 network. In addition, the 
interaction between the preBötC and the potential post-I generator, PiCo, is proposed recently 50. 
When GABAA receptor antagonist is applied to the horizontal slice retaining the connection 
between the preBötC and PiCo, their firing discharges are progressively synchronize in I phase. 
This suggests that inhibitory connection between the preBötC and PiCo helps in coordinating the 
phasing and timing of the breathing rhythms. A concurrent excitatory input of preBötC onto 
PiCo could be unmasked after blocking the inhibitory influence from the preBötC onto PiCo. 
Together, under normal conditions, inhibitory input dominants over the excitatory input from the 
preBötC onto PiCo. Even though the great progress has been achieved on the studies of the 
neuronal control of respiration, our understanding of the underlying mechanisms is still limited. 
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Further studies are imperative to fully elucidate the mechanisms of respiratory rhythmogenesis 
and the oscillatory networks.  
2.2.1.5 Modulation of neuronal excitability  
The medullary respiratory centers, especially VRG, contain both excitatory and inhibitory 
respiratory neurons. The dominant excitatory neurons in the ventrolateral medulla are 
glutamatergic, and the inhibitory neurons are mostly glycinergic 33. Glutamate is the essential 
excitatory neurotransmitter for rhythmogenesis in preBötC, while the role of glycine is in 
shaping the respirator pattern instead 57. Excitatory preBötC pacemaker neurons are necessary 
for rhythmogenesis, and the inhibitory pacemaker neurons also exist. It should be mentioned that 
not all pacemaker neurons are obligatory for rhythmogenesis 58-60. Instead, they could play a 
modulatory or stabilizing role in rhythm generation. In the preBötC, about half of the neurons are 
glycinergic, of which one quarter are with inspiratory pacemaker properties 61. The GABAergic 
neurons are also identified in this area, and some of them are also with inspiratory pattern 62. 
These inhibitory neurotransmissions within preBötC area, possible including BötC, slow down 
the rhythm without inducing apnea 57, suggesting the postsynaptic inhibition in this area is not 
essential for the respiratory pattern generation, but is important for the respiratory rhythmic 
modulation. The rVRG and cVRG also use glycine as the primary neurotransmitter for the phasic 
inhibition of the respiratory network 63.  
Many pain-relieving drugs, such as opioids, barbiturates and benzodiazepines, can lead to 
suppressing of breathing via effecting on neurons in the preBötC 64,65. The use of opioid 
analgesic drugs can cause a reduction in sympathetic nervous system tone, respiratory depression 
and analgesia. By local manipulation, the neurokinin-1 receptor-expressing preBötC is reported 
most sensitive to opioids and fully responsible for respiratory depression even fatal apnea in rats 
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64. This opioid-induced respiratory depression is likely through µ-opioid receptors on NK1R-
expressing preBötC neurons, and can be reversed by serotonin agonists without loose of 
analgesia effect 65-67. The averting effect against opioid-induced breathing cessation is possible 
via serotonin receptors in glycinergic preBötC neurons 67.  
 CNS depressant drugs, such as ethanol, benzodiazepines, barbiturates, γ-hydroxybutyric 
acid, and other sedatives also produce respiratory depression when they are overdosed or used in 
combination. A lot of them work as agonists on the GABA receptors in the mammalian brain. 
For example, benzodiazepines controls the excitability of neurons by binding to the GABAA 
receptor. And barbiturates are relatively nonselective ligands binding to many ligand-gated ion 
channels, including GABAA receptor, glycine receptor, 5-HT3 receptor and nicotinic ACh 
receptor. γ-hydroxybutyric acid could have weak agonist effect on the GABAA receptor when 
reaching high concentration in brain. Acting by enhancing the activities of the inhibitory 
neurotransmitters in respiratory networks may be the mechanisms of breathing depression. 
Therefore, it is necessary to consider the possible respiratory depression for safe medication.  
2.2.2 Rett syndrome 
Because of breathing abnormalities, researchers who are interested in the central 
respiratory function and dysfunction are trying to understand the neuronal mechanisms that 
affect breathing in Rett syndrome (RTT). Although transgenic animal models benefit the studies, 
it remains unclear how the respiratory disturbances occur. 
2.2.2.1 Overview 
RTT is a neurodevelopmental disorder caused mainly by single gene mutations in the 
MECP2 gene on X chromosome encoding the transcription factor methy-CpG-binding protein 2 
(MeCP2) 68. It predominantly affect baby girls with ~ 0.01% morbidity rate worldwide. In the 
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rare case, boys inherit mutations in MECP2. Although MeCP2 is expressed in most tissues, its 
disruption results primarily in neurological symptoms. Normally, the patients develop symptoms 
starting from 6 months of age, and gradually deteriorate the conditions. The symptoms of RTT 
including mental and growth retardation, loss of acquired purposeful hand skills and spoken 
language, autism-like behaviors, walking or gait abnormalities, repetitive stereotypic hand 
movements, and severe breathing disturbances. The severe breathing disorders of RTT usually 
end up with the high incidence of sudden infant death syndrome (SIDS) which kills about 6 in 
1,000 infants younger than 1 year old 58. Unfortunately, there is no cure for RTT at present. 
2.2.2.2 Symptoms of RTT  
RTT is found almost exclusively in girls who are normally heterozygous carrying a 
mutation in MECP2 gene. The lack of extra X chromosome copy makes the boys with mutant 
MECP2 often die before or shortly after birth.  The disease is featured by the random X-
chromosome inactivation (XCI), which means half of the cells have inactivated the mutated X 
chromosome bearing the mutant MECP2 allele. The RTT patients are chimeras for both mutant 
and wide-type cells. As a neurodevelopmental disease, RTT is predominantly affect the brain 
because MeCP2 is mainly expressed in differentiated neurons with highest expression level in 
the more mature neurons 69. 
RTT symptoms progress in four stages 70. The early onset period usually begins when the 
patient is 6 to 18 months old. During this stage, the symptoms are slight and may not be 
noticeable. They could only have delayed skills, such as speaking, sitting and crawling, and loss 
of attention and interest in things. The stereotypic movement and deceleration of the head growth 
appear at this stage. Stage II happens between 1 to 4 years old. Patients exhibit the rapid 
regression of development, losing expressive language and acquired hand skills. Microcephaly is 
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noticeable at this stage. Breathing irregularities, such as episodes of apnea and hyperventilation, 
may occur. Some girls also display abnormal motor and autism-like behaviors. These behavior 
abnormalities become severe at stage III which begins between 2 to 10 years old and last for 
years. Seizures and apraxia often occur during this stage. The last stage may last for years even 
decades. Patients usually suffer from motor and social dysfunctions, anxiety, seizures and life-
threatening breathing disorders. Their phenotype varies among individuals, and some RTT girls 
have shorter lifespan. 
Breathing disturbances are the major problem in RTT. The patients exhibit alternation of 
hypoventilation and irregular hyperventilation 71. The periods of forced breathing, shallow 
breathing, Valsalva’s maneuvers, Biot’s breathing, air swallowing, breath holding and central 
and obstructive apnea 72,73, as well as abnormalities of cardiorespiratory integration 74, are 
observed on RTT patients. These breathing disturbances are reported more apparent during day 
time, but also occurs during sleep 71,73.  
2.2.2.3 RTT mice and rat models 
MeCP2 as a transcriptional repressor binds to methylated DNA and interacts with 
repressor complexes, eventually reducing the target gene transcription. The mutation of gene 
MECP2 is the main cause of RTT clinically. The transgenic mouse and rat models were 
established as tools for studies of RTT. The mouse models of RTT display many of the RTT-like 
symptoms. They are viable and appear relatively healthy at birth and gradually gain featured 
characteristics, such as malocclusion, hindlimb clasping, small body size, and behavior disorders.   
A variety of mouse models were used in the RTT study, in which functional deletion of 
exon 3 and/or 4 in Mecp2 gene is the main strategy of the generation of the RTT models 75-77. 
Other RTT murine models include the ones with site-specific mutations 78-80. Although the 
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genetic background of mouse RTT models varies, these autonomic phenotypes of 
cardiorespiratory dysregulation are also observed in mice with Mecp2 disruption 81-84. On Mecp2 
defect mice, high breathing variation and apnea rate are usually seen starting at ~3 weeks and 
deteriorate with time. The long lasting breath holding often occur when the animal is dying. 
Hyperventilation is also common in mouse models. Since Mecp2−/− female animals cannot be 
produced as the Mecp2−/Y males are infertile, the studies of RTT are performed with Mecp2−/+ 
female and Mecp2−/Y male animals. The hemizygous null male mice begin to display RTT-like 
phenotypes, including autism-like behaviors and motor dysfunction, at postnatal 4 weeks with an 
average survival age of ~8 weeks 75,77. The severe breathing problem is observed as early as 
postnatal 3 weeks. The studies on heterozygous Mecp2−/+ female mice are necessary. XCI makes 
the incidence relatively low in females, because half of the cells have inactivated the X 
chromosome carrying mutant Mecp2 allele. The Skewed XCI which favors the expression of the 
intact wide-type X chromosome makes the symptomized female animals even less with 
heterozygous Mecp2−/+ background 85,86. The female Mecp2−/+ mice have a late symptom onset at 
~4 to 6 months old. Some of the phenotypes can be detected earlier, such as apneic breathing 
difficulties 87. The severity of the symptoms is not as much as null male mice because of the 
potential phenotypic variability. This can also be explained by mosaic expression of the Mecp2 
mutation due to XCI.  
Since multiple animal models are required for RTT studies. Recently, a novel MeCP2 
knockout rat model has been developed by Sage Labs 84,88,89. The Mecp2-null rat has 71 bp 
deletion on exon 4 in the Mecp2 leading to complete elimination of the MeCP2 protein in male 
rats. The null male rats show RTT-like symptoms as early as ~4 weeks of age, which are 
comparable to that in the mouse models. Whereas the Mecp2−/+ female rats display motor 
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behavior and breathing abnormalities later in development. More detailed phenotypes of this rat 
model will be described in the results section. The large body size and the rich behaviors of rats 
provides profound advantages in the studies of disease mechanisms of RTT and towards the 
development of potential therapeutics. 
2.2.2.4 Dysfunction in neurotransmitter and neuromodulator systems of Mecp2-null mice 
The studies on mouse models of RTT as good tools to uncover the underlying neurologic 
mechanism of the ANS dysregulation. It is reported that the neurologic defects resulting from 
abnormal patterns of neurotransmitter and neuromodulator expression throughout the brainstem 
respiratory network are contribute to respiratory dysfunctions in Mecp2 disrupted mice. The 
defects in neurochemical signaling include brain-derived neurotrophic factor (BDNF), biogenic 
amine, glutamate and GABA.  
BDNF is a member of the neurotrophin family of growth factors, involved in neuronal 
survival, differentiation, maturation and synapse plasticity. MeCP2 is reported acting as 
transcriptional repressor of BDNF. BDNF signaling is impaired leading to disturbed Ca2+ 
transients in Mecp2-null neurons within preBötC 90, which is an important process during 
neuronal remodeling during development. Therefore, the disturbance of Ca2+ homeostasis caused 
by inhibited BDNF signaling in RTT mouse models possibly facilitates the morphology changes 
responsible for breathing irregularities in Mecp2-null mice. Other respiratory controlling centers, 
such as K-F, BötC and nucleus NTS may be modulated by abnormal BDNF signaling as well 91-
93, if the Mecp2 is disrupted.  
Serotonin system is reported disturbed by Mecp2 mutation, and median survival rate 
increased by augmenting this inhibitory system using serotonin 1a agonist 94. Serotonin reuptake 
inhibitor treatment helpes improve CO2 chemosensitivity in Mecp2 knockout mice as well 
95. NE 
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involves in modulating the activity of the preBötC, which is significantly reduced in CNS 96-98. 
About 90% of the NE is release from locus coeruleus (LC) in CNS. And hyperexcitability of LC 
neurons as a compensatory mechanism of making up the defect of certain neurotransmitter is 
reported in Mecp2 defect mice 98. Enhancing the NE content by desipramine, an NE reuptake 
blocker, alleviates the respiratory disorders in Mecp2-null mice 99,100. 
Dysfunction in glutamatergic and GABAergic systems is identified in many brain regions 
of Mecp2 KO mice 83,101-103. Studies conducted in both RTT patients and animal models suggest 
increased expression of N-methyl-D-aspartate receptors (NMDARs), and the synaptic 
hyperexcitability can be reversed by NMDA receptor antagonist or conditional deletion of 
NMDAR subunit 104,105. Genetic deletion of the NMDAR subunit, GluN2A, is able to prevent 
some RTT phenotypes, such as regression of vision 105. On another hand, a decrease of the 
inhibitory neurotransmitter GABA is found in many brain regions including hippocampus, 
substantia nigra, cerebellum, and ventrolateral medulla 101,103. Additionally, decreased 
GABAergic inputs is identified in LC whose malfunction could lead to the autonomic deficits 
including breathing disorders 96,106. Deficiency of GABAergic synaptic inhibition within K-F 
area also contributes to respiratory rhythm irregularity in a mouse model of RTT 107. 
Furthermore, conditional knockout Mecp2 from forebrain GABA-releasing neurons reduces the 
inhibitory GABA neurotransmission and recapitulates many RTT-like behaviors in mice 
including severe respiratory irregularity 108. To sum, defect of MeCP2 protein seems to be 
associated with inhibitory and excitatory imbalance. Experimental evidences support that the 
imbalanced excitation and inhibition in CNS plays an important role attributing to RTT-like 
symptom including breathing abnormality 101,109,110.  
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2.2.2.5 Dysfunction in central respiratory network of Mecp2-null mice 
Besides synaptic signaling imbalance, mice studies of RTT also suggest the responses to 
hypercapnia are impaired by Mecp2 disruption 111. Mecp2-null mice lose sensitivity to mild 
hypercapnia (1-3% CO2), while the one to high CO2 level (6-9% CO2) is intact. This affected 
chemosensibility is contributed by the overexpression of the Kir4.1 subunit of the neuronal pH-
sensitive potassium channels leading to the reduction of the pH sensitivity of the Kir4.1-Kir5.1 
channels. This does not allow CO2 to be detected by the chemosensitive site in CNS until 
hypercapnia becomes really severe, contributing to alternation of hyperventilation and 
hypoventilation in Mecp2-null mice. Furthermore, the restoration of MeCP2 in medulla 
containing preBötC, the I phase generator, restores a normal hypoxic respiratory response 82. 
Some studies attributed the respiratory disorders such as apneas, air swallowing and 
periodic breathing to obvious prolonged and enhanced post-inspiratory (post-I) which may due to 
hyperexcitation of the pontine post-I oscillator, K-F nucleus 94,110. The dysregulation of post-I 
activity may contribute to the central apneas caused by failed inspiration initiation in Mecp2-null 
mice. Additional evidences support this ideal. At ~2 postnatal months, the deteriorated breathing 
disorders found on Mecp2-null mice are characterized by reduced breathing frequency 112 which 
is highly possible due to elongated expiration phase or apnea, because the inspiratory phase is 
not reported elongated obviously 73,110. Dysfunction of K-F in mutants may also contribute to 
obstructive apnea due to a poor coordination of glottal closure during swallowing which is a 
common feature of RTT 94. Therefore, the impaired expiratory activity raises the possibility that 
the apneas and upper airway problems in RTT may be caused by increased excitatory input to 
expiratory neurons and/or decreased excitatory input to inspiratory neurons. 
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2.2.2.6 Potential therapeutical strategies  
The inhibitory and excitatory imbalance might be a common feature of RTT. 
Accumulating evidences supports this. Some RTT patients are suffering from recurrent seizures 
113-116, which may due to the defect of GABAergic transmission 117. Additionally, Stereotypic 
hand wringing observed in RTT patients 118, and tremor or striking myoclonic jerk on forelimbs 
and paws observed in mice with truncated MeCP2 protein 119 suggest hyperactivity of the 
cortical neurons. These behavior abnormalities as well as the breathing disruptions mentioned 
above suggest the in RTT patients may due to insufficient inhibitory inputs to the certain brain 
regions. Therefore, one important treatment strategy is targeting on rebalancing the neuronal 
excitation and inhibition by augmentation of the GABAergic system or suppression of the 
glutamatergic system. The GABA reuptake blockers, such as NNC-711 94,107, the extrasynaptic 
GABA receptor agonists, such as THIP 120-122, and the synaptic GABA receptor agonist, such as 
diazepam and L-838,417 94, have been used in the mice studies as the treatment strategies for 
RTT. These treatments can decrease the apnea rate, correct the breathing irregularity, prolong 
survival and alleviate other symptoms. Besides, modulation of glutamate transmission is 
considered as another efficient way to treat RTT. The glutamate NMDA receptor antagonists, 
katamine 105 and memantine 123, also have therapeutic potential to improve the key RTT-like 
phenotypes. These methods targeting on rebalance inhibition and excitation in CNS can shed 
insight into the treatment of RTT. 
In addition, the serotonin 1a receptor agonists, 8-OH-DPAT and F15599 94,124, decreasing 
expiratory neuron activity also reduce apnea and correct irregular breathing pattern. The 
selective serotonin re-uptake blockers which are shown to increase the expression of MeCP2 
proteins could also be a potential therapy 125. Other pharmaceutical intervention includes the 
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interventions to increase the biogenic amine that is also reported decreased with Mecp2 
disruption in RTT mouse models. For instance, an NE reuptake blocker, desipramine, is able to 
alleviate the breathing problems and extend the lifespan in RTT mouse model 99,100. These 
achievements from mouse model build the cornerstone in RTT treatment.   
The clinic or pre-clinic treatments of RTT are difficult. Some clinical trials have been 
conducted but only with minor improvements and questionable side effects.  Currently, a 
preclinical trial is started on the study of the insulin-like growth factor 1 (IGF-1) which shares 
similar signaling pathways with BDNF. IGF-1 is widespread in CNS just like BDNF, but has the 
capability to penetrate the blood-brain barrier (BBB). It is U.S. Food and Drug Administration 
(FDA) approved and currently under clinical trial to test the side effects and the disease 
improvement in RTT 125. Mice Studies show the beneficial effects of IGF-1 to partially reverse 
the RTT-like symptoms 125,126. Similarly, boosting the level of endogenous BNDF by an 
ampakine drug improves the respiratory frequency in RTT mouse model 127. The exogenous 
BNDF application may also benefit the RTT treatment, if the problem of short-life and low BBB 
permeability could be fixed. 
Beside the pharmaceutical intervention mentioned above, genetic strategies are 
challenging but potentially exciting to treat RTT. The cause of RTT is the mutation of MeCP2. 
Working as a transcription factor, MeCP2 activates and represses a large number of target genes. 
The MECP2 mutations shorten the half-life of the MeCP2 proteins. Therefore, a promising way 
to control this disease could be through genetic methods. Two potential therapies are mentioned 
by Chpleau et. al. 125. One way is through stabilizing the expression level of normal MeCP2, 
such as using selective serotonin re-uptake blockers mentioned above to increase MeCP2 
expression thus maintaining the sufficient level of MeCP2 protein. Another potential treatment 
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approach is through taking advantage of XCI. If the mutate allele of MECP2 is turned off and the 
normal one is turned on at the early stage of development, it could markedly reduce the severity 
of the RTT symptoms. 
2.3 Autonomic regulation of cardiovascular system 
2.3.1 Overview  
The cardiovascular system is another critical system controlled by ANS. It is composed 
of the heart, vessels and blood, and controls the blood circulation and transportation of oxygen, 
nutrients, hormones and cellular waste products to target cells in different organs of the body. 
The cardiovascular system plays three major function: homeostasis regulation of the body, cargo 
transportation and protection against pathogens.  
Heart is a hard-working organ of the body. It pumps approximately 5 liters/h of 
circulatory blood throughout the body. The cardiac muscle tissue is known as myocardium which 
is composed of individual cardiomyocytes. These involuntary striated muscles are stimulated by 
the Ca2+ which is stored in the sarcoplasmic reticulum and normally released by stimulation of 
action potentials from cardiac pacemaker cells in the sinoatrial (SA) node. Once one 
cardiomyocyte depolarized, a chain reaction is triggered, in which the electricity flows from one 
cell to another cell via gap junctions of intercalated discs. Intercalated discs secure the 
synchronized contraction of myocardium. The SA node is regulated by the ANS. In general, the 
sympathetic nervous system is attributable to the increased heart rate during exercise, while the 
activation of the parasympathetic nervous system lowers the heart rate.  
Blood vessels allow blood to flow between heart and different regions of the body. There 
are three main types of vessels: arteries, capillaries and veins. All blood vessels are lined with a 
layer of endothelium in the inner layer. The capillary as the smallest blood vessel is only formed 
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by a single layer of endothelium cell. The middle layer consists of elastic fiber, connective tissue 
and vascular smooth muscle, which varies in number depending on the size of the vessels. The 
outer layer is made of connective tissue. In the larger blood vessels, this layer also contains 
innervated nerves and nutrient capillaries.   
An adult human have ~7-liter blood, 5 liters of which is used in circulation, also known 
as the effective circulating volume. It transports numerous substances through the body and helps 
to maintain the homeostasis of gases, water, nutrients, electrolytes and hormones. The contents 
in blood include red blood cells, immune cells platelets and liquid plasma. 
The control of cardiovascular system depends on both local and central mechanisms. 
Blood flow is determined by the integration of the local control via metabolic stimuli, pressure 
changes and tissue resistance, and the central control via the ANS. The heart receives 
innervations from both divisions of ANS. Sympathetic stimulation increases myocardial 
contractility and heart rate as well as induces blood vessel constriction. In contrast, the 
simulation of parasympathetic nervous system decreases heart rate 128.  
2.3.2 Regulation of vascular tone 
Vascular tone which refers to the degree of vasoconstriction and determines the 
resistance of the circulation varies among organs and is determined by a number of dilator and 
constrictor substances and ANS. It is the major determinant of blood flow resistance through the 
circulation. Organs with large vasodilatory capacity usually have high vascular tone, such as 
skeletal muscle, skin, myocardium and splanchnic system 129. Some organs, such as brain and 
kidney, with relatively low vasodilatory capacity in their circulation systems have low vascular 
tone. The neurohumoral factors are primary mechanisms to regulate the blood pressure via 
altering the systemic vascular resistance. 
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Vascular smooth muscle in the middle layer of arteries and veins controls the caliber of 
the vessel, and is innervated primarily by the sympathetic nervous system. The arteriole as the 
major contributor to the peripheral resistance is critical to the regulation of systemic blood 
pressure due to the sympathetic control, while the veins containing less vascular smooth muscle 
receive limited inputs from sympathetic nerves. In contrast, the small vein and capillary lack of 
vascular smooth muscle are not directly innervated by sympathetic nerves. 
2.3.2.1 Regulation by sympathetic nervous system 
The sympathetic nervous system regulated the vascular tone by different stimuli. For 
example, temperature drop, emotional stimuli, exercise activity, hypoglycemia and stimulation of 
baroreceptors can increase sympathetic outflow. In general, the sympathetic nervous system 
regulates the contraction of VSM through adrenergic receptors. And the main endogenous 
agonist for these receptors is NE which is released from the sympathetic vasoconstrictor fiber 
and activates on α1, α2 and β2 adrenergic receptors 130. Since the distribution of α1 receptors is 
greater in the arteries, the activation of sympathetic nervous system leads to the integrated 
vasoconstriction and increases the blood pressure. β2 receptors which show higher affinity for 
EPI can be activated by low level of EPI and leading to vasodilation in vessels 131.  
In vasculature, dopamine can act on dopamine receptors and inhibit the release of NE as a 
vasodilator 132. Its production in the blood stream may be from sympathetic nervous system 4.  
Other neurotransmitters contribute to modulate the vascular tone includes neuropeptide Y (NPY) 
or ATP released from the vascular sympathetic nerve endings 133. These co-transmitters are able 
to increase the intracellular Ca2+ and produce vasoconstrictive effect via NPY Y1 receptors and 
purinergic P2X receptors respectively 
133.  
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Besides, the renin-angiotensin-aldosterone system (RAAS) is believed having a crosstalk 
with sympathetic nervous system. This system is one of the most important regulators of blood 
pressure. The adrenal medulla in RAAS receives sympathetic preganglionic innervation and 
release catecholamines in turn increasing sympathetic tone. Renin can be released from renal 
juxtaglomerular cells into circulation by sympathetic stimulation, and carries out the conversion 
of angiotensinogen released from liver to angiotensin I which is a substance of angiotensin-
converting enzyme (ACE) found in lungs. ACE converts angiotensin I to angiotensin II acting as 
a potent vasoconstrictor that causing blood vessels to narrow 134. Angiotensin II also activates the 
secretion of aldosterone from adrenal gland promoting the reabsorption of Na+ and water and 
excretion of K+. In addition, angiotensin II may act as an endogenous neurotransmitter inside the 
sympathetic coeliac ganglia 135. 
2.3.2.2 K+ channels action in vascular tone regulation 
K+ channels in VSMC play an important role in setting resting membrane potential and 
regulating vascular tones. For example, Ca2+-activated K+ (BK) channels are abundantly 
expressed in VSMCs 136. They are characterized by their large conductance for K+ ions. BK 
channels play important role in vascular tone regulation, in which their activation leads to 
hyperpolarization of cell membrane by a raised intracellular Ca2+ from intracellular stores and 
extracellular influx 137. Micromolar Ca2+ sparks can activate BK channels in rat cerebral artery 
smooth muscle 138. Thus, they regulate vascular tone and function to buffer vasoconstriction. In 
disease conditions, such as diabetes and hypertension, the function of BK channels can be 
impaired 139,140.  
ATP-sensitive potassium (KATP) channels widely distributed in the vascular system are 
also critical in regulating the membrane excitability of VSMC 141. The KATP channels are 
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inhibited by increase of intracellular ratio of ATP and ADP, causing membrane depolarization 
and consequent vasoconstriction. KATP channels can be targeted by multiple vasoconstrictors and 
vasodilators, such as α-adrenoceptor agonists and β-adrenoceptor agonists respectively. A 
subtype of KATP channels, Kir6.1/SUR2B channel, can be targeted by many reactive oxygen 
species (ROS), leading to post-translational modification which alters the channel activity 142. 
Furthermore, in some disease conditions, such as septic shock, an upregulation of Kir6.1/SUR2B 
expression is observed, represented by raised blood pressure through increasing systemic 
vascular resistance 143,144.  
2.3.2.3 Role of endothelium in vascular tone regulation 
The endothelium also contributes to local blood flow regulation by releasing 
endothelium-derived contracting factors, such as thromboxane A2 (TXA2) and endothelin, and 
endothelium-derived relaxing factors, such as nitric oxide (NO), prostacyclin (PFI2) and 
endothelium-derived hyperpolarizing factors (EDHFs) 145,146. The release of these factors varies 
in different vessels 147. For example, NO released in a vessel size-dependent manner is the major 
vasodilator in conduit arteries. And small resistance vessels have more contents belonging to 
EDHFs. Epoxyeicosatrienoic acids (EETs), hydrogen peroxide (H2O2) and endothelium-derived 
K+ ions are considered as EDHFs. Besides, endothelium can communicate with VSMCs through 
gap junction, which is involved in endothelium-dependent hyperpolarization 146. These 
mechanisms driven by endothelium ensure the proper maintenance of vascular tone under 
physiological and pathophysiological conditions.  
2.3.3  Diabetes mellitus and Vascular lesions  
Diabetes mellitus is a group of diseases in which the blood glucose level is too high over 
a prolonged period. There are two main types of diabetes. Type I diabetes results from the failure 
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of sufficient insulin production. Type II diabetes relates to unhealthy lifestyle, and is caused by 
insulin resistance with obesity and insufficient exercise. Cardiovascular diseases are the principal 
cause of morbidity and mortality in patients with diabetes. Hyperglycemia is a major contributor 
of the development of micro- and macro-vascular complications in diabetes through different 
mechanisms 148,149. The microvascular complications in the retina is one major cause leading to 
blindness and visual disability in diabetes. While, atherosclerosis and medial calcification are the 
common macrovascular diseases in diabetes. High blood sugar level in diabetes generates 
oxidative stress, accelerate inflammation, activate protein kinase C (PKC) pathway and increase 
formation of advanced glycation end products (AGEs) contributing to the damages of the 
vasculature.  
2.3.3.1 Oxidative stress in diabetic vascular lesion 
Oxidative stress refers to an elevated intracellular level of reactive oxygen species (ROS), 
such as hydrogen peroxide (H2O2), hydroxyl radical (OH
•), superoxide anion (O2
• ‾), and 
hypochlorous acid (HOCl) 150-152. ROS are generated as byproduct of cellular metabolism. There 
is considerable evidences indicating that hyperglycemia-induced endoplasmic reticulum stress 
and mitochondrial dysfunction promote the accumulation of ROS. ROS can also be generated by 
endothelial NAD(P)H oxidase, a membrane-associated enzyme catalyzing the production of 
superoxide, and endothelial uncoupled eNOS, a mechanism leading to excessive superoxide 153-
155. Without appropriate compensation by the antioxidant defense network, excessive ROS 
contributes to the development and progression of cardiovascular disorders in diabetes. 
Hyperglycemia-caused oxidative stress induces dysfunction of the vascular endothelium, the 
primary defense against thrombosis and other vascular injury. The overproduced ROS results in 
reduced endothelial production of NO and irreversible post-translational modification of KATP 
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channel on the membrane of VSMCs, thus leading to impairment of vasodilation 156,157. 
Oxidative stress may also promote the expression of pro-coagulant and pro-inflammatory factors 
as well as induce cell apoptosis 155. Besides, it also potentially involve in atherosclerotic 
instability and subsequent rupture through promoting both VSMC apoptosis and its proliferation 
158,159.  
2.3.3.2 Inflammatory status in diabetes vascular lesion 
Accumulating evidence suggests that hyperglycemia is associated with inflammatory 
state characterized by increased level of pro-inflammatory cytokines and markers which raise the 
risks of diabetic cardiovascular disorders 160. For example, atherosclerotic cardiovascular disease 
is one of the most common inflammatory diseases in diabetes. Evidence indicates that 
hyperglycemia may play a role in atherosclerosis by promoting pro-inflammatory responses of 
myeloid cells, such as monocytes, macrophages and T lymphocytes, which are rapidly 
accumulated at the site of inflammation in vessel 161-163. In addition, the differentiation and 
maturation of dendritic cells from type II diabetic patients are impaired with high glucose 
exposure 164. The hypoglycemic stress caused by overdose insulin, excessive exercise or fasting 
in diabetes patients also contributes to elevation of the pro-inflammatory leukocytosis and 
cytokines 165.  
Oxidative stress and inflammation state usually interact with each other. ROS whose 
production is enhanced in diabetes by increased dysfunctional mitochondrial can act as a 
mediator of inflammation, aggravating the tissue injury thus progressing the inflammatory 
disorders 166. Activated polymorphonuclear neutrophils at the inflammatory site, in turn, increase 
the generation of ROS 167. 
33 
 
2.3.3.3 Activation of PKC pathway in diabetic vascular lesion 
PKC pathway can be stimulated by hyperglycemia, having a big impact on ROS and NO 
generation. PKC activated by glucose may be implicated in the activation of NAD(P)H oxidase 
and the consequent production of superoxide. Indeed, increased activity of this enzyme is found 
in internal mammary arteries and saphenous veins of diabetes patients 168. In addition, activation 
of PKC inhibits the activity of the phosphatidylinositol 3 kinase (PI3K) pathway, an important 
pathway to generate vasodilator NO in endothelium in response to insulin stimulation in order to 
maintain glucose homeostasis 169. Inhibition of PKC pathway can restore the abnormal 
endothelium-dependent relaxation of animal aorta caused by hyperglycemia 170. In addition, 
hyperglycemia activated PKC signaling may contribute to the hypercoagulable state and the 
formation of thrombus as well, by activation of platelets and clotting factors and impairing 
fibrinolytic capacity 171,172. 
2.3.3.4 Advanced glycation end products (AGEs) in diabetic vascular lesion 
AGEs are glycated proteins or lipids as a result of exposure to glucose 173. AGEs, such as 
glyoxal, 3-deoxyglucosone and MGO, can be generated from many processes 174. Mitochondrial 
superoxide also increases the production of AGEs 175. Increased AGEs induced by 
hyperglycemia is found in diabetic retinal vessels and renal glomeruli 176,177. AGEs can induce 
crosslinking of collagen fibers in the artery walls, leading to vascular stiffening and entrapment 
of low-density lipoprotein particles (LDL). Both of these events are associated with arterial 
complications, such as arteriosclerosis 178. AGEs can also lead to the glycation of LDL which 
promotes its oxidation as one of the major contributors in development of atherosclerosis 179. 
Furthermore, AGEs adversely affect cellular function by activation of the AGEs receptors 
(RAGE), inducing pathological changes in gene expression and increase endothelial permeability 
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to macromolecules 173,180. AGEs also contribute to production of ROS and diminished NO 
activity 173. Oxidative stress caused by hyperglycemia in patients with diabetes facilitates the 
formation of AGEs. In sum, AGEs affect many of molecules and cells, and interact with other 
hyperglycemia-induced mechanisms of vessel lesion. 
2.3.4 Intervention to cardiovascular system 
The study of the cardiovascular system has attracted considerable attention due to the 
large prevalence and the high fatality of cardiovascular diseases. The world health organization 
reports that the death roll of cardiovascular diseases in 2008 is about 17.3 million people, and 
this number is going to increase to over 23 million in 2030 181. Therefore, both the clinic 
assessments and the laboratory interventions to cardiovascular functionality are important in 
diagnosis and treatment of these diseases. The clinic assessments, such as electrocardiogram 
(ECG), heart rate monitoring, invasive and noninvasive blood pressure measurements and 
cardiovascular imaging technology, help the doctors to diagnose the function of the 
cardiovascular system. The laboratory intervention allows researchers to reveal the underlying 
mechanisms of the cardiovascular functions and dysfunctions for potential treatment methods. 
2.3.4.1 In vitro experimental strategies for cardiovascular investigation 
In order to better understand the mechanisms of cardiovascular function and dysfunction, 
novel experimental approaches to the vessel and heart are needed. Under in vivo conditions, the 
cardiovascular system responses to current pharmacological approach may depend on 
complicated events such as different cell types, hormones in blood, neuronal regulators, 
metabolic products from surrounding tissues, shear stress, transmural pressure and certain reflex 
responses. The complexity of the system limits the mechanistic insight. Therefore, the discovery 
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of alternative experimental approaches such as the emerging optogenetics may be helpful (see 
below).  
Multiple cultured cell lines including endothelial cells lines, VSMC lines and 
cardiomyocyte cell lines are used as in vitro model systems for various physiological and 
pathological researches. Parameters such as temperature, osmotic pressure, O2, CO2, nutrition 
and pH can be easily controlled through the culture medium. The obvious advantages of using 
the cultured cell lines include fast growth, minimal care, simplicity of circumstances species 
specificity and instant response to reagents. They are very good tools to study the signaling 
pathways. The disadvantages is also obvious: the change of phenotype over time and no 
crosstalk between cell species.  
Isolated and perfused blood vessels are a useful approach for the studies of functional 
blood vessels. This technique allows us to exam vessel rings with diameter ranging from 20 µm 
to several millimeters. The isolated vessels segments can consist of the intact endothelial cells in 
the tunica intima and VSMCs in the tunica media as well as fibroblasts, fat cells and even nerve 
end in the tunica adventitia. Endothelial cells can be removed in the denuded vessel segments 
according to demands 182. The tunica adventitia can be selectively removed as well. Two 
methods to prepare cylindrical vessel segments are developed. The ring vessel segments are 
prepared by threading vessels segments onto two metal hooks or wires 183,184. In most of the 
recording, vessel rings are prepared under isometric conditions in which the initial loading force 
is given and changes of vascular tone is recorded by a force transducer connected to one of the 
hooks or wires. Another method is cannulated vessel segments which are prepared by fixing the 
vessel segment on two pipettes between which the vessel segment is perfused by applying a flow 
at a desired rate 185. This preparation is considered to be closer to in vivo conditions. These 
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methods help in understanding the mechanisms of vascular regulatory processes in health and 
diseases. However, current technique only allow experiment to be conducted on relatively large 
vessels. The application of this technique is restricted when handling the arterioles, capillaries 
and vessels embedded in the organ and entangled with connective tissues, such as coronary 
artery. 
Isolated and perfused heart (Langendorff isolated heart perfusion system) is a valuable 
approach for study of cardiovascular function and dysfunction since its introduction by Oskar 
Langendorff at the late 19th century. This heart preparation method is still being used even after 
100 years. It can be applied on both large animal models, such as pig, dog, cat and rabbit, and 
small animal models, such as frog, rat and mouse. In the Langendorff preparation, the heart is 
removed from the body and perfused in a reverse direction through aorta root 186-188. The 
retrograde flow closes the aortic valve and force the oxygenated solution into the coronary 
artery. The less-oxygenated solution is collected in the right atrium through coronary sinus, and 
finally drains through vena cava. The Langendorff isolated heart system has led to a number of 
fundamental discoveries in cardiac physiology and pathology. A variety of parameters including 
the condition of the myocardium and the coronary vessels can be measured through this system 
with great pharmacological value, high reproducibility and relatively low cost. Although a few 
shortcomings exist, including the difficulty to maintain the high coronary flow especially in 
larger animal models, and the absence of the neuronal regulation and normal humoral influences, 
it has brought many valuable achievements in studies of ischemia-reperfusion injury, coronary 
occlusion, arrhythmias and heart preservation for transplantation 189. 
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2.3.4.2 Optogenetics in cardiovascular studies 
Optogenetics is a new technique which combines genetic and optical technologies for 
studies of specific biological processes. It has been rapidly progressing since Dr. Boris 
Zemelman and Dr. Miesenböck developed a method to stimulate the genetically designed 
neurons optically in 2002 190. The restricted control of the neuronal activity expends the 
knowledge of the neural remote control, the function of specific types of neurons, and the neural 
circuit mapping through activation of rhodopsin transgenic mice optically. The high temporal 
and spatial resolution makes optogenetics an excellent tool in the neural studies 191,192.  
The optogenetic methods are also useful in cardiovascular field 193,194. The spatiotemporal 
precision and noninvasive control are the major advantages which have been disgusted in some 
of the prior studies. The optoregulatory method is considered to be an ideal alternative to control 
the heart rhythm by conditionally expressing opsins in cardiomyocytes or transplanting a group 
of engineered non-excitable cells with optical excitability into the heart 193,195. The former can be 
achieved by directly delivering opsins to normal myocytes using viral vectors, while the latter 
method can take advantage of the formation of gap junctions between the donor cells and the 
host myocytes 195. The optogenetic technique has a potential to be applied to the cardiac 
arrhythmias termination and the cardiac pacing therapy 196-200. Despite its highly promising 
potentials, whether the optogenetics can be used in in cardiovascular research remains to be 
demonstrated. Thus, we applied optogenetics to the vascular tone manipulation, aimed at 
controlling the vasoconstriction in various tissues and organs. 
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3 SIGNIFICANCE 
The ANS regulates many important body processes in health and diseases, such as the 
rate of breathing and the blood pressure. These two processes are so critical that the disorders of 
any of them can cause severe health problems and even threaten lives.  
RTT is a progressive neurological disorder, predominantly affecting female children 
worldwide with an incidence of 1: 10,000 female births. Children with RTT develop normally in 
the earlier age. By the age of 18 months, most of the RTT patients start to display developmental 
regression. The most serious disorder among the core RTT symptoms is respiratory disturbances, 
such as hyperventilation, apnea, hyperpnoea, breath holding and etc. Mental and growth 
retardations are also observed accompanying with autistic syndromes. The severe breathing 
disorders of RTT usually end up with the high incidence of sudden death and contribute the 
abnormality of the brain during development. Because of lack of understanding of the disease, 
effective therapies are still unavailable. Therefore, it is necessary and significant to reveal the 
mechanisms of RTT. 
Nevertheless, the genetic basis of RTT is known. Mutations of MECP2 gene result in 
more than 90% of RTT pathology. MeCP2 is a transcriptional factor. Its defect or deficiency can 
cause disruptions and dysfunction in the CNS, whereas the neurobiological mechanisms of the 
RTT and the causal relationship between defect of MECP2 and RTT are still poorly understood. 
Animal models have been developed and used in the study of RTT for more than a decade, 
including Mecp2−/Y (Mecp2-null) males and Mecp2−/+ females mouse models. However, the 
mouse models have some limitations. Firstly, the small body size of the mouse models limits the 
feasibility of in vivo neuronal studies under physiological condition, such as in vivo 
electrophysiological recordings from central neurons. Secondly, the timely blood gas analysis 
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cannot be achieved due to the small quantity of blood. Thirdly, information obtained from the 
mouse models in the studies of RTT needs to be validated on another RTT animal models. Also, 
studies in multiple animal models of RTT are highly necessary for drug development to increase 
the translatability. Therefore, we take the advantage of the novel Mecp2–null rat model and 
performed a number of studies that cannot be done in the mouse models.  
Breathing abnormalities are major challenge in RTT patients. More than half of the RTT 
patients show hypoventilation alternating with irregular breathing or hyperventilation (central 
and obstructive apneas, apneustic breathing, breath holding, periodic breathing, Valsalva’s 
maneuvers and Biot’s breathing). The “skipped breathing” usually leads to the retardation of CO2 
and the severe reduction of O2 in the vasculature and organs. The mouse models show similar 
phenotypes as human, displaying apneic and irregular breathing patterns that progressively 
worsen until death 81,112, which facilitate the discovery of the RTT mechanisms. However, the 
mechanism underlying the periodic alternation of hypo- and hyperventilation of RTT is still 
elusive, especially the activity aspects of the neurons involved in respiration. Additionally, due to 
the size limit and fragileness of mice, in vitro electrophysiology, in situ arterially perfused 
brainstem-spinal cord and in vivo plethysmography are the major strategies used before, but not 
in vivo electrophysiological study which provide the straightforward views of the cells in the 
physiological condition. By using the newly available RTT rat model, we are able to perform in 
vivo electrophysiological studies on the respiratory neurons in the ventral respiratory group. The 
new RTT animal model will help us to confirm the truth of the previous findings and open the 
new avenue to the study of RTT. Our studies on rat model of RTT may open up the field of 
research into new treatments for respiratory-control disorders in humans. 
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Cardiovascular regulation is another critical process controlled by ANS. Cardiovascular 
diseases are the number one challenge to medical sciences globally: more people die annually 
from these diseases than from any other diseases. According to WHO in 2015, about 17.7 million 
people dies from cardiovascular diseases, which count almost one third of the global deaths 201. 
A considerable part of these deaths are due to diabetic cardiovascular complications and 
hypertension. Diabetes is the leading health challenge, especially in developing and developed 
countries. This metabolic disorder can have both acute and chronic complications such as 
diabetic ketoacidosis, cardiovascular disease and stroke, in which cardiovascular lesions were 
caused by accumulation of various intermediary metabolites. MGO as one of the intermediary 
metabolites is a highly reactive carbonyl species (RCS) 202,203. It is known that MGO can impair 
structure and function of the vascular wall, which contributes to diabetes-related vascular 
disorders including hypertension 204,205. But what it targets to cause the damage of the vascular 
tone is still unclear. An isoform of the KATP channels in vascular smooth muscles which is 
critical in vascular tone regulation is recently found to be a target of MGO 206. Via certain 
unknown mechanisms, MGO acts on the mRNA of this channel reducing its expression leading 
to augmented vasoconstriction 206. Therefore, we studied how MGO down-regulates KATP 
channel mRNAs.   
  For a long period, the accessibility to the vasculature heavily relies on pharmacological 
agents. The advantage is systemic effect of these agents, but the obvious disadvantage is also 
little spatial resolution. Thus, alternative accesses to the cardiovascular system are needed. The 
advance in optogenetics opens a new avenue to access the cardiovascular system. However, this 
promising technology has not been extended to vascular system. Therefore, we generated a novel 
mouse strain with expression of ChR2 in VSMCs, and tested the expression and excitability of 
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ChR2 in VSMCs of multiple organs. Our studies indicate that the application of optogenetics in 
vasculature could be a potent tool to produce reproducible and light intensity-dependent 
vasoconstriction with high spatiotemporal specificity. 
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4 MATERIAL AND METHODS 
4.1 Animal 
All animal experiments were conducted in accordance with the National Institutes of 
Health (NIH) Guide for the Care and Use of Laboratory Animals and were approved by the 
Georgia State University Institutional Animal Care and Use Committee.  
4.1.1 Rat 
The experiments were performed on male Mecp2−/Y rats. To breed these males, the 
female heterozygous Mecp2+/− rat ((SD-Mecp2tm1sage, strain code: TGRA6090) from the supplier 
company Horizon Discovery Group (Boyertown, PA) were crossbred with the male Sprague-
Dawley wild-type rat (WT). The genotyping protocol from Sage Labs in Horizon Discovery 
Group was used to identify WT, heterozygous, and homozygous animals based on a 71bp 
deletion in the Mecp2 (Primer F: GCAGCATCAGAAGGTGTTCA, Primer R: 
GACCTCAATGCTGACGGTTT). Animals used in the electrophysiological experiments were 
1.5-2.5 month male rats. Humane endpoints of all null rats were determined independently by 
staff members in our school animal facility. 
4.1.2 Mice 
Female heterozygous mice (Genotype: Mecp2+/−; Strain name: B6.129P2(C)-
Mecp2tm1.1Bird/J; Stock number 003890) from Jackson Lab were crossbred with male 
C57BL/6 mice to produce the Mecp2−/Y mice.  
For the generation of Tagln-ChR Mice, two stains of mice were used to generate mice 
with ChR2 expression in VSM cells: 1. Tagln-cre mice (Jackson Laboratories, West Grove, PA; 
004746, STOCK Tg(Tagln-cre)1Her/J) expressing Cre recombinase under the control of Tagln 
promoter, and 2. ChR-LoxP mice (Jackson Laboratories; 012569, B6; 129S-
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Gt(ROSA)26Sortm32(CAG-COP4*H134R/EYFP)Hze/J) expressing the channelrhodopsin2 (H134R)/eYFP 
fusion protein following a LoxP-flanked STOP cassette. The male homozygous Tagln-cre mice 
were crossed with the female heterozygous ChR-loxP mice. Their offspring were found to be 
ChR2+/‒-Tagln-cre+/‒ (Tagln-ChR) or ChR2‒/‒-Tagln-cre+/‒ (Tagln-cre). Genotypes were 
determined by using the primers provided by the Jackson Laboratories. Tagln-ChR and Tagln-
cre mice were used in the present study as the test and control groups respectively. Genotyping 
of these mice was shown (Fig. 8.1). Crossing heterozygous ChR-loxP mice with the homozygous 
Tagln-cre mice led to the removal of the STOP signal before ChR2-eYFP (Fig. 8.1A). The 
offspring Tagln-ChR contained both ChR-loxP and Tagln-cre genes, while ChR-loxP was 
missing in Tagln-cre mice (Fig. 8.1B).  
4.2 Animal behavior tests 
4.2.1 Body Weight and In-cage Conditions 
Body weight of animals was measured and recorded every week starting from postnatal 
day 7 (P 1w) till death. Tooth growth, food and water intake, movements and other body 
condition were regularly checked as well. Overly grown incisors that affected the food intake 
were monitored and trimmed by the veterinarian weekly. 
4.2.2 Grip Strength  
During the experiment, an animal was lifted by the tail, and their forelimbs were allowed 
to grasp the metal mesh fixed to a force-electricity transducer (CB Sciences, Inc., Milford, MA). 
The animal was then gently pulled upward while it grasped the mesh (10mm x 10mm) with both 
forelimbs. The maximal force reached immediately before it released the mesh was taken as the 
grip strength. Signals were amplified, collected with the Clampex 9 software and stored in a 
computer. Comparison between rats and mice was done in animals aged 5~6 weeks. 
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4.2.3 Spontaneous Locomotion Test  
Locomotion activity of male rats aged 4~5 weeks was tested in a test chamber made of 
white plexiglass boards (80 cm × 80 cm × 30 cm). The arenas were divided into 10 cm × 10 cm 
squares (n=64) by drawing thin black lines on the floor. The locomotion apparatus for male mice 
aged 5-6 weeks was constructed with the same material in size 50 cm × 50 cm × 30 cm with 10 
cm × 10 cm square lines. Animals were carried to the test room in their home cages and 
habituated for 30 min before the locomotion test. Each tested animal was placed in a center of 
the box and observed for 5 min. Each trail was recorded with a video camera. Measures of 
square crosses (all four paws cross) were obtained from the video record. After the test, the 
apparatus was thoroughly cleaned using 70% ethanol and then H2O to eliminate potential 
residual odors and contaminants.  
4.2.4 Three-chamber Test  
WT and Mecp2−/Y male rats, aged 4~5 weeks, were tested in a three-chambered apparatus 
(90 cm × 60 cm × 30 cm), where three chambers (30 cm × 60 cm × 30 cm each) were separated 
by two transparent plexiglass walls with an opening in each wall. Two buckets (12 cm in 
diameter × 20 cm in height) made of 1 cm × 1cm metal mesh were placed in the center of the 
two side chambers. Similarly, mice aged 6-7 weeks were tested in an apparatus with three 20 cm 
× 30 cm × 40 cm chambers. The buckets and the metal mesh were 1/3 smaller in mice than in 
rats. On the test day, animals were allowed for 30 min habituation to its environment. A three-
step procedure was performed. First, the tested animal was placed in the center chamber, and 
allowed to freely move over all three chambers for 10 min. The time spent in each chamber was 
recorded with a video camera. Second, sociability was tested, in which a male intruder (Animal 
1) in one mesh bucket was introduced to one of the side chambers randomly, while the other 
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bucket was kept empty. The test animal was allowed to explore both the chambers for 10 min 
with the total time spent in the chamber measured. The intruder was randomly assigned in one of 
the side chambers to avoid the side bias. Lastly, the social novelty was tested by switching the 
familiar intruder into the other chamber and introducing a novel male intruder (Animal 2) to the 
chamber. The tested animal was monitored for 10 min as well. The time spent in each side 
chamber was measured. The apparatus was thoroughly cleaned between trails using 70% ethanol 
and H2O. All behavior tests were performed during the light cycle (from 10 am to 7 pm).  
4.2.5 Plethysmograph Recording  
Breathing activities of awake animal were recorded with a plethysmograph chamber. The 
individual animal was kept in the plethysmograph chamber with air ventilation at a rate of ~1000 
ml/min. After at least 20 min adaptation, breathing activity was recorded continuously for 20 min 
as the barometrical changes between the plethysmograph chamber and the reference chamber 
with a force-electricity transducer (Emka, Oxford, UK). The signal was amplified and recorded 
with AxoScope 10.3 software in a computer. The data was analyzed with Clampfit 10.3 software. 
Apnea rate and respiratory frequency variation were measured. Apnea was considered only if the 
inspiration interval was twice longer than the previous breathing. Breathing frequency variation 
was defined as the standard deviation (SD) of the breathing frequency divided by their arithmetic 
mean. The SD and arithmetic mean were measured from ~200 successive breathing events. 
4.3 Lifespan  
WT and Mecp2−/Y animals were randomly selected from litters. Their lifespan were 
monitored. Death date of each group was recorded. Both in-cage death and the cases reach 
humane endpoint determined by the animal facility at Georgia State University were counted. 
One outlier at each end was removed from the data analysis to minimize the data variation. 
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4.4 Electrophysiology 
4.4.1 In vitro Electrophysiology 
Experimental rats or mice were decapitated after deep anesthesia with inhalation of 
saturated isoflurane. The brainstem was obtained and immediately placed in an ice-cold and 
sucrose-rich cutting (in mM) solution containing 220 sucrose, 33 NaHCO3, 1.9 KCl, 6 MgCl2, 
1.2 NaH2PO4, 0.5 CaCl2 and 10 D-glucose. The solution was bubbled with 95% O2 - 5% CO2 
(pH 7. 40). Transverse pontine sections (150~300 µm) containing the LC were obtained by using 
a vibratome sectioning system and then recovered at 33 °C for 60 min in normal artificial 
cerebrospinal fluid (aCSF) (in mM) solution containing 124 NaCl, 26 NaHCO3, 3 KCl, 2 MgCl2, 
1.3 NaH2PO4, 2 CaCl2 and 10 D-glucose. The brain slices were kept at room temperature before 
usage. At recording, the slices were perfused with oxygenated aCSF at a rate of 2 ml/min and 
maintained at 34 °C in a recording chamber by a dual automatic temperature control (Warner 
Instruments). 
Whole-cell current clamp was performed on LC neurons in the brain slices. Patch pipettes 
with a resistance of 3~5 MΩ were prepared with Sutter pipette puller (Model P-97, Novato, CA). 
Only were the neurons with membrane potential less than -40 mV and action potential larger 
than 65 mV accepted for further experiments. The pipette solution (in mM) contained 130 K 
gluconate, 10 KCl, 10 HEPES, 2 Mg-ATP, 0.4 EGTA and 0.3 Na-GTP (pH 7. 3). The bath 
solution was normal aCSF bubbled with 95% O2 balanced with 5% CO2 (pH 7. 40). Recorded 
signals were amplified with an amplifier Axopatch 200B (Molecular Devices, Union City, CA), 
digitized at 10 kHz, filtered at 2 kHz, and collected with the Clampex 8.2 data acquisition 
software (Molecular Devices).  
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The single-cell voltage clamp was used to record whole cell KATP currents in cells 
transfected with different agents. Patch-clamp protocols were performed as previously described 
206. Briefly, the patch pipettes were made with 1.2 mm borosilicate glass capillaries (with 
resistance of 2~5 MΩ). Current records were filtered with low pass (2 kHz, Bessel 4-pole filter, -
3 dB), digitized (20 kHz, 16-bit resolution), and analyzed with Clampfit 9 software (Axon 
Instruments, Union City, CA) The bath solution contained (in mM) 10 KCl, 135 potassium 
gluconate, 5 EGTA, 5 glucose, and 10 HEPES (pH 7.4). The pipette solution contained (in mM) 
133.0 K+ gluconate, 10.0 KCl, 5.0 EGTA, 5.0 glucose, 1 K2ATP, 0.5 NaADP, and 10.0 HEPES 
(pH 7.4). The final Mg2+ concentration was adjusted to 1 mM. The membrane potential was held 
at 0 mV and stepped to -80 mV every 3~4 s. 
The whole-cell voltage clamp and current patch clamp were used to demonstrate 
optostimulation of isolated aortic VSM cells. Recorded signals were amplified with an Axopatch 
200B amplifier (Molecular Devices, Union City, CA), digitized at 10 kHz, filtered at 2 kHz, and 
collected with the Clampex 10 data acquisition software (Molecular Devices, Union City, CA). 
The patch pipettes with resistance of 4~6 MΩ were made with 1.2 mm borosilicate glass 
capillaries. All recordings were performed at room temperature. The optostimulation was 
performed by using a xenon arc lamp with high speed switcher Lambda DG-4 system (Sutter 
Instruments, Novato, CA). The light source was connected to the incident-light illuminator port 
of the microscope, and passed through a 470 nm bandpass filter (~20 mW/mm2). Light pulse 
trains were generated with the Digitimer D4030 pulse generator (Digitimer Ltd, Letchworth 
Garden City, UK). The solution applied to the bath contained (in mM) 130.0 NaCl, 10.0 KCl, 1.0 
MgCl2, 1.5 CaCl2, 10.0 glucose, 10.0 HEPES and 3.0 NaOH (pH 7.4). The internal (pipette) 
solution contained (in mM) 10.0 KCl, 133.0 K+ gluconate, 5.0 EGTA, 5.0 glucose, 1.0 K2-ATP, 
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0.5 Na-ADP, and 10.0 HEPES (pH 7.4), and the final Mg2+ concentration was adjusted to 1 mM 
using a [Ca2+ ]/[Mg2+ ] calculation software.  
4.4.2 In vivo Electrophysiology  
Rats were anaesthetized with the urethane (1.5 g/kg, i.p.) followed by intercollicular 
decerebration in a stereotactic device. The animals were allowed to breathe spontaneously. 
Phrenic nerve was exposed at cervical cord C3-C6 level from the dorsal side, and its activity was 
recorded with bipolar silver hook electrodes. Mineral oil was applied to prevent the dryness of 
the nerve during recording. Phrenic signal was amplified and filtered (300 Hz to 5 kHz) with an 
A-M systems (Model 1700 Differential AC Amplifier, A-M SYSTEMSTM). Phrenic discharge 
was recorded with Clampex 8.2 software and analyzed with Clampfit 10.3 software. Integrated 
phrenic signal was obtain through a Paynter filter (50 ms time constant, BAK Electronics Inc., 
Rockville, MD.). 
Partial cerebellum was removed using vacuum suction to expose the brainstem. Single 
neuronal activity was recorded with tungsten microelectrodes covered with glass. The signals 
were amplified (Instrumentation Amplifier, Model 210 A, Brownlee BP precision) (Axoclamp-
2B Current and Voltage Clamp Amplifier, Axon Instruments. Inc.), digitized (Digidata 1322A, 
Axon Instruments. Inc.), recorded (Clampex 8.2 software, Molecular Devices) and off-line 
analyzed (Clampfit 10.3 software, Molecular Devices). After completion of the surgery, rats 
were stabilized for 20-30 min. The obex on the dorsal surface of the medulla was used as the 
land marker to locate the recording sites. Body temperature and heart rate were closely 
monitored during surgical and recording procedures. Lost fluid was supplied with warm saline 
through i.p. injection. 
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Stimulation bipolar electrode was inserted controlaterally into the lateral or ventrolateral 
funiculi) of the C2 to stimulate the axons of the inspiratory premotor neurons. The depth of the 
stimulation site was determined by giving the maximum orthodromic monosynaptic response in 
the phrenic recording (~2 mm from the dorsal surface of spinal cord). Single pulse (1 Hz, 0.1 ms 
duration, 3-20 volts) was delivered through a stimulus isolation unit (Model SIU5C, Grass 
Instrument Co., Quincy, MA). Neurons were identified as bulbospinal neurons by collision tests. 
Stimulus intensity was set at the threshold for antidromic activation of bulbospinal neurons. 
4.5 Cell culture and transfection  
HEK293 cells (CRL-1573; American Type Culture Collection, Manassas, VA) and rat 
VSM cells (A10 cell line, CRL-1476; American Type Culture Collection) were cultured in 
complete DMEM (10% FBS) in a 5% CO2 atmosphere at 37°C. Two to four generations were 
used for experiments. After growth arrest, the cells were transfected using lipofectamine. 
Subsequently, the cells were switched to complete DMEM (10% FBS) and cultured in a 5% CO2 
atmosphere at 37°C for another 24~48 h. 
4.6 microRNAs intervention  
4.6.1 Bioinformatics prediction of miR targets 
To identify the candidate miRs that potentially targeted rat Kir6.1 (Kcnj8), we used the 
miRWalk database (https://www.umm.uni-heidelberg.de/apps/zmf/ mirwalk/index.html) that is 
supported by eight miRNA prediction programs on 3’-UTRs of all known genes of the human, 
mouse, and rat. A probability distribution of random matches of a subsequence (miR 5’-end 
sequence) in the given sequence was calculated by using Poisson distribution, where a low 
probability implies a significant hit 207,208. The default P value (0.05), the mirSVR score < 0 209, 
plus at least six complementarity seeds were used for miR/Kcnj8 alignment. A number of miRs 
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potentially target Kir6.1 3’-UTR. To limit the number we used the following criteria: 1) their 
high conservation across a wide range of mammals and 2) their potential involvement in diabetes 
in existing literature. On the basis of these criteria, three potential Kir6.1-targeting miRs were 
selected for further screening. Similarly, six potential miRs for SUR2B CDS targeting were 
predicted using the same database. The targeting site conservation was examined among rats, 
mice, and humans by comparing NCBI BLAST alignment as the similar searches with human 
KCNJ8/ABCC9 showing no miRs matches in the same 3’-UTR/coding region. 
4.6.2 Synthesis of miR-9a-3p and anti-miR-9a-3p 
Chemically synthesized and optimized double-strand nucleotides (m-9) were designed to 
mimic endogenous mature miR-9a-3p in VSM and scrambled RNAs (scmiR) was synthesized as 
negative control (Qiagen, Sample & Assay Technologies, Valencia, CA). Single-strand antisense 
oligonucleotides (anti-9) complementary to the mature miR-9a-3p were synthesized to 
specifically target and knock down endogenous miR-9a-3p in VSM (Sigma-Aldrich). 
4.7 KATP channel expression  
4.7.1 Construction of Kir6.1 and SUR2B mRNA expression vectors 
The cDNAs encoding rat Kir6.1 mRNA (GenBank no. D42145.1) and mouse SUR2B 
mRNA isoform (GenBank no. D86038, mRNA isoform NM_011511) were cloned and inserted 
into pcDNA3.1 (an eukaryotic expression vector), respectively, as previously described 206, 
which were named with Kir and SUR, respectively. 
The mutated pcDNA3.1 construct of the SUR2B (M-SUR) was obtained using the 
Stratagene QuikChange mutagenesis (New England BioLabs, Ipswich, MA) and used for real-
time quantitative PCR (qPCR) and patch studies. The mutagenic oligonucleotide primer pair was 
designed according to the desired mutation in its seed match sequences. Briefly, the M-SUR was 
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cloned with the primer pair (forward: CCCTAAATTACTTTTGGCCTTATTCCTGTACTGG; 
reverse: CCAGTACAGGAATAAGGCCAAAAGTAATTTAGGG), containing two site 
mutations in position 622 and 625 of SUR2B mRNA (Fig. 8.1B). 
4.7.2 Heterologous expression of KATP channel 
KATP channels were heterologously expressed in HEK293 cells as previously described 
206. Briefly, the constructions of Kir6.1 and SUR2B mRNA expression vectors were 
cotransfected to the HEK293 cells (ratio of 1:3), and the pEGFP-N2 (Clontech, Palo Alto, CA) 
was transfected together to identify the positively transfected cells. One day after transfection, 
the cells were again transfected with synthesized m-9 or anti-9. After another day in culture, the 
cells were used for electrophysiological studies and luciferase analysis. 
4.8 Real-time quantitative PCR  
The qPCR analysis was performed with high-capacity cDNA Reverse Transcription Kit 
and Fast SYBR Green Master Mix (Applied Biosystems, Life Technologies, New York, NY) 
following the manufacturer’s instructions. Primers specific for Kir6.1, SUR2B, miRs, RNU6B, 
and GAPDH were synthesized from Sigma Genesis (Sigma). The qPCR was performed with a 
Fast Real-time PCR system (Applied Biosystems 7500) for 40 cycles. The fold increase relative 
to control samples was determined by the 2-2ΔΔCT method. Expression levels of target mRNAs 
were determined using total RNA from A10 or HEK cells. GAPDH was used as internal control 
for SUR2B mRNA expression. RNU6 was used for normalization of miR-9a-3p expression. 
4.9 Histology 
Mice at the age 2 to 3 months were euthanized by deep anesthesia followed by 
thoracotomy. The heart, kidney, mesentery, small intestine, uterus and skeletal muscle tissues 
were collected from the mice. After four hours fixation in 1% Paraformaldehyde (PFA) at room 
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temperature, the tissues were treated overnight with 30% sucrose in Phosphate Buffered Saline 
(PBS) buffer at 4°C. The tissues were embedded in the Tissue-TekTM CRYO-OCT Compound 
(Andwin Scientific, Torrance, CA, 4583), and cut into 8 μm slices by using the Microm HM 550 
Cryostats system (Thermo Scientific, PA, 22-050-337). YFP fluorescence was detected with 
514/527 nm (excitation/emission wavelength) filters under the microscope (Carl Zeiss, 
Gottingen, Germany, Axiovert 200). Images were analyzed with the ImageJ 1.48 (NIH, 
Bethesda, MD). 
4.10 Organ and cell preparation  
4.10.1 Acute dissociation of VSM cells 
Thoracic aorta was dissected free in the dissection solution containing (mM): 140.0 NaCl, 
5.4 KCl, 1.0 MgCl2, 0.1 CaCl2, 10.0 glucose, 10.0 HEPES (pH was adjusted to 7.4), cut into 1-2 
mm segments, and incubated in 0.1 ml dissection solution containing 20 unit/ml papain 
(Worthington, Lakewood, NJ, LK003176) and 1.25 mg/ml DTT for 15 min at 37 ̊C. The tissue 
segments were further digested with 440 unit/ml collagenase type IA (Sigma, St. Louis, MO, 
C0130) for 2-3 min at 37 ̊C, followed by three washes and gentle trituration with a fire polished 
glass Pasteur pipettes. The solution containing individual VSM cells was dropped in a Petri dish 
coated with poly-L-lysine (Sigma, P8920) and prepared for patch clamp and contractile studies. 
The cell suspension was stored at 4 ̊C and used within 4 hrs. 
4.10.2 Contractile assessment of individual VSM cells 
Zeiss Axiovert 200 system was used to observe cell shape changes with optical 
stimulation. The T-Cube LED Driver (Thorlabs, Newton, NJ, LEDD1B) and Blue (470 nm) 
Fiber-Coupled High-Power LED (Thorlabs, Newton, NJ, M470F1) were used to generate 
optostimulation (~24 mW/mm2) with optical fiber (Thorlabs, Newton, NJ, FT400EMT). Cell 
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images were recorded continuously with a 20 s interval. Additional cell contraction was achieved 
with a 5 min exposure to 20 mM KCl. Data were accepted for further analysis if the features of 
VSM cells were seen with YFP signal and KCl response. Cell shortening was measured along its 
longitudinal axis by the ImageJ 1.48 software. 
4.10.3 Arterial rings 
The vascular rings were prepared by the technique stated in our previous studies 210. 
Briefly, mouse mesenteric arteries were dissected free, placed in the Krebs solution containing 
(in mM/L) 118.0 NaCl, 3.6 KCl, 1.2 MgSO4, 2.5 CaCl2, 1.2 KH2PO4, 11.0 glucose, 25.0 
NaHCO3 (pH 7.4). The arteries were cut into 2 mm ring segments in which a stainless steel 
triangle wire was inserted. The prepared rings were placed in the 37 ̊C tissue bath filled with 
Krebs solution bubbled with 95% O2 and 5% CO2. Changes of the contractile force were 
measured with a force-electricity transducer. Signals were amplified, collected with the Clampex 
9 software (Molecular Devices), and stored in a PC computer. Blue light was generated by T-
Cube LED Driver and Blue Fiber-Coupled High-Power LED (Thorlabs). Intensity of six levels 
with equal interval (from 10 to 24 mW/mm2) was given to the rings in light-intensity test. Other 
optical contractile force was generated with ~24 mW/mm2 light intensity. 
4.10.4 Langendorff heart 
After the mouse was euthanized, the heart was rapidly removed and placed in the ice-cold 
Krebs-Henseleit (KH) solution composed of (in mM): 119 NaCl, 4.7 KCl, 2.5 MgSO4, 2.5 
CaCl2, 10 glucose, 0.5 disodium EDTA, 25 NaHCO3 bubbled with 95% O2 and 5% CO2 (pH 
7.4). The left ventricle was intubated, the aorta was tightened, and vena cava was cut open. The 
isolated heart was then placed in a moisture air chamber with the temperature maintained at 
35 ̊C, and perfused with a syringe pump (Syringe Pump, Farmingdale, NY, NE-300, NE4000) at 
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constant flow speed to produce 80 cm H2O ventricular pressure at baseline. The force-electricity 
transducer (Model eTH-400, CB Sciences) was used to monitor the perfusion resistance and 
heart rate. Only hearts that had heart beat >200 times per min with a clear vasodilation response 
to 10 μM isoproterenol were accepted for further studies. The Lambda DG-4 Plus system (Sutter 
Instruments, Novato, CA) with a 470 nm filter (fiber diameter 3 mm) was used to generate the 
blue light. The data was recorded with Clampex 8 (Molecular Devices), and analyzed with 
Clampfit 9 (Molecular Devices). Recording started after 30 min equilibration when the perfusion 
resistance and heart rate were stable.  
4.10.5 Isolated kidney preparation 
Kidneys from both Tagln-ChR and control mice were prepared in ice-cold KH solution. 
The kidney was intubated through one end of the abdominal aorta with the other end tightened. 
The rest of experimental procedure was similar to that for the isolated and perfused heart. 
4.11 Data analysis 
Neuronal activities and phrenic activity were measured with at least 40 consequent bursts 
of eupnea.  
For western blot analysis, proteins extracted from A10 and HEK cells were detected 
using a standard Western blot protocol. GAPDH was used as an internal control. 
Data analyzed with Student’s t test and Two-way ANOVA were presented as means ± 
SE. Comparisons of data were accomplished by one-way ANOVA followed by student’s t-test 
for parametric data. Kruskal-Wallis and Mann-Whitney (U) tests were used for non-parametric 
data. Data analyzed with either Student’s t test, Two-way ANOVA or χ2 test were considered 
with significant difference when P<0.05. 
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5 RESULT 1: CHARACTERIZATION OF RETT SYNDROME-LIKE PHENOTYPES 
IN MECP2-KNOCKOUT RATS 
Published as “Yang Wu, Weiwei Zhong, Ningren Cui, Christopher M. Johnson, Hao Xing, 
Shuang Zhang and Chun Jiang. Optogenetic approach for functional assays of the cardiovascular 
system by light activation of the vascular smooth muscle. J Neurodev Disord. 2016 Jun 
16;8:23.” 
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5.2 Abstract 
Rett Syndrome (RTT) is a neurodevelopmental disease caused by the disruption of the 
MECP2 gene. Several mouse models of RTT have been developed with Mecp2 disruptions. 
Although the mouse models are widely used in RTT research, results obtained need to be 
validated in other species. Therefore, we performed these studies to characterize phenotypes of a 
novel Mecp2−/Y rat model and compared them with the Mecp2tm1.1Bird mouse model of RTT. 
RTT-like phenotypes were systematically studied and compared between Mecp2−/Y rats and 
Mecp2−/Y mice. In-cage conditions of the rats were monitored. Grip strength and spontaneous 
locomotion were used to evaluate the motor function. Three-chamber test was performed to show 
autism-type behaviors. Breathing activity was recorded with the plethysmograph. Individual 
neurons in the locus coeruleus (LC) were studied in the whole-cell current clamp. The lifespan of 
the rats was determined with their survival time. Mecp2−/Y rats displayed growth retardation, 
malocclusion and lack of movements, while hindlimb clasping was not seen. They had weaker 
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forelimb grip strength and a lower rate of locomotion than the WT littermates. Defects in social 
interaction with other rats were obvious. Breathing frequency variation and apnea in the null rats 
were significantly higher than in the WT. LC neurons in the null rats showed excessive firing 
activity. A half of the null rats died in two months. Most of the RTT-like symptoms were 
comparable to those seen in Mecp2−/Y mice, while some appeared more or less severe.  The 
findings that most RTT-like symptoms exist in the rat model with moderate variations and 
differences from the mouse models support the usefulness of both Mecp2−/Y rodent models. The 
novel Mecp2−/Y rat model recapitulated numerous RTT-like symptoms as Mecp2−/Y mouse 
models did, which makes it a valuable alternative model in the RTT studies when the body size 
matters. 
5.3 Introduction 
Rett syndrome (RTT), a progressive neurodevelopmental disorder, affects predominantly 
female children worldwide with an incidence of 1: 10,000 female births. People with RTT 
display a developmental regression which is characterized by a loss of acquired functions such as 
speech and hand skills, and development of stereotypic hand movements, gait apraxia, ataxia and 
seizures 211-213. Breathing disorders are common including hyperventilation, apnea, hyperpnoea, 
breath holding, etc 74,114,214,215, which contribute to the high incidence of sudden death.  
Defects in the X-linked gene MECP2 encoding the methyl CpG binding protein 2 
(MeCP2) known as a transcriptional regulator, are identified in more than 90% RTT patients. 
Mutations or altered expression of Mecp2 in mice result in a spectrum of RTT-like 
neurodevelopmental disorders. Thus, several mouse models of RTT have been developed and 
used in RTT studies over the past years 76,216. For example, Mecp2tm1.1Bird, Mecp2Jae and 
Mecp2neoTam mouse models with exon 3 and/or 4 deletions in the Mecp2 are widely used in the 
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etiologic and therapeutic studies 75-77. Other mouse models with site-specific mutations, such as 
Mecp2T158A/y, Mecp2R168X and Mecp2e1−/Y, were developed in recent years 78-80. By using these 
mouse models, considerable progress has been made in the studies of the neurobiological 
mechanisms underlying or associated with RTT 83,104,108,217,218. Mecp2tm1.1Bird mice, the most 
widely used mouse model of RTT, show several phenotypes similar to human patients with RTT, 
such as early death, motor problems and autistic behaviors, which progressively worsen until 
death 81,112. Autonomic dysfunction is another characteristic manifestation including breathing 
disorders, cardiac arrhythmias and constipation 74,111,219. Brainstem monoamine modulatory 
systems are involved. Electrophysiological and molecular biological studies in the Mecp2tm1.1Bird 
mouse model suggest that neurons in the locus coeruleus (LC) are defective, showing impaired 
neuronal activity, abnormal CO2 chemosensitivity and reduced expression of enzymes for NE 
biosynthesis 83,98,106,111.  
Although the mouse models are widely used in RTT research, results obtained need to be 
validated in other species, which is particularly important when therapeutic modalities are aimed 
to develop. Thus, studies on multiple animal models of RTT are necessary and highly significant. 
A novel Mecp2-knockout rat model, SD-Mecp2tm1sage rat. The null rats had a deletion of exon 4 
in the Mecp2 leading to complete elimination of the MeCP2 protein. Since the rat model may 
provide useful information on RTT mechanisms and treatments, we performed systematic studies 
of the RTT-like symptoms identified previously in Mecp2−/Y mouse models, and compared these 
RTT-like phenotypes with those found in the male mouse model of RTT. 
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5.4 Results 
5.4.1 General RTT Features 
Mutation of the Mecp2 gene in rats caused several developmental abnormalities. Some of 
the abnormalities have previously been identified in Mecp2−/Y mice, and others seemed more or 
less obvious in rats than in mice. The body weight of Mecp2−/Y rats was monitored every week 
starting from postnatal day 7 (P7) till death. In comparison to their WT littermates, Mecp2−/Y rats 
had a much smaller body size and lower body weight. When the body weight was compared 
between Mecp2−/Y and WT rats, significant difference was observed in week 4 (75.6 ± 16.6 g in 
18 Mecp2−/Y rats vs 90.3 ± 14.8 g in 20 WT; P = 0.004, df = 41, t = -3.057), and the difference 
increased with growth (Fig. 5.1A,B). In addition, adult Mecp2−/Y rats showed prolapsed penis 
(Fig. 5.1C) and severe malocclusion (overgrowth of incisor teeth and misplaced midline) (Fig. 
5.1D). Hindlimb grasping, a typical phonotype of Mecp2−/Y mice, was absent in Mecp2−/Y rats 
(Fig. 5.1E). The Mecp2−/Y rats were also occasionally observed with porphyrin (red tear), which 
was not seen the WT littermates, and usually indicated sickness and stress.  
5.4.2  Muscle Strength and Locomotion 
People with RTT have defects in motor functions, some of which have been found in 
Mecp2−/Y mice. Similarly, Mecp2−/Y rats showed fewer movements than their WT littermates. 
Hence, we examined the motor function with grip strength test and the observation of 
spontaneous locomotion. Grip strength of the forelimbs was monitored weekly in 14 Mecp2−/Y 
rats and 19 WT rats. The Mecp2−/Y rats showed a significant decrease in muscle strength starting 
in 4 weeks after birth (P4w), and remained significantly lower thereafter than that of the WT 
(Fig. 5.2A). The maximum grip strength was reached in P7w in null rats. In comparison, the grip 
strength of WT rats continued to increase with growth.  
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When the grip strength was compared in P6w, the muscle strength of both Mecp2−/Y rats 
and mice was significantly lower than that of their WT littermates (Fig. 5.2B). Because of the 
body size, rats were much stronger than mice. We thus normalized the grip strength to the WT in 
each group. After normalization, similar reductions in the muscle strength were observed in both 
Mecp2−/Y rats (by 29% of the WT value) and Mecp2−/Y mice (by 34%) with no statistical 
difference found between species (Fig. 5.2C).  
The spontaneous movement was measured with traveling distance to indicate locomotor 
activity. A rat was placed in the center of an enclosure and allowed to explore around for 10 min. 
The number of the squares crossed by the rat was counted and recorded as locomotion activity 
(squares crossed per min). The less square traveling, the lower locomotor activity. The 
locomotion activity of both Mecp2−/Y strains were significantly lower than the WT littermates 
(35.4 ± 3.1 squares/min in 9 WT mice vs 26.2 ± 2.4 squares/min in 9 Mecp2−/Y mice, P = 0.031, 
df = 17, t = 2.367; 28.3 ± 3.3 squares/min in 12 WT rats vs 16.2 ± 3.3 squares/min in 11 
Mecp2−/Y rats; P = 0.016, df = 21, t = 2.609) (Fig. 5.2D). After normalization to the WT level, 
Mecp2−/Y rats showed 43% reduction in locomotor activity, while Mecp2−/Y mice had 26% 
reduction (Fig. 5.2E). The low locomotion activity of Mecp2−/Y rats suggests that the Mecp2 
disruption causes motor dysfunction in both rats and mice with similar severity. 
5.4.3 Autism-like Behavior  
Another clinic manifestation of RTT is the autism-like behavior that also occurs in 
Mecp2−/Y mice. Using the three-chamber test, therefore, we studied the autism-like behavior in 
Mecp2−/Y rats. During the tests, a rat was placed in the middle chamber of the three-
compartmental box with an opening to each of the side chambers. During the first 10 min 
habituation period, rat preference to either side chamber was recorded as the time spent in each 
60 
 
chamber (Fig. 5.3A,B). Only the animals showing no preference to either side of chambers in the 
habituation time were used for further tests. 
Then, sociability was tested in a three-chamber apparatus with two identical mental-mesh 
buckets introduced to each side chamber. An intruder animal was randomly placed in one of the 
buckets, and the other was kept empty. The mesh bucket allowed the animal to have visual, 
olfactory and auditory contact and exploration. During this 2nd 10 min tests, WT rodents spent 
more time with their kinds than the empty chamber (259.8 ± 24.5 sec vs 183.1 ± 21.3 sec in 10 
WT mice, P = 0.045, df = 19, t = 2.156; 346.4 ± 41.9 sec vs 142.4 ± 24.2 sec in 10 WT rats, P < 
0.001, df = 19, t = -4.217) (Fig. 5.3C,D), consistent with previous reports 220-222. Such a 
preference was not seen in both Mecp2−/Y rodents. Mecp2−/Y rats spent less time in the intruder 
chamber than in the empty one (99.2 ± 48.8 sec with Animal 1 vs 169.5 ± 74.5 sec in empty; n = 
11, P = 0.439, df = 21, t = 0.789), similar to Mecp2−/Y mice (214.5 ± 50.4 sec with Animal 1 vs 
224.4 ± 53.0 sec in empty; n = 8, P = 0.895, df = 15, t = -0.135) (Fig. 5.3C,D). The results 
suggest that the defect of sociability was comparable between Mecp2−/Y rats and mice.  
The social novelty was tested during the last 10 min when a novel stranger (Animal 2) in 
addition to the first intruder (Animal 1 or familiar) was introduced to the previously empty 
bucket. The time spent in either side chambers was measured. Consistent with previous reports 
221,222, the WT animals showed a clear tendency of social novelty by spending a longer time with 
the stranger animal than with the familiar one (363.4 ± 34.5 sec with Animal 2 vs 140.4 ± 27.5 
sec with Animal 1 vs in WT mice, P < 0.001, df = 19, t = 5.052; 395.4 ± 56.3 sec with Animal 2 
vs 101.8 ± 28.1 sec with Animal 1 in WT rats, P  =  0.002, df = 19, t = -4.666) (Fig. 5.3E,F). 
Such a preference disappeared in Mecp2−/Y animals (227.7 ± 63.1 sec with Animal 1 vs 256.7 ± 
55.3 sec with Animal 2 in Mecp2−/Y mice, P = 0.422, df = 15, t = 0.828; 250.1 ± 76.0 sec with 
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Animal 1 vs 171.8 ± 68.1 sec with Animal 2 in Mecp2−/Y rats, P = 0.452, df = 21, t = 0.767) (Fig. 
5.3E,F). Therefore, the results suggest that the Mecp2−/Y rats show the autism-like social defects 
similarly to Mecp2−/Y mice. 
5.4.4 Breathing Abnormality 
People with RTT as well as the mouse models of RTT show breathing abnormalities 
74,114,214,215. Thus, we measured the breathing activity using the plethysmography in conscious 
animals. Two most reliable breathing phenotypes, apneas and breathing frequency variations, 
were analyzed as shown in several previous studies 94,111. High apnea rate and breathing 
frequency variations were seen in Mecp2−/Y rats. They started showing a significant difference 
from those in the WT rats in P4w, and deteriorated with growth (Fig. 5.4A-D). By P7w, the 
apnea rate was raised to 49.3 ± 2.9 hr-1 of Mecp2−/Y rats in comparison to 26.5 ± 2.7 hr-1 of WT 
(Fig. 5.4C), and the breathing variation increased to 0.21 ± 0.02 in 15 Mecp2−/Y rats comparing 
to 0.09 ± 0.01 in 8 WT (Fig. 5.4D). The breathing abnormalities of Mecp2−/Y rats were compared 
with those in the Mecp2−/Y mice at the same age group (5-7 weeks). Both Mecp2−/Y strains had 
severe breathing problems in comparison to their WT littermates with a higher apnea rate (22.8 ± 
6.5 hr-1 in 12 WT mice vs 107.0 ± 7.4 hr-1 in 24 Mecp2−/Y mice, P < 0.001, df = 35, t = -7.335; 
19.7 ± 1.8 hr-1 in 11 WT rats vs 44.8 ± 2.7 hr-1 in 27 Mecp2−/Y rats, P < 0.001, df = 37, t = -5.784) 
(Fig. 5.4E) and a higher respiratory frequency variation (0.12 ± 0.02 in 14 WT mice vs 0.26 ± 
0.02 in 25 Mecp2−/Y mice, P < 0.001, df = 38, t = -6.184; 0.08 ± 0.01 in 11 WT rats vs 0.18 ± 
0.02 in 27 Mecp2−/Y rats, P < 0.001, df = 37, t = -4.454) (Fig. 5.4F). However, the apnea rate was 
significantly lower in Mecp2−/Y rats than in the Mecp2−/Y mice (P < 0.001, ANOVA and 
Student’s t-test) (Fig. 5.4E,G), while the frequency variation had no significant difference 
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between species (Fig. 5.4F,H). These results suggest that the breathing abnormalities seem less 
severe in Mecp2−/Y rats than in Mecp2−/Y mice.  
5.4.5 Hyperexcitability of LC Neurons 
Several groups of brainstem neurons are involved in breathing controls including those in 
the LC. Previous studies indicate that the Mecp2 disruption in mice causes hyperexcitability in 
LC neurons 83,97. To test whether there is a change in LC neuronal excitability in Mecp2−/Y rats, 
we studied the cells in brain slices. In whole-cell current clamp, LC neurons in Mecp2−/Y rats 
(P4w-P6w) showed spontaneous firing rate 3.0 ± 0.3 Hz, which was significantly higher than the 
WT 1.9 ± 0.2 Hz (Fig. 5.5A-C. P = 0.006, df = 34, t = -2.921 Student’s t-test). The firing rate of 
LC neurons in Mecp2−/Y rats was increased by 54.0 ± 14.6 % over the WT level (Fig. 5.5C). 
Similar results were found in Mecp2−/Y mouse model in the same age range as well (Fig. 5.5D). 
There were no differences in the membrane potential, input resistance and action potential 
amplitude between Mecp2−/Y and WT rats (Fig. 5.5E-G), neither between rats and mice. In 
Mecp2−/Y rats, the threshold of action potential was shifted to significantly more hyperpolarizing 
potentials from -34.4 ± 1.2 mV to -37.2 ± 0.8 mV (Fig. 5.5H), which appeared to contribute to 
the increased firing activity of LC neurons.   
5.4.6 Lifespan 
These RTT-like symptoms may affect the lifespan of rats. Therefore, we examined the 
survival time in the novel Mecp2−/Y rat model of RTT. The death was determined by either in-
cage death or the humane endpoint determined by our school veterinarian. A total of 18 WT 
males and 18 Mecp2−/Y rats were used in the studies, and two outliers (the longest and shortest 
survivors) were removed. Figure 5.6A shows that Mecp2−/Y rats died as early as at P45, and all 
died by P82. Only 2 out of 16 tested rats survived beyond 80 days. Similar results were found in 
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mice (not shown). In comparison, 50% of the Mecp2−/Y rats died at P63, while 50% of the 
Mecp2−/Y mice died at P52 (Fig. 5.6C). To compare these two groups of animals, we performed 
the χ2 test, and did not find any statistical difference in the ratio of survival vs death between 
these rats and mice at P52, neither at P63 (Fig. 5.6D,E). 
5.5  Discussion 
RTT is a progressive neurodevelopmental disorder caused mostly by different mutations 
in the MECP2 gene. The disease affects females mainly. Male infants rarely survive with 
pathogenic MECP2 variations, because knockout of MECP2 gene causes lethal miscarriages and 
early death in males 223,224. However, the male mice with Mecp2 disruption survive, and show 
reliable and consistent RTT-like symptoms. This leads to wide uses of these mice in RTT 
studies. Experimental approaches to the female mouse models have limitations because of the X-
chromosome inactivation and the large symptomatic variation among individuals. With the same 
consideration, our experiments were performed on the Mecp2−/Y male rats as well. This novel 
RTT rat model has a 71-bp deletion in exon 4 at 53900-53970 of the Mecp2 gene by Zinc Finger 
Nuclease technology. This results in a fragment deletion as well as a shift of the open reading 
frame leading to a complete knockout of MeCP2 225. Consistently, our studies demonstrate that 
the male Mecp2-null rats experience severe RTT-like symptoms. 
5.5.1 Recapitulation of RTT-like Phenotypes in Mecp2−ec Rats 
Many general RTT-like features have been recapitulated in the rat model of RTT, 
including growth retardation, malocclusion, lack of movement and early death. The Mecp2−/Y 
rats show weaker forelimb grip strength and less locomotion activity than the WT littermates, 
which are similar to those observed in their mouse counterparts. Defects in sociability and social 
novelty were seen in these Mecp2−/Y rats. Breathing abnormalities of the Mecp2−/Y rats including 
64 
 
irregular respiratory rhythm and high apnea rate resemble closely respiratory dysfunction in RTT 
patients and mouse models. Besides, LC neurons of Mecp2−/Y rats show excessive firing activity, 
which has also been observed in the mouse models before. A half of the Mecp2−/Y rats died in 
two months. These RTT-like symptoms observed in Mecp2−/Y rats thus are comparable to those 
seen in Mecp2−/Y mice 94,111,220. Consistently, a recent study has demonstrated that the Mecp2−/+ 
rats had similarly impaired auditory responses as Mecp2 heterozygous female mice 225,226, which 
is seen in RTT patients as well 227. Therefore, Mecp2−/Y rats recapitulated most of the RTT-like 
symptoms, making them a quality RTT model. 
5.5.2 Onset Time of RTT-like Symptoms in Mecp2−ns Rats  
RTT is characterized by relatively normal development at the earlier stage of life. The 
asymptomatic time window is usually from birth to 6 months in humans with RTT 228. In mouse 
models, the onset time and the disease progression vary depending on the nature of Mecp2 
variants and genetic background of mice. Most studies agree that Mecp2−/Y mice have no overt 
RTT symptoms within the first 3 weeks of life. After that, the null mice show rapid development 
and progression of RTT-like symptoms. Growth retardation can be observed in P4w 112,229,230. 
Locomotor problems appear in P3w-P4w in mouse models 75,231. Social defects are observed as 
early as 4 weeks after birth in mice 232. Breathing disturbances occur in null mice at P3w-P4w 
112. In Mecp2−/Y rats, these RTT-like symptoms also take place as early as 3 weeks, and become 
obvious at P4w. Thus, the onset time of the RTT-like phenotypes in the Mecp2−/Y rats is 
comparable to that in Mecp2−/Y mice. 
5.5.3 Defects of Neuronal Activity in Mecp2−ef Rats  
LC neurons are the predominant source of noradrenergic modulation in the CNS 233,234. 
They project to various regions in the brain, including forebrain, diencephalon, brainstem, 
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cerebellum and even spinal cord 233,234. Defects of LC neurons lead to dysfunction of autonomic 
nervous system, consistent with the characteristic RTT-like symptoms. In Mecp2−/Y mice, the LC 
neurons show electrophysiological defects as increased neuronal firing activity, which is likely to 
be a result of the impaired intrinsic membrane properties and the deficiency in GABA-ergic 
inhibition 98,106,235. Similar hyperexcitability of LC neurons is found in Mecp2−/Y rats, suggesting 
that the Mecp2−/Y rats may develop similar neuronal defects as Mecp2−/Y mice. In addition to LC 
neurons, neuronal hyperexcitability is seen in neurons in the hippocampus, neocortex and other 
brainstem areas in Mecp2−/Y mice, which contributes to the defects in motor function, cognition, 
sleep and other autistic features 102,104,117. These, though still unclear, may occur in other neurons 
of the Mecp2−/Y rats.  
5.5.4 Symptomatic Difference between Mecp2−ym Rats and Mice 
Although the Mecp2−/Y rat model has many similarities to the Mecp2−/Y mouse models, 
our studies suggest that the former is not a complete replica of the latter. Indeed, some RTT-like 
phenotypes are quite different between rat and mouse models. All Mecp2−/Y rats displayed 
malocclusion that appears more severe than null mice. The incisor teeth overly grow which may 
be due to the reduction of the central command of chewing activity, sick jaw muscles and/or 
abnormal propriosensation in the transgenic rats. Besides, the Mecp2−/Y rats had a proportional 
reduction in body size compared to their WT littermates, which seems more obvious than that 
seen in Mecp2−/Y mice. Another difference found in over a half of Mecp2−/Y rats is the penile 
prolapse. This symptom has been reported in transgenic mice with neurodegeneration 236 but not 
in Mecp2−/Y mice. This often hinders the penis from retraction even with the lubrication 
treatment, which contributes to the humane endpoint of the rats. Mecp2−/Y rats did not show the 
typical hindlimb grasping as Mecp2−/Y mice did 237. In the three-chamber test, old (P7w) 
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Mecp2−/Y rats barely switched between each chamber due to the poor locomotor activity, which 
has caused rejection of them from social behavioral tests. In contrast, mice do not show such 
age-dependent deterioration in locomotor activity as defects in social behaviors are reported at 
various ages from P4w to P12w in different mouse models 112,238. Furthermore, breathing 
abnormalities appear less severe in Mecp2−/Y rats than in Mecp2−/Y mice. This may be related to 
the low breathing frequency of the rats. In general, these symptomatic differences between 
Mecp2−/Y mice and Mecp2−/Y rats are rather moderate and quantitative rather than qualitative. 
5.5.5 Advantages and the Applications of the RTT Rat Model 
The rat model has several potentials in RTT studies. The understanding of the link 
between RTT phenotypes and the neuronal cellular and network mechanisms relies on in vivo 
approaches that are still difficult to be fulfilled in mice. The larger body size of rats may satisfy 
the requirement for the in vivo studies. The larger body size may benefit certain tests that need 
repetitive and timely samplings, such as measurement of blood gases, electrolytes and hormonal 
levels in circulation blood and cerebrospinal fluid, monitoring of systemic physiological 
parameters and EEG recordings. The richness of the social and communication repertoire of rats 
may also benefit the behavior studies, such as cognitive processes, anxiety, social acoustic 
memory, cooperative behaviors and auditory responses 239. Most importantly, studies on multiple 
animal models can benefit RTT research, especially when therapeutic agents are to be developed. 
Our studies indicate that the novel Mecp2−/Y rats recapitulate numerous RTT-like 
symptoms as the Mecp2−/Y mouse model do. The RTT rat model, as a valuable model in the 
studies of RTT, may provide a useful alternative in RTT studies when body size is considered to 
be a critical factor.   
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Figure 5.1 General abnormalities of Mecp2−/Y rats.  
(A) Body weight of Mecp2−/Y rats was significantly lower than that of WT littermates at P4w, 
and the difference became larger with growth (*** P < 0.001, ** P < 0.01; Student’s t-test). 
Mecp2−/Y rats also showed growth retardation (B), prolapsed penis (C), and malocclusion (D). 
(E) Typical hindlimb grasping seen in Mecp2−/Y mice was not observed in Mecp2−/Y rats.  
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Figure 5.2 Reduced muscle strength and locomotor activity.  
(A) Mecp2−/Y rats exhibited decreased forelimb grip strength compared to WT (*** P < 0.001, 
** P < 0.01, * P < 0.05; Student’s t-test). (B) In comparison to the WT, both Mecp2−/Y rats and 
mice showed a significant decrease in grip strength (Student’s t-test). (C) No statistical 
significance in the grip strength differences was found between species after normalization to the 
WT levels. (D,E) Locomotor activity was also significantly reduced in Mecp2−/Y rodents. No 
statistical significance was found between species either although the null rats appeared to move 
less (Student’s t-test). 
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Figure 5.3 Social behavior defects of Mecp2−/Y rats.  
(A,B) The habituation time in side chambers had no significant difference in Mecp2−/Y animals 
and WT littermates. (C,D) The time spending of both Mecp2−/Y animals in the intruder chamber 
(Animal 1) was more than in the empty bucket chamber (Empty). (E,F) The animal preference 
disappeared in both Mecp2−/Y animals. Familiar animal is indicated as Animal 1, and unfamiliar 
animal is labeled as Animal 2. (*** P < 0.001, ** P < 0.01, * P < 0.05; Student’s t-test)  
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Figure 5.4 Breathing abnormalities.  
(A,B) Abnormal breathing activity including apnea and irregular breathing were observed in 
Mecp2−/Y rats at P35 and P81. (C,D) Apnea rate and respiratory frequency variation were 
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significantly more in Mecp2−/Y rats than in the WT (*** P < 0.001, ** P < 0.01, * P < 0.05; 
Student’s t-test). (E-H) the breathing abnormalities were compared between mouse and rat (*** 
P < 0.001; Student’s t-test). (G) The apnea rate of Mecp2−/Y rats was significantly lower than the 
Mecp2−/Y mice after data normalization to the WT levels. (H) The severity of breathing 
frequency variation was not significantly different between rats and mice. 
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Figure 5.5 Increased excitability of LC neurons.  
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(A,B) Typical recordings of spontaneous firing activity in WT and Mecp2−/Y rat LC neurons. (C) 
In Mecp2−/Y rats, LC neurons showed a significant increase in firing frequency in comparison to 
the WT. (D) The ratio of increased spontaneous firing rate, however, was similar between rats 
and mice. (E,F) No significant differences were found in membrane potential and resistance 
between WT and Mecp2−/Y rats, which was similar as in the mouse model. (G,H) In comparison 
to the WT, Mecp2−/Y rats showed more hyperpolarized threshold of the action potential in LC 
neurons, whereas the amplitude was not altered. Similar results were found in the mouse model 
(** P < 0.01,* P < 0.05; Student’s t-test). 
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Figure 5.6 Survival rate.  
(A) The survival time of Mecp2−/Y rats was plotted in comparison to WT littermates (n = 16). (B) 
The 50% lethality was shown after normalization of the initial rate to 1. (C) A half of Mecp2−/Y 
rats died at P63, while 50% Mecp2−/Y mice dies at P52. (D) At P52 when 50 % mice were 
survived, while about 3/4 rats were still alive. (E) At P63 or the half survival age of Mecp2−/Y 
rats, only about one third of the mice were still alive. Despite these, no statistical significance 
was found between rats and mice (D,E). 
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6 RESULT 2: MECP2-DISRUPTION IN RATS CAUSES BREATHING DISORDERS 
BY RESHAPING MEDULLARY RESPIRATORY NEURONAL FIRING 
PATTERNS 
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6.2 Abstract 
Brainstem mechanisms underlying respiratory disorders of Rett Syndrome (RTT) are still 
unknown. Here we show a cellular mechanism for the respiratory disorders. In comparison to 
their wild-type counterparts, both inspiratory and expiratory neurons in Mecp2-null rats extended 
firing duration and fired more action potentials during each burst in vivo. Most inspiratory 
neurons changed their firing pattern to phase-spanning type, and kept firing during expiration 
and even apneas. Excessive activity of the inspiratory neurons raised bulbospinal drive to 
motoneurons, producing ectopic phrenic discharges during expiration. The firing patterns suggest 
inadequate synaptic inhibition necessary for phase switching. Testing this hypothesis, we found 
that the abnormalities in respiratory neuronal firing, phrenic discharge and breathing all can be 
rescued by augmenting GABAergic inhibition. Thus, the respiratory disorders in Mecp2-null rats 
appear to result from prolonged firing of the respiratory neurons, likely due to insufficient 
synaptic inhibition for phase switching. 
6.3 Introduction 
Rett Syndrome (RTT) is a neurodevelopmental disease caused mainly by mutations in the 
MECP2 gene 240. People with RTT show breathing disorders, especially hypoventilation. The 
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hypoventilation including hypopnea, gasping and apnea occurs as more severe state of the 
disease and is contributting to a high incidence of sudden death and developmental illnesses of 
the central nervous system 72,241-243. The underling mechanisms for the hypoventilation are 
unclear, while dysfunction in brainstem respiratory neuronal activity seems critical. The 
hypoventilation in RTT is believed to result from insufficient central inspiratory activity and/or 
deficient inspiratory premotor output. To prove that this scenario is correct, following events 
should occur: 1) Brainstem inspiratory neurons including bulbospinal cells switch to a firing 
pattern with shorter burst and lower overall activity; 2) phrenic nerve stop activity during 
expiration (E2 phase); 3) during central apnea that manifests itself as cessation of inspiratory 
motor neuronal activity, the inspiratory neurons suspend their activity, and phrenic discharges 
pause completely. In the rat model of RTT that shows frequent hypoventilation 84, we found that 
all these were surprisingly opposite. Both inspiratory and expiratory neurons reshaped their 
firing patterns with extended firing duration, fired more action potentials in each burst, kept 
firing even during apneas, and produced ectopic phrenic discharges during expiration. These 
firing pattern changes suggest inadequate synaptic inhibition for phase switching. By enhancing 
GABAergic inhibition, we found that the abnormalities in respiratory neuronal firing, phrenic 
discharge and breathing all can be rescued. 
6.4 Results 
6.4.1 Activity and grouping 
Experiments were performed in WT and Mecp2-null (Mecp2−/Y) rats that underwent 
intercollicular decerebration following initial anesthesia. Phrenic nerve discharges of null rats 
showed breathing rhythmic abnormalities consistent with previous plethysmograph recordings 
(Fig. 6.1) 84,88. In the rats, we performed in vivo recordings from neurons in the ventral 
respiratory column which resembled the ventral respiratory group (VRG) and the Bӧtzinger 
Complex (BӧtC) in cats 244-246. Because of this, we adopted the same terminologies as used in 
cats for each subgroup. Expiratory (E) neurons were mostly recorded in the caudal and far rostral 
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parts of the ventral respiratory column, corresponding to the cVRG and BӧtC in cats, 
respectively. Inspiratory (I) neurons were found in between, or the rostral VRG (rVRG), 
although there were overlaps (Fig. 6.2). Such cell-type grouping did not show evident difference 
between Mecp2-null and WT rats.  
6.4.2 Firing patterns of E and I neurons 
Although respiratory neurons were still retained in three major subgroups, their firing 
patterns were clearly altered in Mecp2-null rats (Fig. 6.3A-C). In comparison to the WT, 
averaged firing frequency of rVRG and cVRG neurons in null rats was significantly reduced, 
while no difference was found in BӧtC neurons (Fig. 6.3D). However, the peak frequency of all 
three groups of neurons remained the same to their WT counterparts (Fig. 6.3E). One obvious 
and consistent change in null rats was the extension of burst duration of all three types of 
neurons (Fig. 6.3F). Such a change seems to lead to underestimation of neuronal firing activity as 
the burst duration is the denominator for calculation of the averaged frequency of all neurons. 
Thus, we analyzed the overall neuronal firing activity as spikes number per burst, as well as 
frequency (in Hz) multiplied by duration (in sec). Both I and E neurons in the ventral column 
showed a higher overall firing activity in Mecp2-null rats than in the WT (Fig. 6.3G,H).  
6.4.3 E-I phase-spanning neurons 
Strikingly, we found that most neurons in the rVRG of null rats showed E-I phase-
spanning firing pattern (Fig. 6.4A-D), which accounted for two thirds of all cells (85 out of 120 
cells), in comparison to 18% (18 out of 100 phase-spanning neurons) in WT rats (P<0.001, χ2 
test) (Fig. 6.4C). Like other respiratory neurons in null rats, the burst duration of the phase-
spanning neurons was much longer than that of the WT phase-spanning cells (Fig. 6.4D). 
Because the phase-spanning neurons can be converted to I type by enhancing GABA inhibition 
(see below), the presence of a large number of these cells also indicates the extended firing of I 
neurons in Mecp2-null rats.  
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6.4.4 Post-I neurons 
A group of neurons fired action potentials in the post-inspiratory (Post-I) phase of the 
phrenic discharge 247,248. These post-I neurons have previously been shown to exist in the BӧtC 
area. We found 49 Post-I neurons in 105 BӧtC cells in the WT, but only 15 of 101 BӧtC neurons 
in Mecp2-null rats (P<0.001, χ2 test) (Fig. 6.4E,F; Fig. 6.5). The reduction in Post-I cell number 
was likely to be a result of the extension of the burst length of the cells, making them merge in 
other E neurons in null rats. 
6.4.5 Changes in phrenic discharge patterns 
As previously reported, only 50% Mecp2-null rats survive up to two months of postnatal 
age 84,88,89. At the age their breathing was much slower than that of the WT (Fig. 6.4G,H). 
Analysis of the eupneic phrenic activity revealed that the inspiration time (TI) had no significant 
difference between null and WT animals (Fig. 6.4I), while the expiration time (TE) of Mecp2-
null rats was significantly elongated (Fig. 6.4J). The elongated TE was consistent with increased 
burst length of medullary E neurons (above) and the increased excitability of E neurons. 
With the changes in TI vs TE, their ratio was significantly reduced in null rats, leading to 
slow breathing (Fig. 6.4K). In contrast, the frequency per burst of phrenic discharges was 
increased in null rats, which measured as the amplitude of integrated phrenic activity twice as 
high as the WT (Fig. 6.4L). A similar phenomenon was observed in plethysmograph breathing 
recording in conscious rats. This suggests that the Mecp2-null rats seem to switch their phrenic 
output to a slow and deep respiratory pattern that may allow decent blood gas levels despite the 
low breathing frequency. 
6.4.6 Neuronal activity during apnea 
Apnea is considered when the bursting phrenic activity escaped at least one regular 
breathing cycle, which was believed to be a result of suspension of central I activity. Studying 
activity of I and phase-spanning neurons in the rVRG during apneas, we found that most of them 
did not pause their activity during apnea, although their firing became irregular (Fig. 6.6A,B). In 
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the meantime, E neurons in the BötC and cVRG maintained their firing frequency as during 
eupneic expiration (Fig. 6.6C,D). Statistical analysis indicated that firing frequency of these I 
and phase-spanning neurons was significantly higher during apnea than during eupneic 
expiration, while E neurons in BötC and cVRG did not change firing rate (Fig. 6.6E,F). These 
results indicate that apneas in the null rats may not result from suspension of central I activity. 
6.4.7 Ectopic phrenic activity 
Although phrenic activity is exclusively inspiratory with brief post-I activity in mammals, 
expiratory phrenic activity was found in Mecp2-null rats (Fig. 6.6A-C, Fig. 6.7). Such expiratory 
phrenic activity was produced by discharges of a small number of motor neurons (Fig. 6.7A), 
which occurred in middle or late expiration in some null rats (Fig. 6.7A), or throughout the entire 
expiration phase in others (Fig. 6.7B). Such ectopic phrenic activity remained during apneas 
(Figs. 6.6A-C, 6.7A). The ectopic phrenic activity was seen in ~ one third (8 of 22) of null 
animals (Fig. 6.7C), and appeared to be related to rat physical conditions. Seven out of the 8 
animals had reached humane endpoints at the time of experiments (Fig. 6.7D). The association of 
the ectopic phrenic activity with the health status as well as its potentially adverse effects on 
ventilation suggests that such unexpected motor neuronal excitation may be one of the terminal 
events of lives in null rats.  
Antidromic stimulation of the contralateral bulbospinal pathway in the cervical cord 
showed that some of the E-I phase-spanning neurons projected to the spinal cord (Fig. 6.6G-I), 
suggesting that the ectopic phrenic activity is likely produced by the phase-spanning drive from 
the brainstem. 
6.4.8  Effects of GABA inhibition 
The excessive firing activity of medullary respiratory neurons may be due to the 
insufficient GABAergic inhibition in Mecp2-null mice 96,101,103,106,108. If so, augmentation of 
GABAergic synaptic inhibition should diminish the abnormalities in the respiratory neuronal 
firing. With this reasoning, we applied NNC-711, a GABA uptake transporter blocker, to the 
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rats. The NNC-711 treatment (10mg/kg, i.p.) reduced the difference of neuronal firing activity 
between null and WT rats, even eliminated the difference in some cell types (Fig. 6.8A-F, Fig. 
6.9), which appeared to be more potent on rVRG and cVRG neurons, whereas BӧtC neuronal 
activity of null rats was only modestly reduced by the GABA uptake blocker. The extrasynaptic 
GABA receptor agonist THIP had similar effects (Fig. 6.8A-F, Fig. 6.9). 
A single dose of NNC-711 started to have an evident effect ~20 min after injection. The 
ratio of phase-spanning neurons in the rVRG of Mecp2-null rats was reduced to ~49% and ~57% 
after NNC-711 and THIP treatment respectively (Fig. 6.8G), in comparison to ~71% in null rats 
with saline injection. Both changes were statistically significant. The same treatments had no 
significant effects on WT neurons. Moreover, the difference of burst duration of phase-spanning 
neurons between Mecp2-null and WT rats was reduced after drug treatments (Fig. 6.8H,I).  
A long period of recordings was made, including two phase-spanning neurons before and 
during NNC-711 exposure (Fig. 6.10). The acute NNC-711 treatment converted the firing pattern 
of both cells from phase-spanning to I type (Fig. 6.10A,B), while in control rats with saline 
injection, phase-spanning neurons did not change their firing pattern (Fig. 6.11). Meanwhile, the 
acute NNC-711 treatment reduced the firing frequency of these cells and shortened their 
discharge duration (Fig. 6.10C,D). The ectopic activity of phrenic nerve was drastically reduced 
with the NNC-711 treatment, accompanied by reduction of breathing rhythmic variation (Fig. 
6.10B,E). Acute THIP treatment had robust effects in some null rats as well, in which the 
breathing rhythmic variation was suppressed, the rhythmic breathing rate was increased, the 
amplitude of integrated phrenic discharges was reduced, and the ectopic phrenic activity was 
totally eliminated (Fig. 6.12A). As a result, the breathing pattern of null rats appeared to be 
rescued to the WT pattern. Such a rescue effect of THIP was also seen in awake rats tested in 
plethysmograph (Fig. 6.12B-D). Of 5 null rats that had reached humane endpoints with severe 
apnea and dyspnea, one dose of THIP injection (20mg/kg, i.p.) made the breathing patterns of all 
rats resemble the WT. Oral THIP administration in the drinking water (10mg/kg/day) was given 
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to four of these rats 48 h later for 7 consecutive days. Three of them extended their lifespan 
longer than 2 weeks with no obvious apnea and dyspnea during the period (Fig. 6.12E). 
6.5 Discussion 
This is the first demonstration of central respiratory neuronal activity in RTT models in 
vivo. Using the decerebrate preparation with spontaneous breathing, known to have no evident 
side-effects on respiratory neuronal activity, we have systematically studied all major types of 
respiratory neurons in the ventral respiratory column of the medulla oblongata. A number of 
findings has been made, many of which were unknown and unexpected.  
Our results have shown that the high incidence of hypopnea, gasping and apnea in the 
RTT model is not due to insufficient central I activity. Instead, I neurons, as well as the E 
neurons, show excessive firing activity with extended firing duration. The extended firing 
duration of these neurons can cause destabilization of the rhythmic respiratory oscillation that 
depends on coordinated synaptic interactions of the E and I neurons. A critical step in the events 
is the transition from E phase to I phase. Such a phase transition may rely on synaptic inhibition 
where GABA seems to play a role, while GABA is known to be deficient in Mecp2-null mice 
96,101,103,106,108,249. With the GABAergic defect, presynaptic neurons need to fire more action 
potentials for sufficient GABA release, while postsynaptic neurons need a longer time to become 
silent. Therefore, E neurons may not terminate their activity in a timely manner when I neurons 
have begun firing, leading to the increased firing durations of both E and I neurons. The presence 
of a large number of phase-spanning neurons also supports it, as they would fire only during I 
phase if a fast phase transition took place in a brief period of time. This idea is also supported by 
neuronal activity during apneas, as none of them stops firing during apneas indicating that the 
apnea is likely to result from incomplete termination of E activity instead of a cessation of 
central I activity. Further supporting this idea are our data showing that enhancing endogenous 
GABAergic inhibition can correct firing patterns of the respiratory neurons in null rats. 
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Another novel finding in this study is the ectopic phrenic nerve activity of null rats during 
expiration, which is likely to derive from increased central I activity rather improper projections 
from E neurons for following reasons: 1) Its appearance time and firing course resemble the E-I 
phase-spanning neurons but not the E cells. Most of the ectopic phrenic discharge starts in the 
middle of expiration, when the phase-spanning neurons begin to fire. 2) Regarding ectopic 
phrenic activity running throughout expiration, its frequency increases at a time when phase-
spanning neurons start firing (Fig. S4B). 3) Most E neurons within the cVRG and BötC start 
firing immediately after the I phase even with some overlaps with the post-I phase of phrenic 
activity. 4) Our experimental evidence indicates that some bulbospinal neurons have the E-I 
phase-spanning firing pattern. 
The ectopic phrenic discharges are produced by a small number of motor neurons shown 
as a few single-unit phrenic activities in null rats. Although we did not find evident chest 
movements during the ectopic activity, their adverse effects are obvious. With these ectopic 
phrenic discharges, a portion of diaphragm may not be relaxed during expiration, making these 
muscle fibers vulnerable to fatigue. Without a total diaphragm relaxation, exhalation may not be 
well fulfilled, requiring active expiration mediated by internal intercostal muscles. The active 
expiration normally should occur only during forced ventilation in WT animals, which may 
potentially cause fatigue of the intercostal muscles as well. Thus, the ectopic phrenic activity 
resulting from of excessive central I neuronal activity seems to be an important contributor to 
symptom development in RTT, which is consistent with our finding that the ectopic phrenic 
activity occurs most frequently in animals reaching humane endpoint.  
The demonstration of the extended firing activity of respiratory neurons with Mecp2 
disruption not only is a striking finding, but also suggests potential pharmacological 
interventions. Indeed, acute treatment of the null rats with the GABA uptake inhibitor NNC-711 
significantly reduces the extended firing activity of the respiratory neurons, converts phase-
spanning neurons to I type, and reduces the ectopic discharges of phrenic nerve. The 
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extrasynaptic GABAA receptor agonist THIP has similar neuronal effects which powerfully 
corrected the respiratory disorders in null rats. With the GABAergic interventions, the rhythmic 
phrenic activity is markedly improved, and rescued to the WT breathing phenotype. Indeed, the 
THIP treatment rescue 3 of 4 null rats that have reached humane endpoints. These suggest that 
the extended firing activity of medullary respiratory neurons plays a major part in respiratory 
disorders of null rats, and perhaps in people with RTT as well. Effective correction of such a 
general defect in the respiratory neurons appears to be a promising therapeutic strategy for the 
disease.  
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Figure 6.1 Breathing abnormalities in Mecp2-null rats.  
Plethysmograph recording (Pleth, A-C) and phrenic activity (PhN, D-F) from WT and Mecp2-
null rats. The latter exhibited variations in breathing frequency and amplitude as well as apnea 
starting from postnatal 4 weeks. The respiratory abnormalities became severe when animal 
reached humane endpoint. 
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Figure 6.2 The localization of inspiratory (I) and expiratory (E) neurons in ventral respiratory 
column.  
Location was measure from the obex on the left side of brainstem. Cells with different firing 
pattern were clearly separated into three areas with overlapping to some extent.  
86 
 
 
 
Figure 6.3 Firing activity and patterns of respiratory neurons.  
(A-C) Neurons with expiratory (E) rhythm were recorded from cVRG and BӧtC, and cells with 
inspiratory (I) rhythm were found in rVRG. (D) Firing frequency of rVRG I neurons and cVRG 
E neurons was significantly lower in null rats than in WT rats, while firing frequency of BӧtC E 
neurons did not show significant difference between WT and null rats (I neurons in rVRG: n = 
48 in WT and n = 63 in Mecp2-null rats, respectively; cVRG E neurons: n = 29 and n = 29; BӧtC 
E neurons: n = 43 and n = 65). (E) Peak frequency of all three groups of neurons had no 
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difference between WT and null rats. (F) Neuronal burst duration of all types of cells was 
measured with significant increase in null rats. (G) Spike number of each burst was measured in 
all groups of neurons, which was significantly higher in null rats than in WT rats. (H) Neuronal 
activity calculated as frequency (Hz) × duration (sec) was significantly higher in null rats than in 
the WT.  , P<0.05;   , P<0.01;    , P<0.001 (Student’s t-test); NS, no significance. Traces: 
phrenic nerve activity (PhN), integrated phrenic nerve discharge (ʃPhN). Note the presence of 
ECG activity in PhN. 
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Figure 6.4 Phase-spanning, Post-I neurons and discharge patterns of phrenic nerve in WT 
and Mecp2-null rats.  
(A and B) Neurons with E-I phase-spanning activity were recorded from rVRG in WT and 
Mecp2-null rats. Black bar, phase-spanning duration in expiration. (C) The number of E-I phase-
spanning cells in rVRG was significantly greater in Mecp2-null rats than in the WT (*** 
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P<0.001, χ2 test). (D) The phase-spanning duration in expiration (TE) was significantly longer in 
null rats as well (P<0.001, n = 43, Student’s t-test). (E and F) Post-I neurons and its ratio with all 
other E cells in the BӧtC area (*** P<0.001, χ2 test). (G) Phrenic discharge (PhN) and integrated 
phrenic activity (ʃPhN) recorded from a WT rat show relatively stable rhythmicity and amplitude. 
(H) In a Mecp2-null rat, such phrenic activity was slow and irregular with large amplitude. (I) 
Inspiratory duration (TI) of phrenic activity did not show significant difference between WT and 
null rats (P = 0.936, measured in 21 WT and 18 Mecp2-null rats, with at least 20 phrenic bursts 
from each animal). (J) Expiratory duration (TE) was significantly longer in null than WT rats 
(P<0.001). (K) The ratio of inspiration vs expiration duration (TI/TE) was significantly smaller in 
null rats than the WT (P<0.001). (L) The amplitude of integrated phrenic activity was larger in 
null rats than the WT at age 1.5 to 2.5 months (30 WT rats vs 21 Mecp2-null rats with P = 
0.033). Arbitrary unit (a.u.). Student’s t-test. 
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Figure 6.5 The localization of Post-I neurons in Mecp2-null and WT rats.  
The axes indicate distances from obex (A and C) and the dorsal surface (B and D).  
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Figure 6.6 Neuronal activity during apneas in null rats.  
(A) An inspiratory (I) neuron recorded in rVRG. It stopped firing completely during eupneic E 
phase, but started firing in the middle of apnea (double-head arrow). In the null rat, the phrenic 
nerve displayed single-unit discharges (arrows) during expiration. Such ectopic phrenic 
discharges were also seen during apnea. (B) An E-I phase-spanning cell recorded in rVRG. 
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During eupnea its firing started in the early E phase, and lasted to the end of I phase. During 
apnea, the cell started firing after a similar pause, and continued its firing throughout the apnea 
period. (C and D) E neurons in cVRG and BӧtC remained active during apnea. Note that ectopic 
phrenic discharges are seen in B and C, but not in D. (E) Parallel comparison of firing rates 
during eupneic expiration vs. apnea. Significant increases in firing rate was found in I and E-I 
phase-spanning (PhS) cells in rVRG. The firing rats of E neurons in cVRG and BӧtC did not 
show any significant difference between eupneic expiration and apnea (**, P<0.01; ***, 
P<0.001; paired Student’s t-test). (F) The net difference of the firing rate between eupneic 
expiration and apnea in I and PhS cells. Data are obtained from E. G. Schematic of the 
antidromic stimulation experiment to identify bulbospinal neurons. (H and I) I and PhS cells 
with antidromic stimulation in the collision test. Lower panel: Both cells showed steady 
responses to antidromic stimulation (arrow) and collision test, i.e., the antidromic response (star) 
was eliminated with a prior action potential (dot) in a short latency. 
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Figure 6.7 Ectopic phrenic activity in Mecp2-null rats.  
(A1) Ectopic phrenic discharges occurred in the middle of expiration and apneas in a Mecp2-null 
rat that had reached humane endpoint. (A2 and A3)With extended time scales, the ectopic phrenic 
ectopic activity consisted of three single units of action potentials with two of them shown in A3 
by arrows and arrow heads, respectively. (B) In another Mecp2-null rat, the ectopic phrenic 
discharges occurred throughout the expiration and apnea. (C) Eight out of 22 Mecp2-null rats 
had the phrenic ectopic signal. (D) Seven out of these 8 rats reached humane endpoint. 
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Figure 6.8 Effects of GABAergic augmentation on respiratory activities.  
(A-F) Neuronal firing activities were tested with THIP or NNC-711. The drug treatments 
significantly reduced the differences between WT and Mecp2-null rats in burst spikes and firing 
activity of neurons. Spike number of THIP: rVRG: 19.1 ± 2.1, n = 45 in WT vs 24.3 ± 2.0, n = 41 
in Mecp2-null; cVRG, 13.5 ± 1.7, n = 24 vs 18.1 ± 4.0, n = 14; BӧtC, 14.7 ± 2.0, n = 22 vs 
25.6 ± 4.0, n = 16. Spike number of NNC-711: rVRG: 18.0 ± 1.5, n = 63 vs 14.7 ± 1.9, n = 30; 
cVRG, 11.2 ± 1.0, n = 41 vs 15.2 ± 2.1, n = 21; BӧtC, 8.4 ± 0.8, n = 31 vs 19.2 ± 4.3, n = 12. 
Activity of THIP: rVRG, 23.2 ± 2.9 vs 39.5 ± 3.9; cVRG, 16.9 ± 2.7 vs 22.1 ± 5.3; BӧtC, 
16.2 ± 2.4 vs 28.7 ± 5.0. Activity of NNC-711: rVRG, 22.0 ± 2.3 vs 23.4 ± 3.2; cVRG, 15.0 ± 2.0 
vs 21.7 ± 2.8; BӧtC, 8.8 ± 1.2 vs 27.2 ± 6.3. (G) The ratio of E-I neurons vs total rVRG cells was 
significantly reduced after THIP or NNC-711 treatment in Mecp2-null rats (χ2 test). WT: 16% to 
16% or 19%; Mecp2-null: 71% to 57% or 49%. (H) Duration of E-I neurons in Mecp2-null rats 
reduced by GABAergic augmentation. TE of phase-spanning cells in WT changed from 
217.3 ± 20.9 ms (n = 14) to 427.8 ± 103.4 ms (n = 11) or 217.7 ± 24.0 ms (n = 14) respectively 
after THIP or NNC-711 treatment, while TE of phase-spanning cells in Mecp2-null reduced from 
1031.5 ± 125.1 ms (n = 43) to 690.5 ± 144.7 ms (n = 38) or 682.4 ± 123.0 ms (n = 29). (I) 
Difference of normalized burst duration of E-I cells between Mecp2-null and WT disappeared 
after intervention of GABAergic augmentation. Normalized phase-spanning ratio of WT 
maintained similar (0.61 ± 0.03 to 0.62 ± 0.03 or 0.60 ± 0.02 respectively after THIP or NNC-
711 treatment), while that of Mecp2-null reduced from 0.70 ± 0.02 to 0.64 ± 0.02 or 0.60 ± 0.02. 
(Two-way ANOVA followed by a Bonferroni post hoc test. *, significant difference comparing 
WT to Mecp2-null in same treatment group, #, significant difference comparing sham to THIP or 
NNC-711 groups within the same genetic background.) 
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Figure 6.9 Neuronal firing pattern was changed by intervention of GABAergic augmentation.  
The THIP or NNC-711 treatment shortened the firing duration of Mecp2-null rats and reduced 
the difference of neuronal frequency between null and WT rats, while the peak frequency was 
intact. (A) Firing duration of WT in rVRG maintained at 322.3 ± 19.5 ms (n = 45) or 
335.9 ± 21.0 ms (n = 63) respectively after THIP or NNC-711 treatment, and that of Mecp2-null 
reduced to 744.0 ± 66.6 ms (n = 41) or 621.4 ± 97.4 ms (n = 31). (B) Firing duration of WT in 
cVRG maintained at 501.2 ± 64.4 ms (n = 24) or 388.5 ± 31.6 ms (n = 41), and that of Mecp2-
null reduced to 730.3 ± 173.5 ms (n = 14) or 876.6 ± 113.75 ms (n = 21). (C) Firing duration of 
WT in BӧtC maintained at 556.4 ± 90.66 ms (n = 22) or 392.5 ± 30.46 ms (n = 31) respectively, 
and that of Mecp2-null reduced to 895.6 ± 139.4 ms (n = 16) or 774.3 ± 144.5 (n = 12). (D) 
Firing frequency in rVRG reduced to 62.8 ± 6.2 Hz or 60.8 ± 4.2 Hz in WT vs 58.0 ± 4.0 or 
44.0 ± 4.9 ms Hz in Mecp2-null respectively. (E) Firing frequency in cVRG reduced to 
33.2 ± 3.5 Hz or 34.5 ± 2.6 Hz in WT vs 30.2 ± 5.2 Hz or 27.6 ± 3.2 Hz in Mecp2-null 
respectively. (F) Firing frequency in BӧtC didn’t change much, only reduced to 30.4 ± 3.1 Hz or 
21.0 ± 2.1 Hz in WT vs 34.9 ± 6.2 Hz or 31.9 ± 7.0 Hz in Mecp2-null respectively. (G-I) Peak 
frequency of all cells were not affected by drug treatments. Two-way ANOVA followed by a 
Bonferroni post hoc test. 
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Figure 6.10 Firing pattern changes of phase-spanning neurons after NNC-711 treatment.  
(A) Continuous recordings from a phase-spanning neuron before and after NNC-711 injection 
(10 mg/kg, i.p.). The cell changed its firing pattern to I type 20 min after the injection, and 
maintained it throughout the rest of recording period. (B) Similar phenomenon was seen in 
another phase-spanning neuron from a different rat where phrenic recording showed severe 
irregularity, apneas and ectopic discharges. After NNC-711 injection, the cell changed its firing 
to a pattern more like I type with improvements of all other abnormalities in phrenic activity. (C-
E) The NNC-711 treatment reduced firing frequency and burst duration of both the phase-
spanning neurons as well as phrenic breathing variation. Circle, cell A; triangle, cell B.  
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Figure 6.11 Saline injection had no effect on PhS activity in Mecp2-null.  
Firing activity and pattern did not change in 20 min continuous recording. 
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Figure 6.12 Rescue of phrenic activity and breathing pattern with THIP treatment.  
(A) Continuous recording of phrenic activity from a Mecp2-null rat before and after THIP 
injection (20 mg/kg, i.p.). The rat had reached humane endpoint before the experiment. Its 
physical condition was confirmed by phrenic activity and discharge patterns, showing extremely 
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slow breathing, large variations in breathing rhythm and amplitude, widespread apneas, and 
severe ectopic phrenic activity. The first sign of symptomatic improvement was the robust 
inhibition of the ectopic phrenic activity 40 min after THIP injection (also compare A1 with A2). 
A marked increase in breathing frequency and a reduction in the amplitude of integrated phrenic 
activity occurred 58 min after THIP injection with total elimination of the ectopic phrenic 
activity (A3). The phrenic activity and discharge pattern resembled very much the WT with 
disappearance of apneas 76 min after the injection. (B) Breathing activity of an awake null rat 
was recorded using whole-body plethysmography at baseline and different time points after 
20mg/kg THIP injection. The THIP treatment eliminated the abnormal breathing and rescued 
this Mecp2-null rat that had reached humane endpoints. The same study was done in 5 Mecp2-
null rats reaching humane endpoints. A single dose of THIP injection (20mg/kg, i.p.) reduced 
their averaged apnea counts per hour (C), and breathing frequency variation (D). (E) After the 
THIP injection, 4 of the 5 rats were also treated with oral THIP in the drinking water 
(10mg/kg/day). Three of them extended the lifespans longer than 18 days.  
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7 RESULT 3: THE SUR2B SUBUNIT OF RAT VASCULAR KATP CHANNEL IS 
TARGETED BY MIR-9A-3P INDUCED BY PROLONGED EXPOSURE TO 
METHYLGLYOXAL 
Published as “Shan-Shan Li,* Yang Wu,* Xin Jin,* and Chun Jiang. The SUR2B subunit of rat 
vascular KATP channel is targeted by miR-9a-3p induced by prolonged exposure to methylglyoxal. Am J 
Physiol Cell Physiol. 2015 Jan 15;308(2):C139-45.” 
* S-S. Li, Y. Wu, and X. Jin contributed equally to this study. 
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7.2 Abstract 
ATP-sensitive K+ (KATP) channels regulate plasma membrane excitability. The 
Kir6.1/SUR2B isoform of KATP channels is expressed in vascular smooth
 muscles and plays an 
important role in vascular tone regulation. This KATP channel is targeted by several reactive 
species. One of them is methylglyoxal (MGO), which is overly produced with persistent 
hyperglycemia and contributes to diabetic vascular complications. We have previously found that 
MGO causes posttranscriptional inhibition of the KATP channel, aggravating vascular tone 
regulation. Here we show evidence for the underlying molecular mechanisms. We screened 
microRNA databases and found several candidates. Of them, miR-9a-3p, increased its expression 
level by ~240% when the cultured smooth muscle cell line was exposed to micromolar 
concentrations of MGO. Treatments with exogenous miR-9a-3p downregulated the SUR2B but 
not Kir6.1 mRNA. Antisense nucleotides of miR-9a-3p alleviated the effects of MGO. 
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Quantitative PCR showed that the targeting sites of the miR-9a-3p were likely to be in the coding 
region of SUR2B. The effects of miR-9a-3p were mostly eliminated when the potential targeting 
site in SUR2B was site-specifically mutated. Our functional assays showed that KATP currents 
were impaired by miR-9a-3p induced with MGO treatment. These results suggest that MGO 
exposure raises the expression of miR-9a-3p, which subsequently downregulates the SUR2B 
mRNA, compromising KATP channel function in vascular smooth muscle. 
7.3 Introduction 
Diabetes mellitus is a major challenge to biomedical sciences 250. Diabetes causes 
metabolic alterations leading to excessive production of various intermediary metabolites 180. 
One of them is methylglyoxal (MGO), a highly reactive carbonyl species (RCS) 174,202,203. MGO 
can react with proteins, nucleotides, and lipids, damaging these molecules and promoting 
inflammation and cell injuries 251-253. Normally, MGO is rapidly detoxified by metabolic and 
redox enzymes so that it is maintained at a rather low level 254. Under diabetic conditions, 
however, the increased production of precursor molecules and impaired carbonyl detoxification 
system result in overproduction and accumulation of this RCS 255. The imbalance in the 
production and clearance of RCS then leads to carbonyl stress, which is known to play an 
important role in the development of diabetic complications, especially in the vasculature 256-258.  
In the vasculature, an increase in MGO levels can impair structure and function of the 
vascular walls by acting on the vascular smooth muscle, endothelium, or both. This in turn 
disrupts the signaling network in these cells, triggers structural remodeling of the vascular wall, 
propagates vascular inflammation, and causes vascular dysfunction 259-261. Indeed, our recent 
studies have shown that an important molecular target of MGO in the vasculature is the ATP-
sensitive K+ (KATP) channel 
206. 
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The vascular KATP channel consisting of Kir6.1 and SUR2B subunit is expressed in VSM 
cells. This KATP channel is modulated by a number of vasoactive substances and metabolites 
262. 
Changes in channel activity in altered metabolic states affect membrane excitability as well as 
vascular tones and permeability 141,263,264. Disruption of the KATP channel has severe 
consequences as shown in KATP channel-knockout mice 
265-268. In diabetic patients, KATP channel 
dependent vasodilation is impaired, suggesting that KATP channel dysfunction occurs under 
diabetic conditions 269,270. In our recent studies, we have found that a prolonged exposure to 
MGO brings about inhibition of the KATP channel and augmentation of vasoconstriction 
responses 206. However, the underlying mechanisms for the MGO-induced inhibition of KATP 
channel are still unclear. 
MicroRNAs (miRs) are important regulators of gene expression especially in diseased 
conditions. In eukaryotes, miRs are encoded by nuclear DNA and transcribed as longer hairpin 
transcripts known as pre-miRs. After processed by the Drosha and Dicer enzymes, one strand of 
the hairpin duplex is loaded to an Argonaute family protein to form the core of miR-induced 
silencing complex that subsequently functions via base-pairing with complementary sequences 
of the target mRNA to regulate the mRNA life and its capability of translation. In the process, 
the binding of miRs to the target mRNA is important for their recognition. Most miR binding 
sites sufficient for the transcript silencing are located in the 3’-untranslated region (3’-UTR), 
while some are in the coding sequence (CDS). Our previous studies have suggested that MGO 
acts on the CDS of SUR2B mRNA, impairing their stability as well as KATP channel activity 
206. 
Thus, it is possible that under diabetic conditions, the reactive carbonyl stress raises the 
expression of miRs that subsequently target the KATP channel, and impair the vascular tone 
regulation. To test this hypothesis, we performed the present studies. 
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7.4 Results 
7.4.1 Expression profiling of candidate miRNAs in reactive carbonyl stress.  
In diabetic patients, persistent hyperglycemia leads to overproduction of MGO to ~400 
µM 271,272. In our previous study, we found that exposure to 300 µM MGO causes disruption of 
vascular KATP channels 
206. Therefore, we used this concentration of MGO in the present study. 
We first screened the potential miR candidates targeting mRNAs of rat Kir6.1 and 
SUR2B subunits using bioinformatics, as our previous experiments were mostly done in the rat 
A10 VSM line. On the basis of their mammalian conservation and potential involvement in 
diabetes in existing literature, nine diabetes-associated miRs were found. Among them, three 
miRs were potentially targeting Kir6.1, and six miRs were potentially targeting SUR2B. 
Subsequently, the expression profiles of the nine mature miRs were determined in A10 VSM line 
following MGO exposure. Our qPCR analysis showed that the MGO treatment resulted in a 
significant increase of miR-9a-3p level by 2.4 ± 0.2-folds (n = 3 separated experiments with 3–6 
samples each), while none of the other miRs increased their expression significantly (Fig. 7.2). 
We did not further study miRs that showed reductions in their expression as according to current 
literature they did not seem to have a direct effect on KATP channel inhibition by MGO exposure. 
Because of this and because miR-9a-3p is highly conserved in mammals (Fig. 7.1A), all further 
studies were performed on miR-9a-3p. 
7.4.2 Inhibition of KATP channel expression by MGO and miR-9a-3p 
To show whether miR-9a-3p affects KATP channel expression, one chemically 
synthesized and optimized double strand sequence to the mature endogenous miR-9a-3p. Also 
synthesized was one single-strand nucleotide complementary to the mature miR-9a-3p (anti-9). 
104 
 
We then transfected the A10 cells with these synthetic nucleotides and studied their effects on 
the expression of SUR2B subunit after MGO exposure. 
Our qPCR analysis showed that the m-9 transfection caused suppression of the SUR2B 
mRNA expression (Fig. 7.3), which resembled the effect of MGO. Meanwhile, the effect of 
MGO was markedly diminished when the cells were transfected with anti-9 (Fig. 7.3). Consistent 
with qPCR results, Western blot analysis showed that m-9 inhibited SUR2B expression at the 
protein level, while anti-9 partially blocked the MGO effect (Fig. 7.4A,B). To determine whether 
m-9 also acts on Kir6.1 in the same conditions, we tested the expression of Kir6.1 at protein 
level. Our data showed that m-9 had no effect on Kir6.1 protein expression (Fig. 7.4C,D). These 
results suggest that miR-9a-3p regulates vascular KATP channel expression, which appears 
necessary for MGO to produce its effect. 
7.4.3 Targeting at the CDS of SUR2B  
Our bioinformatics analysis showed that a 9 seed-nucleotide region in the position 661–
685 of rat SUR2B mRNA matches the miR-9a-3p, which also can be recognized in mouse (608–
632) and human (2720 –2744) SUR2B mRNAs (Fig. 7.5A). Several constructs were made to 
demonstrate whether such a potential binding site interacts directly with miR-9a-3p. The mouse 
SUR2B mRNA was cloned into the pcDNA3.1 vector (SUR). Site-directed mutagenesis of two 
nucleotides at positions 622 and 625 without changing the amino acids (M-SUR) was also 
carried out using the same vector (Fig. 7.1C). We then cotransfected the HEK293 cells together 
with the M-SUR and m-9. The cotransfection of HEK293 cells with the SUR alone or scmiR was 
used as negative control. As shown in Fig. 7.5B, the cotransfection of HEK293 cells with the 
SUR and m-9 resulted in downregulation of SUR mRNA expression compared with controls, 
which is consistent with our findings in the A10 cells. This effect of m-9 was abrogated when the 
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miR-9a-3p binding site was mutated (Fig. 7.5B). Therefore, these results suggest that miR- 9a-3p 
is likely to target the SUR2B CDS, and the position 608–632 seems to be an important target 
site. 
7.4.4 Inhibition of functional KATP currents by miR-9a-3p  
To prove that exogenous m-9 and anti-9 had a functional impact on KATP channels, we 
studied its effects on heterologously expressed Kir6.1/SUR2B channels in HEK293 cells, in 
which KATP currents were relatively large and sufficient for a long-term analysis. Equal high 
concentrations of K+ (145 mM) were applied to both sides of the membranes. The membrane 
potential was held at 0 mV and stepped to -80 mV every 3 s in voltage clamp. Pinacidil (Pin), a 
specific KATP opener, and glibenclamide (Glib), a KATP inhibitor, were used to set a window of 
KATP channel activity. At the basal level, KATP channel activity was low. Exposure to 10 µM Pin 
strongly activated KATP currents, which were subsequently suppressed by 10 µM Glib (Fig. 
7.6A). 
Consistent with our previous study 206, a marked inhibition in KATP currents occurred 
after cells were treated with MGO for 12 h (Fig. 7.6B). In cells transfected with anti-9, the MGO 
effect was drastically attenuated (Fig. 7.6C,D).  
A significant inhibition in KATP currents was found after the cells were cotransfected with 
m-9 (Fig. 7.7B), to the degree similar to the effect of MGO on KATP currents (Fig. 7.6B). KATP 
current inhibition was reversed partially when the binding sites for miR-9a-3p were mutated in 
SUR2B (M-SUR) (Fig. 7.7C,D). In contrast, scmiR had no effect on KATP channel activity (data 
not shown). 
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7.5 Discussion 
This is the first demonstration of regulation of KATP channel by miRs. The miR-9a-3p is 
upregulated in MGO-induced carbonyl stress. By targeting the CDS of SUR2B, the miR-9a-3p 
inhibits KATP channel expression, leading to a reduction in KATP channel activity. 
In diabetic conditions, persistent hyperglycemia leads to overproduction of a variety of 
RCS including the highly reactive MGO, contributing to the development of diabetic 
complications. Acting on proteins, lipids, or nucleotides, excessive 
MGO can cause carbonyl stress and cell damage. Our previous studies have shown that 
MGO acts on KATP channels in VSM cells, causing instability of Kir6.1 and SUR2B mRNAs, in 
which the 3’-UTR of Kir6.1 and the CDS of SUR2B are likely to be targeted 206. As a result, a 
loss of functional KATP channels occurs followed by dysregulation of vascular tone 
206. 
Emerging evidence suggests that miRs contribute to the pathogenesis of diabetes and 
diabetic complications 273-276. Since each miR has its potential targeting genes, information of 
miR involvement in diabetes is helpful for identification of the targeted molecules as well. The 
expression of these miRs may be upregulated by several pathological conditions in diabetes 
including the carbonyl stress. Therefore, it is reasonable to believe that the instability of Kir6.1 
and SUR2B mRNAs shown in our previous studies is attributable to certain miRs. 
With bioinformatics prediction, nine diabetes-associated miRs were selected for the 
profiling in carbonyl stress. With the information, we treated the A10 VSM cell line with 300 
µM MGO, a concentration that is seen in serum of diabetic patients and also found effective for 
KATP disruption 
206. With the MGO treatment, we have found that miR-9a-3p is upregulated, 
while none of the other eight miRs show a significant increase in their expression levels. miR-9a-
3p is highly conserved in mammals and has potential targeting sites in the human SUR2B gene 
107 
 
as well. Under diabetic conditions, miR-9 is suggested as being involved in insulin secretion by 
targeting Sirt1 in pancreatic β-islets 277. However, no previous study has reported that miR-9a-3p 
is regulated by RCS under diabetic conditions. Therefore, our current study provides the first 
evidence for the upregulation of miR-9a-3p in reactive carbonyl stress. 
In A10 cells, we overexpressed m-9 with/without MGO treatment and found inverse 
correlations between the exogenous miR-9a-3p and SUR2B mRNA levels. Consistently, 
antagonizing the endogenous miR-9a-3p with anti-9 reversed the MGO-induced reduction of 
SUR2B expression. In HEK cells, our qPCR and Western analysis further proved that the CDS 
of SUR2B was directly targeted by miR-9a-3p. These results thus indicate that miR-9a-3p is 
involved in MGO-induced disruption of vascular KATP channels by targeting at the CDS of 
SUR2B. 
The SUR2B targeting by miR-9a-3p should have an impact on KATP channel activity. Our 
data indeed show that miR-9a-3p inhibits functional KATP currents to the degree similar to MGO 
treatment. The effects of MGO on KATP channel can partially be reversed when the endogenous 
miR-9a-3p was knocked down with anti-9, further supporting that miR-9a-3p mediates the 
modification of KATP channels in carbonyl stress. Our site-directed mutagenesis studies confirm 
that miR-9a-3p targets SUR2B mRNA at the CDS region. 
In our previous studies, we have found that MGO causes instability of both Kir6.1 and 
SUR2B mRNAs 252. Although miR-9a-3p is likely to target SUR2B, the Kir6.1-targeting miR(s) 
remains to be demonstrated. Since none of the three conserved miRs that we have studied seems 
to be the player, and since miR-9a-3p does not affect Kir6.1 expression either, we speculate that 
the Kir6.1 may be targeted by miRs that are either non-conserved or missing in the database. 
Alternatively, the Kir6.1 inhibition by MGO may not be mediated by miRs at all. 
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Mouse models of loss-of-function of SUR2 genes have shown the critical role of the 
vascular KATP channel in the coronary circulation. KATP channel dysfunction in mice leads to 
coronary vasospasm and sudden death 265,268. Notably, in SUR2-/- mice, loss of hyperpolarizing 
KATP current causes abnormally elevated [Ca
2+]i, leading to a reduction in coronary artery 
vasospasm 265. Therefore, vascular KATP channel targeting by miR-9a-3p appears consistent with 
the adverse effects of MGO on vasculatures. 
Recent studies indicate that the activity of the vascular isoform of KATP channels is 
necessary for the systemic responses in diabetes. The increased metabolic rate requires a 
corresponding elevation in cardiac output to meet the metabolic demands. Therefore, KATP-
mediated vasodilation may act as compensatory role for several vital organs perfusion. Our 
studies indicate that miR-9a-3p modulates the KATP channel, which compromises the 
compensatory vasodilation in several vital organs and leads to inadequate perfusion, contributing 
to tissue hypoxia and cell injury. Therefore, our studies on miR mediated KATP channel 
regulation in diabetes may help in the understanding of diabetic organ dysfunction.  
A number of diabetes-associated miRs have been identified. Some miRs are involved in 
tissue dysfunction, including retina, kidney, peripheral nerves, heart, and the vasculature. For 
instance, some miRs modulate the renin-angiotensin-aldosterone system, like miR-181a, miR-
663, miR-155, miR-29b, miR-129-3p, and miR-132, and oxidative stress like miR-377, miR-
23a/b, miR-27a, miR-24, miR-335, miR-205, and miR-210 in diabetic nephropathy 278. Some 
miRs have been proved to be involved in vascular endothelial damage like miR-195, miR-503, 
and miR-146a in diabetic retinopathy 279-281, and some miRs like miR-34b, miR-34c, miR-199b, 
miR-210, miR-650, and miR-223 are shown to be dysregulated in diabetic ischemic heart failure 
patients 282. Therefore, our present study illustrating the role of MGO-induced miR-9a-3p in 
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VSM cells helps in the understanding of the molecular mechanisms of vasculature dysfunction in 
diabetes. 
At present, the mechanisms regulating miR expression and activity are still not fully 
understood. There is no information on the up- and downregulation of miRs by MGO in VSM 
cells either. Since the basic miR biogenesis pathways involve miR transcription, Drosha and 
Dicer processing, RNA editing, RNA modification, Argonaute loading, and RNA decay, MGO 
as a reactive carbonyl may act on one or some of these molecules affecting miR expression. 
Accumulating evidence suggests that aberrant DNA methylation of tumor suppressor genes 
occurs commonly in cancer, and events for miR hypermethylation/hypomethylation are found to 
play a role in human metastasis 283,284. Indeed, MGO-mediated DNA demethylation has been 
found to alter the cellular redox balance in human cataract formation 285. Similar mechanisms 
may work in the VSM cells in reactive carbonyl stress. Thus, our findings in the present study 
may stimulate further studies of the regulation of miRs by RCS as well as the resulting vascular 
complications in diabetes. 
Other unidentified targets may exist as miR-9a-3p sequence has multiple partial matches 
with Abcc9, Kir6.1, and other mRNAs. Indeed, miR-9a-3p seed match regions are found at three 
places in rat Abcc9 (675-AGCTTTAT-682, 5404-GCTTTAT-5398, and 5978-GCTTTAT-5972). 
Thus, we cannot rule out the possibility that other sites may also be targeted by miR-9a-3p in rat 
SUR2B and perhaps Kir6.1 as well. 
In conclusion, the present study provides the first evidence for regulation of KATP 
channels by miRs. Our results indicate that miR-9a-3p plays an important role in the regulation 
of vascular KATP channels in reactive carbonyl stress, acting on the CDS of the SUR2B and 
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inhibiting KATP channel activity. Therefore, the stabilization of miR-9a-3p levels may be a novel 
strategy for clinical treatment of diabetic vascular complications. 
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Figure 7.1 Mutation sites in Kir6.1 and SUR2B mRNA.  
(A) Evolutionary conservation of miR-9a-3p among mammals. (B) Sequences of SUR2B mRNA 
(SUR). (C) Sequences of mutated SUR2B mRNA (M-SUR). Mutated sites were numbered in 
SUR2B mRNA. Some omitted sequences are represented with “N”. Underlined letters are 
targeting sites for miR-9a-3p. 
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Figure 7.2 Profiling of MGO-regulated microRNAs (miRs) in A10 cells.  
A10 cells were treated with 300 µM MGO for 6h. Real-time quantitative PCR (qPCR) analysis 
then was performed to show changes in expression levels of candidate miRs targeting on Kir6.1 
(A) and SUR2B mRNA (B). U6 was used for normalization. **, P <0.01 (n = 3 separated 
experiments with 3-6 samples each). 9a-3p, miR-9a-3p; 29b-2-5p, miR-29b-2-5p; 139a-5p, miR-
139a-5p; 146a-5p, miR-146a-5p; 152-3p, miR-152-3p; 185-5p, miR-185-5p; 199a-5p, miR-199a-
5p; 200b-3p, miR-200b-3p; 708-5p, miR-708-5p; U6, RNU6. 
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Figure 7.3 Inhibitions of SUR2B mRNA expressions by MGO and exogenous miR-9a-3p.  
After transfection with m-9, A10 cells were cultured for 12-24h. Cells transfected with anti-9 
were also treated with 300 µM MGO and cultured under the same condition. A marked reduction 
in the relative quantity (RQ) of SUR2B mRNA was found in cells transfected with m-9, to the 
similar degree as the effect of 300 µM MGO treatment. The effect of MGO was significantly 
reduced in cells transfected with anti-9. Cells transfected with scrambled RNA (scmiR) were 
used as control. GAPDH was used for internal normalization. *, P <0.05; **, P <0.01 (n = 4). 
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Figure 7.4: Effects of miR-9a-3p on MGO-induced inhibition of SUR2B/Kir6.1 expression at 
the protein level.  
After transfection with m-9, A10 cells were cultured for 12–24 h. Cells transfected with anti-9 
were also treated with 300 µM MGO and cultured under the same conditions. Cells transfected 
with scmiR were used as negative control, and GAPDH was used for normalization. (A, C) 
Western blot assay of expression of protein levels of SUR2B (A) and Kir6.1 (C). (B, D) bar 
graphs represent the photodensity of each protein. *, P <0.05; ***, P <0.001 (n = 3–4). 
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Figure 7.5 Targeting sites in SUR2B mRNAs by miR-9a-3p.  
(A) Seed matches region of miR-9a-3p to the SUR2B mRNA. The seed regions were numbered 
in positions of SUR2B mRNA. The conserved seed matches in different species were 
represented with dots. (B) qPCR assay for SUR2B mRNA reduction by CDS targeting. 
Cotransfection of HEK293 cells with m-9 and the SUR2B mRNA construct (SUR) led to 
significant inhibition of SUR2B expression level. Such inhibition was abrogated when cells were 
cotransfected with m-9 and M-SUR (2 site mutations in SUR2B mRNA). ***, P <0.001 (n = 3). 
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Figure 7.6 Effects of MGO and miR-9a-3p on functional KATP currents.  
One day after Kir6.1/SUR2B channels were expressed in HEK293 cells, the cells transfected 
with anti-9 were treated with 300 µM MGO and cultured for 12-24h. Cells transfected with 
scmiR was used as negative control. (A) KATP currents were recorded using symmetric K
+ 
concentration of internal and bath solutions. Inward K+ currents were elicited with voltage 
commands from 0 to -80 mV every 3 s. The KATP currents were strongly activated by 10 µM 
pinacidil (Pin) and were inhibited by 10 µM glibenclamide (Glib). (B) MGO treatment 
significantly suppressed KATP current in HEK cellS. (C) MGO-induced reduction of KATP 
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currents was reversed in anti-9-transfected cells. (D) Current density was represented as the bar 
graph. **, P <0.01 (n = 8-10 cells). 
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Figure 7.7 Inhibitions of KATP currents by miR-9a-3p.  
Experiments were done as described in Fig. 7.6. Cells transfected with scmiR was used as 
negative control. (A) KATP Currents were recorded from the negative control (Ctl). (B) Pin-
induced currents became much smaller in m-9 transfected cells. (C) The m-9 induced current 
inhibitions were abrogated when their targeting sites in SUR2B subunit was mutated. (D) Effect 
of miR-9a-3p on the current density was represented in the bar graph. **, P <0.01 (n = 8 to 10 
cells). 
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8 RESULT 4: OPTOGENETIC APPROACH FOR FUNCTIONAL ASSAYS OF THE 
CARDIOVASCULAR SYSTEM BY LIGHT ACTIVATION OF THE VASCULAR 
SMOOTH MUSCLE 
Published as “Yang Wu, Shan-Shan Li, Xin Jin, Ningren Cui, Shuang Zhang and Chun Jiang. 
Optogenetic approach for functional assays of the cardiovascular system by light activation of 
the vascular smooth muscle. Vascul Pharmacol. 2015 Aug;71:192-200.” 
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8.2 Abstract 
Cardiovascular diseases are the major challenge to modern medicine. Intervention to 
cardiovascular cells is crucial for treatment of the diseases. Here we report a novel intervention 
to VSMCs by optogenetics. Channelrhodopsin in a tandem with YFP was selectively expressed 
in smooth muscle of transgenic mice in which YFP fluorescence was found in arterial walls of 
various tissues. In dissociated VSM cells from the mice blue light evoked inward currents, 
leading to depolarization and contraction. In isolated mesenteric arterial rings, optostimulation 
produced vasoconstriction that was reproducible, sustained, light intensity-dependent and 
comparable to popular vasoconstrictors. Blue light raised robustly coronary resistance without 
significant effects on heart rate and pulse pressure. Optostimulation produced renal 
vasoconstriction as well. The optical vasoconstriction had temporal resolutions less than 40s in 
these organs. These results indicate that optical vasoconstriction can be effectively produced in 
various organs with channelrhodopsin expression in VSM cells.  
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8.3 Introduction 
Cardiovascular diseases are the leading causes of deaths worldwide. According to the 
National Vital Statistics Reports by the Center for Disease Control in 2010, 29.4% of total causes 
of death in the USA involve the cardiovascular and cerebrovascular systems. One limitation for 
therapeutic intervention is the accessibility to the cardiovascular system, especially to the 
vasculature. At present, treatments of the cardiovascular diseases heavily rely on 
pharmacological agents. Thus, more accessibility to the cardiovascular system is needed for 
development of effective therapies, especially those with better temporal and spatial resolutions. 
Recent development in optogenetics suggests a new way to access the cardiovascular 
system. The optogenetics is a research approach based on transgenic expression of 
photosensitive opsins to one group or a few groups of cells, and then these cells are available for 
optical activation and inhibition 190,286. Such an optical control of cellular activity has been 
demonstrated to be highly effective in the manipulation of excitability of individual neurons and 
recruitment of cells in selective neuronal networks 287-292. Indeed, the optogenetics has been 
rapidly applied to studies of a number of types of neurons and glial cells 190,286-294. However, 
research in the cardiovascular field has barely taken the advantage of the newly developed cell-
selective optical intervention. To our knowledge, there is no report on the application of 
optogenetics to the blood vessels, although optogenetic control of myocardium has been recently 
demonstrated 193,195,295. 
Therefore, we generated a novel mouse strain with expression of a variant of 
channelrhodopsin2 (ChR2 H134R) in VSMCs. Using tissues from the mice, we tested the 
expression, membrane excitability, contraction of VSM cells, and vascular tone regulation in 
several organs. Our results indicate that optical activation of VSM cells can produce potent 
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vasoconstriction that is fast, reproducible, light intensity-dependent and comparable in strength 
to popular vasoconstrictors. 
8.4 Results 
8.4.1 VSM expression of ChR2 
We developed a new strain of transgenic mice, in which ChR2 was selectively expressed 
in smooth muscle cells. Genotyping shows that the offspring of ChR-loxP and Tagln-cre mice 
are supposed to express ChR2 with the present of Cre recombinase under the control of Tagln 
promoter (Fig. 8.1).In various tissues, we have systematically examined the expression of YFP 
engineered in frame with ChR2. All arteries in the heart, skeletal muscle, kidney and intestine 
showed YFP fluorescence in the Tagln-ChR mice but none in the control mice (Fig. 8.2). Similar 
expression of YFP was found in dissociated individual VSM cells from Tagln-ChR mice (Fig. 
8.4A). In the Tagln-ChR mice YFP fluorescence was also observed in smooth muscle in the 
intestine and uterus (Fig. 8.2K-R). 
8.4.2 Optical activation of acutely dissociated VSM cells 
Whole-cell currents were studied in VSM cells acutely dissociated from aorta. In voltage 
clamp, the aortic VSM cells exhibited typical voltage-dependent outward currents with the 
membrane potential held at -50 mV and stepped from -100 to 40 mV (Fig. 8.3A). Under this 
condition, exposure of the VSM cells obtained from Tagln-ChR mice to 10 ms pulses of blue 
light (470 nm) evoked large inward currents (Fig. 8.3B). The photo currents had a fast onset (0.7 
± 0.04 ms by 10%-90% peak, n = 6 cells) and slow decay with the time constant (30.8 ± 1.7 ms 
by 90%-10% peak, n = 6 cells). The slow decay was apparently produced by passive membrane 
properties, as the photo currents showed very little inactivation. With prolonged optical 
stimulations in 200 ms and 300 ms, blue light evoked persistent inward photo currents showing 
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very little adaptation or inactivation over the time periods (Fig. 8.3C). In the current-voltage (I-
V) relationship, the photo currents had the reversal potential ~0 mV with moderate inward 
rectification (Fig. 8.3D). In current-clamp, 300 ms blue light stimulation produced depolarization 
reliably (Fig. 3E), which significantly changed the membrane potentials of VSM cells from -45.4 
± 1.5 mV to -35.1 ± 2.1 mV (n = 5 cells, P<0.01) (Fig. 8.3F).  
8.4.3 Blue light evoked VSM cell contraction 
The light-evoked depolarization was expected to affect the contractility of VSM cells. 
Therefore, we measured the length of isolated VSM cells with and without 470nm light 
exposure. In Tagln-ChR mice, 10 s blue light exposure shortened individual aortic VSM cells. 
Typical VSM contraction was the shortening in the longitudinal axis of the VSM cells. The 
contraction was quantified by measurement of the size in the longitudinal axis of VSM cells. The 
blue light produced significant shortening in the VSM cells from the Tagln-ChR mice (P<0.01, n 
= 8) (Fig. 8.4A, B), which could have been even greater if there had been a way to add a preload 
to the cells. No change in cell shape from WT mice was observed (Fig. 8.4C). Cell length was 
recovered to about original level within 2 min (P<0.01, n = 8). The contractility was tested by 
additional 20 mM KCl with further length shrinkage observed (Fig. 8.4B, C). 
8.4.4 Optostimulation initiated contractions of isolated and perfused mesenteric arteries 
The light-evoked VSM contraction should have impact on vascular tones. To demonstrate 
this, we studied vascular constriction in isolated and perfused mesenteric arterial rings from 
control and Tagln-ChR mice. Vasoconstriction was observed with the blue light exposure (Fig. 
8.5A). Using high intensity and long-lasting (up to 1 hr) optical stimulation, we studied the 
kinetics of vasoconstriction. The vasoconstriction started fast with a 100 ms latency, reached the 
peak level within 10 s, and was maintained at the level throughout the photo stimulation period 
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with only a slight decline in the contractile force (Fig. 8.5A, F). Clear vasoconstriction occurred 
with the light intensity ~10 mW/mm2, and stronger photo stimulations produced stronger 
vasoconstrictions (Fig. 8.5B). The contractile force generated by blue light (~24 mW/mm2) was 
comparable to that produced by 1 μM phenylephrine 296, a selective α-adrenergic receptor 
agonist, and even larger than that produced by 60 mM KCl (Fig. 8.5C, E). To test the contraction 
reversibility, we repetitively stimulated the rings by 1 min light followed by 2 min time interval. 
As shown in the figure (Fig. 8.5C), the repetitive optical stimulations triggered repetitive 
vasoconstrictions with modest augmentation in the contractile force to subsequent stimulations. 
After each photo constriction, baseline contractile force was slightly elevated, which dropped to 
original level in 1-2 min (Fig. 8.5C). In contrast, the rings from control (Tagln-cre) mice showed 
no response to any optostimulation (Fig. 8.5D). Contractile force which was produced by 1 μM 
PE (0.26 ± 0.03 g, n = 7), 60 mM KCl (0.19 ± 0.04 g, n = 7) and light (0.23 ± 0.02 g, n = 7) were 
compared (Fig. 8.5E). No significant differences were found among these groups. The 
vasoconstriction force at the peak level of light exposure (0.24 ± 0.03 g, n = 7) was not 
significantly different from the force in the plateau (0.23 ± 0.02 g, n = 7) (Fig. 8.5F). The 
optostimulation had no significant residual effect on subsequent PE- and KCl- induced 
vasoconstrictions (Fig. 8.5G). Long-lasting optostimulation (1 hr) produced sustained 
vasoconstriction without any relaxation (Fig. 8.5H). Indeed, the contractile force increased by 
24.7 ± 17 % (n = 4) at the end of the 1 hr simulation (Fig. 8.5I). The sustained vasoconstriction 
was reversible, and vascular tension returned the baseline level within 10 min after light was 
turned off (Fig. 8.5H). 
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8.4.5 Manipulation of coronary arterial tones with optical stimulation 
To further test the effects of light-controlled vascular tones on tissue perfusion at the 
organ-typical level, we studied coronary vascular responses using the Langendorff heart 
preparation 297. The heart was prepared to enable the coronary circulation at a constant perfusion 
volume. The basal perfusion volume was firstly determined at the arterial pressure 80 cm H2O. 
Then the perfusion volume was maintained constantly at this level, and the pressure of the 
coronary arteries was measured with a force-electricity transducer. The viability of the 
preparation was verified in each heart by the stable heart rate >200 bpm (beat/min) and the 
vasodilation response to isoproterenol, a β-adrenergic receptor agonist 297-299. 
The heart rate averaged 300 bpm at about 35°C, consistent with previous observations in 
isolated heart preparations 187,300. In the Tagln-ChR heart, optostimulation produced a marked 
increase in coronary resistance which stands for the coronary resistance with the constant pump 
output (Fig. 8.6A), which was not seen in the control heart (Fig. 8.6B). In both hearts, PE (10 
μM) gave rise to a small increase of coronary resistance (Fig. 8.6A, B). The exposure to 10 μM 
isoproterenol brought about a clear vasodilation of coronary arteries with increases in the heart 
rate and the pulse pressure (Fig. 8.6A, B). Optostimulation (3 min) did not have any evident 
effects on the heart rate and pulse pressure in both groups of hearts (Fig. 8.6A, B). In 
comparison, the light exposure raised the coronary pressure by 20.1 ± 1.6 cm H2O with ~20 
mW/mm2 intensity (n = 11 hearts), while 10 μM PE increased the pressure by 15.1 ± 3.1 cm 
H2O (n = 11) (Fig. 8.6C).  
The temporal resolution was studied by measuring the onset and offset times for the 
coronary vasoconstriction (Fig. 8.6D). The onset latency was 1.1 ± 0.2 s (n = 7), and the time to 
90% peak vasoconstriction was 29.5 ± 8.4 s (n = 6).  The offset latency was 1.1 ± 0.3 s (n = 7), 
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and the time of withdrawal to 10% peak vasoconstriction was even shorter as 15.0 ± 3.1 s (n = 
7). These indicate that the optical vasoconstriction has a high temporal resolution in isolated 
hearts. 
With a prolonged period (30 min) optostimulation, the increase in coronary resistance 
was well maintained showing only modest or no relaxation (Fig. 8.6E, F).  However, such a 
long-lasting optostimulation had an effect on the heart rate. Arrhysmia occurred after 10 min, 
and became very severe at 20 min (Fig. 8.6G), suggesting that coronary perfussin is indeed 
restrained.  
8.4.6 Light stimulation increased vessel resistance in perfused kidneys 
In isolated and perfused kidneys from Tagln-ChR and Tagln-cre mice, renal vascular 
tension was measured with a constant perfusion flow that produced the renal pressure 100 cm 
H2O at baseline. The viability of kidney was tested by 10 μM PE and 10 μM isoproterenol. In 
the Tagln-ChR kidney, optostimulation with ~20 mW/mm2 intensity raised the renal pressure by 
20-30 cm H2O (Fig. 8.7A). Such a light response was not seen in control kidney (Fig. 8.7B), 
although its PE response was the same to the Tagln-ChR kidney. Vasodilation effects of 10 μM 
isoproterenol were relatively small in both groups of kidneys, likely due to the lack of expression 
of β2 adrenoceptors 301. In comparison, the Tagln-ChR kidney responded to light with an 
increase of renal pressure by 27.2 ± 2.5 cm H2O (n = 7), while the pressure reached 126.9 ± 12.0 
cm H2O  with 10 μM PE exposure (Fig. 8.6C). The temporal resolution was 38.3 ± 8.7 s (n = 6) 
for the onset time of 90% peak vasoconstriction, and 30.4 ± 4.43 s (n = 6) for the time to return 
to baseline (10% peak vasoconstriction) (Fig. 8.7D). 
The renal vasoconstriction was well maintained with prolonged optostimulation (up to 30 
min). After the peak pressure increase was reached at about 4 min, renal vascular pressure 
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dropped modestly at 30 min followed by a full recovery (Fig. 8.7E). On average the renal 
resistance did not significantly decline by the end of 30 min of opteostimulation (Fig. 8.7F). 
8.5 Discussion 
This is the first demonstration of optical vasoconstriction using an optogenetic approach. 
By taking the advantage of Cre-Lox mice, we have generated a new strain of transgenic mice 
that express ChR in VSMs. This allows us to stimulate the VSM cells and produce optical 
vasoconstriction. The optical vasoconstriction is robust, reproducible, light intensity-dependent, 
and superb in temporal resolution, which we have observed in various tissues. 
8.5.1 Successful generation of VSM optogenetic mice 
The Tagln gene encodes the protein transgelin, an actin cross-linking protein found in 
smooth muscle cells. Tagln mRNA is detected in the aorta, uterus, intestine and lung at high 
levels, especially in the SMC lines 302,303. The promoter Tagln has been well characterized, and 
used previously to deliver genes in the tissue-specific manner 304-306. By cross-breeding mice 
with Cre driven by the Tagln promoter with LoxP-ChR2 mice, we have developed a new mouse 
strain, in which ChR is expressed in VSM cells. This is supported by our morphological studies 
of YFP fluorescence in various tissues. Strong YFP fluorescence is found only in vessel walls, 
although several tissues in both control and Tagln-ChR mice have weak background 
fluorescence that can be easily distinguished by the fluorescence intensity. Weak YFP 
fluorescence has been observed in veins of Tagln-ChR mice, especially large veins that have a 
thin layer of smooth muscle as well. In addition to VSM, we also examined YFP fluorescence in 
the skeletal muscle, heart, kidney, intestine and uterus. YFP fluorescence is negative in skeletal 
muscle, adipocyte, heart, and kidney, and is weak in intestine and uterus. In kidney tissues where 
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pericytes and intraglomerular mesangial cells are located, we did not find any YFP fluorescence, 
suggesting that ChR may not be expressed in these cells.  
8.5.2 Characteristics of the optical activation of VSM cells 
Photo currents have been recorded in VSM cells dissociated from aorta of Tagln-ChR 
mice in voltage clamp. These are inward currents seen more clearly at hyperpolarized membrane 
potentials. Their reversal potential is close to 0 mV, indicating that the currents are carried by 
cations non-selectively. These currents show very little adaptation/inactivation with a prolonged 
light exposure, and show moderate inward rectification in the I-V relationship, which are 
consistent with our results of optical vasoconstriction showing little/no adaption as well. In 
current clamp, optical activation of these currents produces depolarization known to be necessary 
for VSM contraction. The VSM cells in our study seem to have a high level of ChR2 expression 
although the critical expression intensity for activation individual VSM cell is unknown. All 
these indicate that ChR has been successfully expressed in VSM cells of the Tagln-ChR mice 
306,307. 
8.5.3 Effective vasoconstriction by optical stimulation 
We have studied the effects of optostimulation on vascular tones in several tissues. In 
isolated VSM cells from the aorta, shortening in cell length is seen. We believe that the optical 
activation effect is under-presented in the dissociated cell preparation. The VSM cell contraction 
could be greater if there were a preload added to the cells. It is known that the preload can 
drastically enhance muscle contraction according the muscle length-tension relationship.  
Indeed, the optical vasoconstriction is found quite robust in the isolated and perfused 
mesenteric rings. The force produced by the optical vasoconstriction is comparable to 1 μM PE 
or 60 mM KCl, both of which are known to contract VSMs in mesenteric rings potently. The 
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optical vasoconstriction is reproducible, which is seen with repetitive optical stimulation, and 
shows no decline in the contractile force. The optical vasoconstriction is light intensity-
dependent, which is seen with blue light as low as ~10 mW/mm2. 
We have observed optical vasoconstriction in isolated and perfused heart and kidney. 
Light penetration is limited in these organs, allowing the blood vessels on and close to the 
surface to be stimulated. Even with the poor transparence, optostimulation produces strong 
vasoconstriction. In the coronary circulation, the optical vasoconstriction is more potent than the 
vasoconstrictions produced by 10 μM PE. In addition to the robustness, optical vasoconstriction 
has an extraordinarily high temporal resolution in isolated organs. The onset and offset times 
(measured as the 10-90% peak value) are within 40 s, which cannot be achieved by any non-
invasive approaches at present. The optical vasoconstriction is weaker in the renal circulation, 
which is likely to be due to anatomical nature of the kidney. Unlike the heart, the kidney is not a 
hollow organ in which substantial blood vessels may be not accessible to surface light. In 
perfused heart, light source was positioned on the surface of the heart, adjacent to aortic root 
from which left and right coronary arteries branch off. About 30% of the superficial vessels of 
the heart can be directly illuminated (single beam, 3mm diameter light guide). In contrast, the 
coverage area of the light accounts for up to 35% of the entire kidney surface. Attenuation 
coefficients of solid portion of heart and kidney at 470 nm are similar 308. Therefore hollow 
chamber of the heart helps the heart to gain better light transmittance. In addition, a change in the 
tissue thickness from 1.0 to 1.1 mm leads to a 10% decrease of light intensity. Thus, only a small 
proportion of blood vessels near to the surface are activated by optical stimulation. As a result, 
optostimulation may not lead to strong vasoconstriction.  
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No evident injury or side effect was seen in the vasculature even after repetitive and long-
lasting optostimulation (1 hr in rings and 30 min in perfused organs). This is consistent with the 
fact that VSM cells unlike neurons can survive relatively hight Ca2+ load to maintain persistent 
contractile forces 309.  
8.5.4 Potential usage in biomedical research 
The preparation of optical vasoconstriction has several potentials for research 
applications. Firstly, owing to the nature of optical stimulation, blood vessels in a well-defined 
region can be activated, an approach that is not currently available with systemic administration 
of vasoconstrictors. Such an approach can be useful for the understanding of cortical functions of 
the brain. The spatial accuracy of optical vasoconstriction could be used to reveal the mechanism 
of neuron-astrocyte-vascular coupling in certain brain areas, such nucleus regulating breathing 
293,310. Secondly, the temporal resolution and robustness of optical vasoconstriction may allow a 
better control of vascular tension where timing is critical. The approach may be useful for the 
study of microcirculation when precision controls of the arteriole tone are needed. In the 
presence of a basal level of vasodilator, optical vasoconstriction may allow a fast manipulation 
of the arteriole tone to desired levels. Thirdly, the optical vasoconstriction can be used to set a 
basal vascular tone for further vasodilation by potential therapeutic agents. The optogenetic 
approach does not involve vasoconstrictors, many of which may interfere with the vasodilators to 
be studied. Finally, the optical vasoconstriction may be useful to manipulate the metabolic rate 
temporospatially by reducing O2 and nutrient supplies to certain tissue. This even allow clinical 
applications when rhodopsins can be delivered to a specific tissue. Our findings thus may open 
an avenue for future studies to achieve such a therapeutic objective. 
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In conclusion, this study shows a novel intervention to vascular tones by optical 
activation of VSM cells that express ChR. In dissociated VSM cells, blue light evokes large 
inward currents, leading to depolarization and contraction. In isolated mesenteric arterial rings, 
optostimulation produces vasoconstriction that is reproducible, sustained and light intensity-
dependent. In isolated and perfused heart, blue light raises coronary resistance even more 
potently than that produced by 10 μM PE with fast onset and offset responses. These results 
indicate that the optogenetics can be effectively applied to the vasculature, and thus opens a 
brand new avenue for intervention to the cardiovascular system.  
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Figure 8.1 Design and genotyping of transgenic mice.  
(A) Constructs of parental ChR-LoxP and Tagln-cre mice as well as the expected offspring that 
express both ChR-loxP and Tagln-cre by removal of the stop codon (asterisk) flanked by loxP 
(solid triangle). This led to expression of ChR2-eYFP in a tandem driven by the CAG promoter 
in Tagln-ChR mice. (B) Mice were genotyped with primers provided by Jackson Laboratory, 
which are targeted at the 3” UTR with a 212 bp expected product. The presence of the 212 bp 
band indicated ChR2-eYFP mRNA expression in ChR-loxP and Tagln-ChR mice. Note that a 
300 bp non-specific band was found in all mice. Another pair of primers yielding a 100bp PCR 
product in the cre sequence, which was found in Tagln-cre and Tagln-ChR mice. Abbreviations: 
CAG, cytomegalovirus-immediate-early (CMV-IE) enhancer/chicken β-actin/rabbit β -globin 
hybrid promoter; PolyA, bovine growth hormone polyadenylation signal and flippase recognition 
target flanked phosphoglycerate kinase-Neo-polyA cassette; GAPDH, glyceraldehyde 3-
phosphate dehydrogenase. 
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Figure 8.2 Comparison of YFP fluorescence in various tissues between Tagln-ChR and 
Tagln-cre mice.  
In Tagln-ChR mice (A, C, E, G, I), strong YFP fluorescence was found on arterial walls of the 
aorta, coronary arteries, skeletal muscle, kidney and gastrointestinal arteries, respectively. In 
Tagln-cre mice (B, D, F, H, J), arteries in these tissues showed no or rather weak background 
fluorescence. YFP fluorescence was found in the muscularis externa of small intestine in Tagln-
ChR mice (K, M) but not in Tagln-cre mice (L, N) (The lower panel was obtained in the same 
field of the upper one). Blood vessels in the mucosa were also fluorescent in the Tagln-ChR 
mice. Similar YFP fluorescence expression was seen in the uterus of the Tagln-ChR mice (O, Q) 
but not of the Tagln-cre mice (P, R). Scale bars are 200 μm. 
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Figure 8.3 Optical excitation of dissociated VSM cells.  
(A) Whole-cell currents were recorded from a VSM cell dissociated from aorta of a Tagln-ChR 
mouse in voltage clamp. Steps of voltage commands (from -100 to 40 mV with a 10 mV 
increment) were applied to the cell at a holding potential of -50 mV. (B) Stimulation of the VSM 
cell with 10 ms pulses of blue light (470 nm) (~24 mW/mm2) evoked inward currents. The photo 
currents onset rapidly, and decayed slowly with the light on and off, which are better seen in the 
expanded display on the right panel. (C) Responses of another VSM cell to longer durations of 
blue light stimulations. The inward photo currents induced by 200 ms and 300 ms blue light 
showed only modest reduction in current amplitudes. (D) Current-voltage (I-V) relationship of 
the photo currents showed a reversal potential at 5 mV with moderate inward rectification. (E) In 
current clamp, blue light stimulation produced large depolarization in a VSM cell. (F) 
Comparison of membrane potentials before and during light exposure. Data are presented as 
means ± s.e. (P<0.01, Student’s t-test; n = 5 cells). 
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Figure 8.4 Contraction of the dissociated VSM cell by optostimulation.  
(A) Fluorescence expression of dissociated individual VSM cells was compared between Tagln-
ChR and control groups. (B) Longitudinal length of a VSM cell for a Tagln-ChR mouse was 
measured with and without light stimulation (~24 mW/mm2). Complete recovery was seen 2 min 
after light stimulation. Final length was measured 5 min after addition of 20 mM KCl. (C) 
Statistically, the blue light produced significant shortening in the longitudinal length (**, P<0.01, 
n = 8). Scale bar in A is 10 μm.  
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Figure 8.5 Characterization of optical vasoconstriction in isolated mesenteric arterial rings.  
(A) A mesenteric ring was obtained from a Tagln-ChR mouse and studied in-vitro with a 0.3 g 
preload. Exposure of the ring to blue light (~24 mW/mm2) produced vasoconstriction that started 
fast when the light was on, was maintained roughly at the same level during the light exposure, 
and returned to the baseline level rapidly. (B) Graded increases in the light intensity led to 
graded increases in forces of vasoconstriction (from ~10 mW/mm2 to ~24 mW/mm2). (C) In 
another ring from a Tagln-ChR mouse, vasoconstriction was first produced with PE at 0.1, 1 and 
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10 μM, followed by the vasodilator acetylcholine (Ach, 1 μM) and washout (WS). The lack of 
Ach effect indicated that endothelium was denuded. Exposures to 60 mM KCl also produced 
vasoconstriction. Subsequently, the ring was exposed to three pulses of blue light, each of which 
led to vasoconstriction. The amplitude of the light-evoked vasoconstriction increased slightly in 
the 2nd and 3rd exposures. After 15 min rest, the PE and KCl vasoconstrictions were repeated, and 
the same results were shown. Pinacidil (10 μM), a vasodilator, relaxed rings. (D) The same 
experiments were done in another ring from control mice. The ring showed the same responses 
to all treatments except light. (E) Contractile force was produced by PE, KCl and light. No 
significant differences were found among these treatments. (F) The vasoconstriction force at the 
beginning of light exposure (peak) was not significantly different from the force in the later 
steady level. (G) Comparison of vasoconstrictions by PE and KCl. The vasoconstriction forces at 
all tested concentrations of PE and KCl showed no significant difference before and after light 
exposure. Constant optical stimulation was indicated as blue bars. (H) Long-term stimulation 
(~24 mW/mm2, 1 hr) produced vasoconstriction that started fast when the light was on and did 
not decline during the light exposure. The vascular tension returned to the initial baseline level 
within 10 min after light off. (I) With the long-lasting optical stimulation, the stable contractile 
force lasted for 1 hr without decline (n = 4). 
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Figure 8.6 Constriction of coronary arteries by optical stimulation.  
(A) In an isolated and perfused heart from a Tagln-ChR mouse, a marked increase in coronary 
perfusion resistance was produced by blue light followed by PE and isoproterenol (Isop) 
treatments. Note that the optical vasoconstriction with ~20 mW/mm2 blue light was much greater 
than that produced by 10 μM PE. The optical coronary vasoconstriction did not cause evident 
changes in heart rate and pulse pressure, while both were augmented by Isop. The heart rate and 
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pulse pressure were obtained from areas indicated by arrows. (B) In a control heart, light did not 
produce coronary vasoconstriction. (C) In comparison, the vasoconstriction force was greater by 
light than by 10 μM PE (n = 11). (D) Time responses of the optostimulation. (E) long-term 
stimulation (30 min) raised coronary pressure to a relatively stable level with a slight decline. 
The coronary perfusion resistance went back to the initial baseline level in a few minutes after 
optostimulation. (F) The coronary resistance was maintained at a relative stable level during a 30 
min optostimulation without obvious decline (n = 4). (G) long-lasting light stimulation induced 
the cardiac arrhythmia. Severe arrhythmia was observed after 15 min optical stimulation, such as 
heart block and cardiac arrest. 
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Figure 8.7 Optical vasoconstriction in isolated kidney.  
(A, B) Optical vasoconstriction was observed in an isolated and perfused kidney from a Tagln-
ChR mouse but not that from a control mouse. (C) The optical renal vasoconstriction was 
compared with that produced by 10 μM PE. (D) Onset/offset time responses to optostimulation. 
(E) Long-lasting optical stimulation (30 min) induced a prolonged increase in vessel resistance. 
(F) The renal vascular resistance took about 4 min to reach the peak level and slightly declined 
(by 19 %, n = 4) at the end of 30 min stimulation. 
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9 GENERAL DISCUSSIONS 
Excitable cells rely on the excitation status to generate their functions. In peripheral 
tissues, excitation arises from motor neurons receiving central regulation. Such neural controls 
can be voluntary as in most somatic motor activity, involuntary as in cardiovascular function, 
and both as in breathing. Multiple excitable tissues including central nerves, peripheral nerves 
and muscles are involved during this process. Disorders in either may result in changes in 
excitation status. Therefore, information of cellular excitability control under certain 
physiological and pathophysiological conditions helps the understanding of diseases in the ANS. 
And novel approaches to cellular excitability have great impacts on the ANS diseases as well. 
These are indeed what are presented in this thesis study. 
9.1 Respiratory dysfunction and intervention: from the view of RTT 
9.1.1 Alternation of respiratory neurons excitability in Mecp2 rat model 
With the transgenic animal models, many progresses in RTT research have been made in 
RTT showing widespread disorders in motor, social and respiratory behaviors. Our study 
indicates that the over excitation or prolonged discharge of both I and E respiratory neurons in 
VRC caused by Mecp2 mutation may contribute to the slow breathing rate and frequent apnea. 
Additionally, the disruption of cellular excitation is not only found in VRC, but also in LC in our 
studies, which is consistent with the literatures that attributes the respiratory disorders such as 
apneas, air swallowing and periodic breathing to obvious prolonged and enhanced respiratory 
activity 94,110. Consistent with our findings in rats, Mecp2 mouse exhibits hyperexcitability of 
brainstem neurons and depressed spontaneous inhibitory synaptic currents. The alternations of 
neuronal excitability may affect the functional integrity of the brainstem respiratory network. 
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The disrupted coordination of the respiratory oscillators in brainstem become noticeable 
only when the animals reach certain age. In our study, the normal and abnormal breathing 
appears alternatively on Mecp2-null rats. The obvious breathing abnormalities were detected 
around 2 months after birth through plethysmography tests. However, our neuronal recording 
indicates the enhanced or prolonged neuronal activity appears not only when apnea or breathing 
variation occurs, but also during relatively normal breathing. In addition, the ectopic phrenic 
discharge only appears at the latter stage of life. These indicate that the molecular changes 
happen before the symptoms can be detected, and the change of overall cellular excitability is a 
step by step process. The molecular changes caused by Mecp2 disruption in different brain 
regions contribute to the alternation of the neuronal excitability. In brain, these molecular 
changes include the changes of neurotransmission. Normal autonomic functions depend on the 
fine control of neuron activities in different brain regions via neurotransmission which is 
impaired by Mecp2 disruption. The animal body may be able to do certain adjustment to adapt 
the minor changes at early stage. With the progress of the disease, the severity excesses the 
compensatory mechanism making the symptoms detectable.  
As a multifunctional protein, MeCP2 regulates many gene expression and influences 
various biological metabolism. Neuronal excitabilities in different brain region can be altered 
with Mecp2 disruption. Seizure and tremor were not analyzed in our studies, but also can be seen 
on Mecp2-null animals, which may be also caused by alternation of neuronal excitability. Mecp2 
disruption in the forebrain lead to cortical hyperexcitation represented as spontaneous seizures 
associated with a defect of GABAergic transmission 117. And tremor or striking myoclonic jerk 
on forelimbs and paws was observed simultaneously with hyperactive cortical 
electroencephalographic (EEG) signal in mice expressing a truncated MeCP2 protein 119. By 
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using the rat models, the underlying molecular mechanisms causing these excitability changes 
are expected to be uncovered, and the development of the potential therapeutic strategies of RTT 
becomes possible. 
9.1.2 Transgenic and pharmacological interventions of RTT 
Although the molecular pathogenesis of respiratory dysfunction is still not fully 
understood due to the complicity of the downstream regulation of MeCP2, the therapeutic 
interventions can be developed and help to alleviate the RTT symptoms with information 
generated in this and other studies. It is encouraging that developmental absence of MeCP2 does 
not cause irreversibly damage of neurons 237. Therefore, the expression of normal MeCP2 during 
a specific time window might reverse RTT. The mature gene therapy or alternative therapy to 
restore the MeCP2 level is still missing. Therefore, potential RTT treatment could be focused on 
maintaining the hemostasis of neurotransmission by using existing agents. THIP, also known as 
Gaboxadol, has promising effects on the alleviation of RTT-like phenotypes in both mouse 
models and our rat model. This agent is considered in the treatment of insomnia 311. Although it 
reached a phase III trial before it was called off with safety and efficacy concerns, animal 
experiments on THIP shows it effectively rescues the neurophysiological and behavioral deficits 
in fragile X syndrome and Angelman Syndrome 312-314. The pilot study on THIP as hypnotics 
supplies precise knowledge to guide its usage on other diseases. In our study, THIP rescuing the 
Mecp2-null rats suggests the possibility of certain GABA enhancers as RTT treatment reagents. 
NNC-711 is another agent having delightful and potent rescuing effects on RTT phenotypes. 
Although the side effects of these GABA enhancers including sedation, dizziness, confusion and 
hallucination are reported, these drugs may still be used under restrictive control, and their side 
effects seem less important when considering its life-rescuing effects. In addition, systemic 
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division of RTT subtypes based on phenotypes and severity is needed to make medication 
guideline. Hopefully, technical development in future will allow more accurate application of 
transgenic or pharmacological intervention to avoid unnecessary side effects and to target 
specifically the subdivided phenotypes of this disease. 
9.2 Vascular dysfunction and intervention: from the view of VSMC  
9.2.1 Alternation of VSMCs excitability in MGO model 
Besides influence on CNS, alternation of membrane excitability on executive cells such 
as VSMCs, cardiomyocytes and other smooth muscle cells can also lead to autonomic 
dysfunctions. The excitability of these cells is influenced by the membrane potential. The 
transmembrane proteins, such as ion transporters and ion channels, are the key setters of the 
electrical potential across the membrane. Membrane potential is used by the excitable cells to 
transmit electric signals in the cells. The opening and closing of ion channels producing a local 
electric change on the membrane influence the membrane potential, and determine the activation 
status of the cell. The resting membrane potential established by Na+/K+-ATPase is affected by 
K+ channels, such as KATP channels, to a large extent. In the case of the KATP dysfunction, 
reduced outflow of K+ ions will lead to a depolarized membrane potential, and increase 
vasoconstrictor-induced vasoconstriction 206. We demonstrated that the cumulated MGO targeted 
on mRNAs of KATP channels in VSMCs via miRs, causing instability of Kir6.1 and SUR2B 
transcripts. This suggests that the function of the widely-expressed KATP channels can be 
impaired by excessive MGO in diabetes leading to abnormalities of cellular excitability of 
VSMCs, which contributes to the diabetic vascular disorders including hypertension 204,205 and 
cardiovascular complications including ischemic coronary artery disease and stroke 202,315. 
Indeed, increased contractility of VSMCs was demonstrated under diabetic conditions 316,317.  
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Emerging evidence suggests that hyperglycemia and high MGO level affects the miRs 
expression in vascular tissues, and this may be associated with the altered vascular reactivity. 
The relation between excessive MGO and altered expression of several miRs is studied firstly in 
dysfunction of endothelial cells. For example, reduced level of miR-190a is reported associated 
with impaired aortic endothelial insulin resistance 318. The dysfunction of umbilical vein 
endothelial cells is induced by miR-221 in persistent hyperglycemia 319. Our study demonstrates 
that VSMC is also involved in miRs-caused vascular dysfunction in hyperglycemia. 
Downregulation of SUR2B mRNA in VSMCs is induced by elevation of miR-9a-3p in high 
MGO exposure. Besides miR-9a-3p, miR-29 is another miRs increasing VSMC contractile 
phenotypes in hyperglycemic conditions 320. It directly interacts with mRNA of a transcription 
factor called KLF4 which is a potent inhibitor of cell proliferation, causing downregulation of 
KLF4, inducing vascular smooth muscle contractile markers calponin, and leading to consequent 
proliferation of VSMCs. Therefore, there are possibly more miRs besides mi9-9a-3p induced by 
high glucose or excessive reactive species involving in diabetic vascular dysfunctions. And 
Kir6.1 subunit may be targeted by other undetected miRs, together with mi9-9a-3p, contributing 
to downregulation of the KATP channels. The consequences include hypotension and insufficient 
blood flow to main organs when sympathetic system is activated.  
Specific miRs regulate cellular excitability by affecting the genetic programs. In our 
study, increased mi9-9a-3p triggered by MGO influences the VSMCs excitability via impairing 
the function of the KATP channels. Evidence suggests that increased mi9-9a-3p is detected in 
human epileptic plasma samples 321. The blood mi9-9a-3p may be a putative biomarkers of 
epilepsy. Although it needs to be proved, we have a bold guess that mi9-9a-3p might affect the 
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neuronal excitability in the brain and increase the risk of epilepsy via its impact on KATP 
channels as well.  
9.2.2 Transgenic interventions of vascular tone  
Traditional intervention to vasculature intensively depends on the usage of 
pharmacological agents. Here, two novel transgenic approaches could be used as alternatives to 
vascular system. One is through manipulation of miRs which supplies a systemic intervention, 
the other is through optogenetic engineering which enable the spatiotemporal controlling of 
vascular tone.  
Manipulation of miRs may offer a novel therapeutic intervention in vascular diseases. It 
is feasible to use miRs as a therapeutic tool in vascular system. Evidence suggests that exosomes 
may contain miRs which can be delivered to another cell and function in the new location 322. 
Furthermore, miRs can be detected in circulation as potential biomarkers of epilepsy 321. These 
suggested miRs delivery can be used as a minimally invasive tool to intervene vascular system 
with specificity. Pilot studies on therapeutic miRs delivery as a replacement therapy have some 
success in the suppression of liver tumorigenesis with adeno-associated virus (AAV) 323. Our 
study demonstrated that elevated miRs in disease condition can be lowered down with antisense 
oligonuecleotides complementary to the target mature miRs. These approved that miRs level can 
be manipulated using replacement therapy or antisense oligoneucleotides depending on 
endogenous miRs levels in disease conditions. Although, at current stage, further studies are 
needed to gain insight into the miRs expression pattern in vascular system, manipulation of miRs 
provides attractive therapeutic targets for the treatment of vascular diseases. 
The application of optogenetics in vascular system supplies an exquisite tool in vascular 
manipulation. Different from pharmacological and miRs intervention, this transgenic method 
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produces quick onset and withdrawal without obvious sequela. And the potency of 
vasoconstriction triggered by optostimulation is comparable with endogenous vasoconstrictor 
PE. The coupling of the cerebral blood flow and neuronal activation makes Tagln-ChR mice an 
ideal model in studies of the neuronal function. Furthermore, it may useful in regulating the 
filtration of glomerulus by controlling the vasoconstriction of renal afferent and efferent 
arterioles, where the blood pressure may be influenced without other unwanted ANS 
interference. Although we did complete in vitro test to approve the optogenetic approach has the 
potential in the studies of the relation of reginal blood flow and neuronal activity in CNS, 
subsequent experiment encountered bottleneck when we tried to reveal the mechanism of RTN 
chemosensitivity in in vivo studies because of the limited resolution of light source and the 
unwanted heat radiation generated by laser stimulator. Before these problems can be solved, the 
applications of optogenetics will be limited in vascular system. Currently, some labs are 
dedicated to break through the technique issues. Hopefully, with the development of light 
delivery technique, such as a high resolution integrated image-stimulation system 324, optical 
modulation of vasoconstriction can be achieved on living animals with low damage to blood 
vessels and local tissues. 
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10 CONCLUSION 
In these studies aimed at addressing regulation of autonomic system, specifically 
respiratory and vascular systems, we have found that the alternation of the cellular excitability is 
the key reason for ANS dysfunctions. The novel Mecp2-null rat model recapitulates many RTT 
phenotypes and is ideal in the studies of cellular mechanisms. With the RTT rat model, we have 
demonstrated that RTT type of breathing is likely due to increased excitability of the respiratory 
neurons in brainstem, which can be rescued by augmentation of GABAergic synaptic inhibition. 
The change in cellular excitability plays equally important role in VSMCs where dysfunction of 
the vascular KATP channels is caused by elevation of miR-9a-3p during oxidative stress. Because 
of the importance of the cellular excitability, we have tried to control the excitability of VSMCs 
using the optogenetic approach that appears helpful in laboratory research. Therefore, these 
thesis studies demonstrate the relationship between the hemostasis of the cellular excitability and 
the molecular mechanism of RTT respiratory disorders as well as the vascular dysfunction under 
oxidative stress. Furthermore, this dissertation also provides a good perspective on the potential 
usage of transgenic tools including transgenic animal, miRs and optogenetics in basic studies and 
potential therapeutical interventions to ANS dysfunctions. 
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